

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28893 A2

(51) International Patent Classification⁷: C07K 14/47,
C12N 9/12, 15/54, 15/82, C07K 16/40, A01H 5/00, G01N
33/573

18, B-9310 Moorsel-Aalst (BE). HATZFELD, Yves
[FR/FR]; 292, rue Nationale, F-59000 Lille (FR).

(21) International Application Number: PCT/IB01/01492

(74) Agent: DE CLERCQ, Ann; De Clerq, Brants & Partners,
E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem (BE).

(22) International Filing Date: 29 June 2001 (29.06.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/218,471 14 July 2000 (14.07.2000) US
60/241,219 13 October 2000 (13.10.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant (for all designated States except US):
CROPDESIGN N.V. [BE/BE]; Technologiepark 3,
B-9052 Gent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FRANKARD,
Valérie, Marie-Noëlle, S. [BE/BE]; 40, rue du Ham,
B-1180 Bruxelles (BE). PERES BOTA, Adrian, Marius
[RO/BE]; Holdaalstraat 31, B-9000 Gent (BE). DROUAL,
Anne-Marie [FR/BE]; Voskenslaan 437, B-9000 Gent
(BE). MIRONOV, Vladimir [BE/BE]; Gentbruggestraat
142, B-9040 Gent (BE). INZE, Dirk [BE/BE]; Driesstraat

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/28893 A2

(54) Title: NOVEL PLANT CYCLIN-DEPENDENT KINASE INHIBITORS

(57) Abstract: The invention provides isolated nucleic acids molecules, designated ICK nucleic acid molecules, which encode novel plant cyclin-dependent kinase inhibitors. The invention also provides antisense nucleic acid molecules, gene silencing and recombinant expression vectors containing ICK nucleic acid molecules, host cells into which the expression vectors have been introduced, and transgenic plants in which an ICK gene has been introduced or disrupted. The invention still further provides isolated ICK proteins, fusion proteins, antigenic peptides and anti-ICK antibodies. Agricultural, diagnostic, and screening methods utilizing compositions of the invention are also provided.

Wm J. Gordon-Kamm
Serial No. 09/993,308

REF
A24

NOVEL PLANT CYCLIN-DEPENDENT KINASE INHIBITORS

5 Related Applications

This application claims priority to U.S. provisional patent application serial number 60/218,471, filed July 14, 2000 and to U.S. provisional patent application serial number 60/241,219, filed October 13, 2000. The contents of these provisional patent applications are incorporated herein by reference in their entirety.

10

Background To The Invention

When eukaryotic cells, *e.g.*, plant cells, divide they go through a highly ordered sequence of events collectively termed as the "cell cycle." Briefly, DNA replication or synthesis (S) and mitotic segregation of the chromosomes (M) occur with intervening
15 gap phases (G1 and G2) and the phases follow the sequence G1-S-G2-M. Cell division is completed after cytokinesis, the last step of the M-phase. Cells that have exited the cell cycle and have become quiescent are said to be in the G0 phase. Cells at the G0 stage can be stimulated to re-enter the cell cycle at the G1 phase.

The transition between the different phases of the cell cycle is basically driven
20 by the sequential activation/inactivation of a kinase, known as "cyclin-dependent kinase" or "CDK" by different molecules. Required for kinase activation are proteins called cyclins which are also important for targeting the kinase activity to a given (subset of) substrate(s). Other factors regulating CDK activity include CDK inhibitors (known as CKIs, ICKs, Kips, Cips, Inks, or KRPs, *i.e.*, Kip-related proteins), CDK
25 activating kinase (CAK), CDK phosphatase (Cdc25), and CDK subunit (CKS) (Mironov *et al.* (1999) *Plant Cell* 11, 509-522 and Reed (1996) . *Prog. Cell Cycle Res.* 2, 15-27).

The existence of an inhibitor of mitotic CDKs was inferred from experiments with endosperm of maize seed (Grafi and Larkins (1995) *Science* 269, 1262-1264) but only recently were ICKs identified in plants. A total of seven *Arabidopsis*, one
30 *Chenopodium rubrum*, and one alfalfa ICK cDNAs have to date been described. The encoded proteins are characterized by a stretch of approximately 35 carboxy-terminal amino acids showing homology to the amino-terminal cyclin/Cdk binding domain of animal ICKs of the p21^{Cip1}/p27^{Kip1}/p57^{Kip2}-types. Outside the carboxy-terminal region, the plant ICKs are unrelated to one another and no homologies have been detected with
35 other protein sequences.

Arabidopsis ICK1 is able to inhibit the kinase activity of plant Cdc2, but not the kinase activity of human Cdc2 or of *S. cerevisiae* Cdc28. *Arabidopsis* ICK3 also inhibits plant Cdc2 kinase activity. ICK1 and ICK3 interact both with *Arabidopsis*

Cdc2a (A-type Cdk) and cyclin D3, but not with *Arabidopsis* Cdc2b (B-type Cdk). ICK1 also interacts with cyclin D1 and cyclin D2, but not with cyclin A2, cyclin B1, cyclin B2, or PCNA. As determined by yeast two-hybrid assays, interaction between ICK1 and cyclin D3 is much stronger than between ICK1 and Cdc2a. The carboxy-terminal region of ICK1 (homologous to the Cip1/Kip1,2 animal ICKs) is required for association with Cdc2a and cyclin D3. Binding to either of these partners is, however, strongly enhanced with an amino-terminally deletion mutant comprising the approximately 50 amino acid stretch upstream of the ICK1 cyclin/Cdk binding domain in conjunction with this domain. Wild-type ICK1 does not fit as tightly to Cdc2a or cyclin D3 as the foregoing deletion mutant, suggesting the presence of destabilizing elements in the amino-terminal region of ICK1.

ICK1 expression is highest in leaves and both abscisic acid and incubation at low temperature conditions, which inhibit plant cell division, induce the accumulation of ICK1 transcripts in *Arabidopsis* seedlings. Expression of ICK2 is most prominent in stems and in florescence apices, lowest in 1-week-old seedlings and upregulated by treatment with 0.1% NaCl (WO9914331, Lui *et al.* (2000) *Plant J.* 21, 379-385, Wang *et al.* (1997) *Nature* 386, 451-452, WO9964599).

Transgenic *Arabidopsis*, *Brassica napus* and *B. carinata* plants have been generated expressing ICK1 under the control of the AP2 promoter sustaining pollen-preferred expression or under the control of the anther-specific Bgl1 promoter. Increased ICK1 mRNA levels in AP2-ICK1 transgenic *Arabidopsis* plants (T1 and T2) correlated with phenotypic effects ranging from no visible petals to visible petals of reduced size to normal petals. Only plants with normal petals are self-fertile. Seed setting in the male sterile transgenic plants with the other phenotypes can be restored by fertilization with wild-type pollen. No significant male sterility was observed in Bgl1-ICK1 transgenic *Arabidopsis* plants. The effects of AP2-ICK1 and Bgl1-ICK1 were less severe and more pronounced, respectively, in transgenic *Brassica* plants (WO9964599).

Many different functions have been described for ICKs of animal origin and these include: differential inhibition of cyclin-Cdk kinase activity, regulation of cyclin-Cdk complex assembly, regulation of commitment of cells to divide by integrating mitogenic and antimitogenic signals, regulation of cell cycle progression, regulation of DNA replication and DNA repair, regulation of gene transcription, regulation of cyclin degradation, involvement in cell cycle withdrawal and cell differentiation, regulation of apoptosis, control of organ and organism size and regulation of endoreduplication (Nakayama and Nakayama 1998 *Bioessays* 20, 1020-1029). Many of these functions have been attributed to the ICK domains outside the cyclin/Cdk binding regions.

In view of the unusually pronounced sequence heterogeneity between the ICKs of a single plant species and the differences in expression patterns, it can be expected that each of the plant ICKs serves a unique function in controlling plant development. Such plant ICK functions may include interference with cell cycle events similar as those regulated by ICKs in animals but as yet unidentified in plants.

Summary Of The Invention

The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as "Inhibitors of Cyclin Dependent Kinases" or "ICK" nucleic acid and polypeptide molecules. The ICK nucleic acid and polypeptide molecules of the present invention are useful as modulating agents in regulating cell cycle progression in, for example, plants. The ICK nucleic acid and polypeptide molecules of the present invention are particularly useful in agriculture and plant cell and tissue culture.

In one aspect, the present invention features a method for modulating the cell cycle in a plant, *e.g.*, *arabidopsis thaliana*, rice, wheat, maize, tomato, alfalfa, oilseed rape, soybean, sunflower, or canola, by introducing into the plant an ICK modulator, such that the cell cycle in the plant is modulated. In one embodiment, the plant is a monocot plant. In another embodiment, the plant is a dicot plant.

In one embodiment, the ICK modulator is a small molecule. In another embodiment, the ICK modulator is capable of modulating ICK polypeptide activity. For example, the ICK modulator can be an anti-ICK antibody or an ICK polypeptide comprising the amino acid sequence of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44, or 55, or a fragment thereof.

In another embodiment, the ICK modulator is capable of modulating ICK nucleic acid expression. For example, the ICK modulator can be an antisense ICK nucleic acid molecule, an ICK gene silencing molecule, a ribozyme, or a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or a fragment thereof.

In another aspect, the invention features a method for modulating plant growth and/or plant cell fate and/or plant morphology and/or plant biochemistry and/or plant physiology by introducing into a plant an ICK modulator, such that said plant growth and/or plant cell fate and/or morphology and/or plant biochemistry and/or plant physiology is modulated.

In a further aspect, the invention features a method for improving tolerance to an environmental stress condition, *e.g.*, drought, salt, temperature, or nutrient deprivation, in a plant by introducing into the plant an ICK modulator, such that tolerance to an environmental stress condition in the plant is improved.

In another aspect, the invention features a method for improving tolerance to a plant pathogen, *e.g.*, a pathogenic bacterium such as *Agrobacterium tumefaciens*, plant pathogenic fungi including *Plasmodiophora brassicae*, *Crinipellis pernicioso*, *Pucciniastrum geoppertianum*, *Taphrina wiesneri*, *Ustilaga maydis*, *Exobasidium*
5 *vaccinii*, *E. camelliae*, *Entorrhiza casparyana* and *Apiosporina morbosum*, that abuses the cell cycle in a plant by introducing into the plant an ICK modulator, such that tolerance to a plant pathogen that abuses the cell cycle in the plant is improved.

In a further aspect, the invention features a method for modulating ICK activity in a plant by introducing into the plant an ICK modulator, such that ICK activity in the
10 plant is modulated.

The present invention also features a method for modulating the cell cycle in a plant cell by contacting the plant cell with an ICK modulator, such that the cell cycle in the plant cell is modulated.

In another aspect, the invention provides a method for modulating plant cell
15 growth and/or plant cell fate and/or plant morphology and/or plant biochemistry and/or plant physiology by contacting a plant cell with an ICK modulator, such that plant cell growth and/or plant cell fate and/or plant morphology and/or plant biochemistry and/or plant physiology is modulated.

Methods for improving tolerance to an environmental stress condition in a plant
20 cell and methods for improving tolerance to a plant pathogen that abuses the cell cycle in a plant cell are also provided by the present invention. These methods include contacting the plant cell with an ICK modulator, such that tolerance to an environmental stress condition or to a plant pathogen that abuses the cell cycle in the plant cell is improved.

25 Methods for modulating ICK activity in a plant cell are also provided. The methods include contacting the plant cell with an ICK modulator, such that ICK activity in the plant cell is modulated.

In another embodiment the invention provides transgenic plants (*e.g.*, monocot or dicot plants) containing an isolated nucleic acid molecule of the present invention.
30 For example, the invention provides transgenic plants containing a recombinant expression cassette including a plant promoter operably linked to an isolated nucleic acid molecule of the present invention (*e.g.*, a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:9, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:54 or SEQ ID NO:56). The present invention also provides seed, pollen, cuttings,
35 and flowers from the transgenic plants. In another embodiment the invention provides methods of modulating, in a transgenic plant, the expression of the nucleic acids of the invention.

Isolated nucleic acid molecules which include the nucleotide sequence set forth in SEQ ID NO: 9, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:54 or SEQ ID NO:56, or complements thereof, are also encompassed by the present invention.

In one aspect, the invention features an isolated nucleic acid molecule which
5 encodes an ICK polypeptide comprising the amino acid sequence set forth in SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44, or 55, or a complement of the isolated nucleic acid molecule.

In another aspect, the present invention features an isolated ICK polypeptide comprising the amino acid sequence of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44, or
10 55, or fragments thereof.

The proteins of the present invention or portions thereof, *e.g.*, biologically active portions thereof, can be operably linked to a non-ICK polypeptide (*e.g.*, heterologous amino acid sequences) to form fusion proteins. The invention further features
15 antibodies, such as monoclonal or polyclonal antibodies, that specifically bind to the ICK polypeptides of the invention. In addition, the ICK polypeptides or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides a method for identifying a compound which binds to an ICK polypeptide of the present invention. The method
20 includes contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and determining whether the polypeptide binds to the test compound. In one embodiment, the binding of the test compound to the polypeptide is detected by direct detection of test compound/polypeptide binding. In another embodiment, the binding of the test compound to the polypeptide is detected by detection of binding using a
25 competition binding assay. In yet another embodiment, the binding of the test compound to the polypeptide is detected using an assay for ICK activity.

In yet another aspect, the present invention provides a method for modulating the activity of an ICK polypeptides of the present invention. The method includes
30 contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

In a further aspect, the present invention provides a method for identifying a compound which modulates the activity of an ICK polypeptide of the present invention. The method includes contacting an ICK polypeptide with a test compound; and
35 determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5 **Brief Description of the Drawings**

Figure 1 depicts the nucleotide sequence of the full length OsICK2 cDNA (SEQ ID NO:9). The open reading frame (between rounded brackets) the start codon and the stop codon (underlined) are indicated. Also indicated are the polyadenylation sites (double underlined), the AU-rich elements or AREs (*italic*), and the extra 3'UTR region of SEQ ID NO:9 compared to SEQ ID NO:1 (underlined between square brackets).

Figure 2 depicts the nucleotide sequence of the full length OsICK4 cDNA (SEQ ID NO:43). The open reading frame (between rounded brackets) the start codon and the stop codon (underlined) are indicated. Also indicated is the AU-rich element or ARE (*italic*).

Figure 3 depicts an amino acid alignment of the full-length OsICK2 amino acid sequence (SEQ ID NO:10), the full-length OsICK4 amino acid sequence (SEQ ID NO:43) and the predicted full-length OsICK5 amino acid sequence (SEQ ID NO:55) with the amino acid sequences of other known plant ICKs: the seven *Arabidopsis* ICKs (ICK1 to ICK7), the *Medicago sativa* ICK (alfalfa ICK), and the *Chenopodium rubrum* ICK (Chenopod ICK). The alignment was made using ClustalW as part of the VNTI (version 5.5; InforMax Inc.) software using default parameter settings (blosum 62 scoring matrix; gap opening penalties for pairwise and multiple alignment = 10; gap extension penalty for pairwise alignment = 0.1; gap extension penalty for multiple alignment = 0.05). Identical amino acid residues are indicated in black shaded boxes. Conserved amino acid residues are indicated in grey shaded boxes according to the groups (M,I,L,V), (A,G,S,T), (R,K,H), (F,W,Y), (D,E) and (N, Q).

Figure 4 depicts an amino acid alignment of the relevant parts of the full-length OsICK2 amino acid sequence (SEQ ID NO:10), the full-length OsICK4 amino acid sequence (SEQ ID NO:43) and the predicted full-length OsICK5 amino acid sequence (SEQ ID NO:55) with the partial amino acid sequence of OsICK1 (SEQ ID NO:11), the partial amino acid sequence of OsICK3 (SEQ ID NO:12), the partial amino acid sequence of the *Zea mays* ICK1 (SEQ ID NO:14), the partial amino acid sequence of the *Zea mays* ICK2 (SEQ ID NO:15), the partial amino acid sequence of the *Sorghum bicolor* ICK (SEQ ID NO:16), and the partial amino acid sequence of the *Pinus taeda* ICK (SEQ ID NO:17). The alignment was made using ClustalW as part of the VNTI

(version 5.5; InforMax Inc.) software using default parameter settings (blosum 62 scoring matrix; gap opening penalties for pairwise and multiple alignment = 10; gap extension penalty for pairwise alignment = 0.1; gap extension penalty for multiple alignment = 0.05). Identical amino acid residues are indicated in black shaded boxes.

- 5 Conserved amino acid residues are indicated in grey shaded boxes according to the groups (M,I,L,V), (A,G,S,T), (R,K,H), (F,W,Y), (D,E) and (N, Q).

Figure 5 is a schematic representation of the motifs conserved in plant ICK molecules (using the same numbering indicated in Table 1). Further indicated in Figure 4 are the secondary structure elements predicted to be present in the plant ICK

- 10 molecules. (H: predicted α -helical structure in a stretch of at least 4 consecutive amino acid residues. E: predicted extended β -sheet structure in a stretch of at least 4 consecutive amino acids).

- Figure 6* depicts the Cy-box-regions present in different mammalian proteins and the derived consensus sequence. p21Cip1, p27Kip1 and p57kip2 are three types of mammalian cyclin-dependent kinase inhibitors. Cdc25A is a G1/S specific protein phosphatase which has Cdc2-related proteins as substrates. p107 belongs to the family of pocket proteins also including p130 and pRB. E2F1 is a transcriptional activator involved in activation of S-phase specific gene expression. X may be any amino acid and H may be M,I,L or V.

- 20 *Figure 7* is a blot depicting the expression of OsICK1 ('ICK1'), OsICK2 ('ICK2') and OsICK4 ('ICK4') in different tissues of rice plants. cDNA obtained by RT-PCR was subjected to DNA gel blot analysis with biotin-labeled probes specific for OsICK1, OsICK2 and OsICK4. (R: root tissue, L: leaf tissue, STM: stem meristem tissue, ST: stem tissue, S: seeds).

- 25 *Figure 8* is a blot depicting the expression of OsICK1 ('ICK1'), OsICK2 ('ICK2') and OsICK4 ('ICK4') in developing rice grains. cDNA obtained by RT-PCR was subjected to DNA gel blot analysis with biotin-labeled probes specific for OsICK1, OsICK2 and OsICK4. (DAP: days after pollination).

- 30 *Figure 9* depicts the results from an *in situ* hybridization analysis of OsICK2 expression in rice seeds collected 7 days after pollination. Dark field microscopy (right panel) visualizes a clear (bright white) hybridization signal in the cell layer(s) surrounding the developing endosperm (white arrow). A patchy hybridization signal is

also obvious in the developing embryo (white arrow). The bright field microscopic image (left panel) shows the morphology of the toluidine blue-stained section.

Figure 10A-I depicts the results from an *in situ* hybridization analysis of OsICK2 expression in rice seeds collected 20 days after pollination. (A) and (B) are dark field and bright field microscopic images, respectively, of the same longitudinal section. (C) is a magnification of a part of (A). Clearly visible is the (bright white) hybridization signal in the scutellum (white arrow). (D) and (E) are dark field and bright field microscopic images, respectively, of the same cross section. (F) is a magnification of a part of (D). Hybridization signals in (D) and (F) show expression of OsICK2 in the cell layer(s) lining the developing endosperm (white arrows). (G) and (H) are dark field and bright field microscopic images, respectively, of the same longitudinal section again showing OsICK2 expression in the cell layers surrounding the developing endosperm (white arrow). The same is shown in the bright field microscopic image (I) where the hybridization signal is black (black arrow).

Figure 11 depicts A comparison of the OsICK4 cDNA sequences (Panel A) and OsICK4 protein sequences (Panel B) obtained by (i) yeast two-hybrid interaction screening of rice two-hybrid cDNA library using Cdc2-Os1 as bait and by (ii) hybridization screening of the same library. The full-length OsICK4 cDNA sequence obtained by hybridization screening is given in Panel A with the ORF between brackets. Further indicated in Panel A is the part of the OsICK4 cDNA missing in the clone identified by yeast two-hybrid interaction cloning, said part being indicated in underlined italics. The corresponding full-length OsICK4 amino acid sequence is given in Panel B where it is identified as "HYB ICK4". Further indicated in Panel B is the part of the amino acid sequence encoded by the partial OsICK4 clone as outlined in Panel A. The partial amino acid sequence is identified in Panel B as "2-H ICK4". Amino acids common to both proteins are shaded in grey.

Figure 12 shows the wrongly predicted OsICK4 protein sequence present in GenBank (GenBank accession number AC069145 version 5 of September 30, 2000; protein ID = AAG16867.1). The 48 superfluous amino acids in the predicted protein sequence not present in the protein sequence derived (SEQ ID NO:44) from the experimentally obtained OsICK4 cDNA (SEQ ID NO:43) are indicated between square brackets and as underlined boldface characters.

Figure 13 depicts the binary plant transformation vector p0428 ICK4 comprising the OsICK4 ORF operably linked to the GOS2 promoter.

Figure 14 depicts the pUC18 derivative vector pUC18-ICK4 CS comprising the cassette with inverted repeats of an OsICK4 cDNA fragment separated by the tobacco
5 MAR sequence. This cassette is used for co-suppression of OsICK4 expression in transgenic plants.

Figure 15 depicts the binary plant transformation vector p0490 comprising the OsICK4 co-suppression cassette of pUC-ICK4 CS (see *Figure 13*) operably linked to the GOS2 promoter.

10 *Figure 16* depicts the binary plant transformation vector p0489 comprising the OsICK4 co-suppression cassette of pUC-ICK4 CS (see *Figure 13*) operably linked to the prolamine promoter.

Figure 17 depicts the binary plant transformation vector p0488 comprising the OsICK4 co-suppression cassette of pUC-ICK4 CS (see *Figure 13*) operably linked to the
15 oleosine promoter.

Figure 18 depicts the binary plant transformation vector p0559 comprising the OsICK4 co-suppression cassette of pUC-ICK4 CS (see *Figure 13*) operably linked to the gluteline promoter.

Figure 19 depicts the genomic fragment corresponding to the full-length
20 OsICK4 cDNA.

Figure 20 depicts the genomic fragment corresponding to the predicted full-length OsICK5 cDNA. The depicted fragment (SEQ ID NO:56) corresponds to the inverse complement of nucleotides 6331 to 7403 of GenBank accession number AP003525.1 as available on June 26, 2001. Indicated in grey shaded boxes are the
25 positions of the primers (SEQ ID NO:57 and 58) used to amplify the OsICK5 genomic fragment.

Figure 21 depicts the predicted full-length OsICK5 cDNA sequence (SEQ ID NO:54; panel A) and the full-length OsICK5 protein sequence deduced thereof (SEQ ID NO:55; panel B). Uncertain residues in the predicted cDNA are indicated by 'N' and
30 marked by a grey shaded box. The translation of the uncertain nucleotide residues in the cDNA result in an uncertain amino acid residue 'X' in the deduced protein sequence also marked by a grey shaded box. Further indicated in panel (A) in grey shaded boxes

are the positions of the primers (SEQ ID NO:57 and 58) used to amplify the OsICK5 cDNA. Indicated in black shaded boxes are the start and the stop codon.

Detailed Description Of The Invention

5 The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as "Inhibitors of Cyclin Dependent Kinases" or "ICK" nucleic acid and polypeptide molecules. In particular, the present invention is based on the discovery of the first monocotyledonous (monocot), *e.g.*, cereal, ICK molecule. The ICK molecules of the present invention were identified by database mining using the
10 "GRYEW" amino acid motif as a query sequence. This motif is present at the carboxyl-terminus of all known plant ICK molecules.

As used herein, the terms "Inhibitors of Cyclin Dependent Kinases" and "ICK" include molecules of the present invention which are capable of inhibiting the activity of a Cyclin Dependent Kinase (CDK), *e.g.*, a plant CDK. CDKs are a group of
15 serine/threonine kinases which regulate the progression of the cell cycle in eukaryotes, *e.g.*, plants. CDKs are typically complexed with cyclins forming an enzyme complex, CDK being the catalytic subunit and cyclin being the regulatory subunit of the enzyme complex (Wang, H. (1997) *The Plant Journal* 15(4):501-510). ICK molecules of the present invention, *e.g.*, ICK molecules from a monocot plant such as rice, typically have
20 one or more of the following activities: inhibition of CDK activity (*e.g.*, cyclin-CDK activity); regulation of cyclin-CDK complex assembly; regulation of the commitment of cells to divide, *e.g.*, by integrating mitogenic and antimitogenic signals; regulation of cell cycle progression; regulation of DNA replication and/or DNA repair; they regulate gene transcription; regulation of cyclin degradation; involvement in cell cycle
25 withdrawal and/or cell differentiation; regulation of cell death, *e.g.*, apoptosis; control of organ (*e.g.*, plant organ) and/or organism (*e.g.*, plant organism) size; and regulation of endoreduplication.

As used herein, the term "cell cycle" includes the cyclic biochemical and structural events associated with growth, division, and proliferation of cells, and in
30 particular with the regulation of the replication of DNA and mitosis. The cell cycle is divided into periods called: G₀, Gap₁ (G₁), DNA synthesis (S), Gap₂ (G₂), and mitosis (M). Normally these four phases occur sequentially, however, the term cell cycle also includes modified cycles wherein one or more phases are absent resulting in a modified cell cycle such as endomitosis, acytokinesis, polyploidy, polyteny, and
35 endoreduplication.

As used herein, the term "plant" includes whole plants, plant organs (*e.g.*, leaves, stems, or roots), plant tissue, plant seeds, and plant cells and progeny thereof. The class of plants which can be used in the methods of the invention is generally as broad as the

- class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. Particularly preferred plants are *Arabidopsis thaliana*, rice, wheat, barley, sorghum, maize, tomato, potato, cotton, alfalfa, oilseed rape, soybean, cotton, sunflower or canola. The term plant also includes
- 5 monocotyledonous (monocot) plants and dicotyledonous (dicot) plants including a fodder or forage legume, ornamental plants, food crops, trees, or shrubs selected from the list comprising *Acacia* spp., *Acer* spp., *Actinidia* spp., *Aesculus* spp., *Agathis australis*, *Albizia amara*, *Alsophila tricolor*, *Andropogon* spp., *Arachis* spp., *Areca catechu*, *Astelia fragrans*, *Astragalus cicer*, *Baikiaea plurijuga*, *Betula* spp., *Brassica*
 - 10 spp., *Bruguiera gymnorhiza*, *Burkea africana*, *Butea frondosa*, *Cadaba farinosa*, *Calliandra* spp., *Camellia sinensis*, *Canna indica*, *Capsicum* spp., *Cassia* spp., *Centroema pubescens*, *Chaenomeles* spp., *Cinnamomum cassia*, *Coffea arabica*, *Colophospermum mopane*, *Coronillia varia*, *Cotoneaster serotina*, *Crataegus* spp., *Cucumis* spp., *Cupressus* spp., *Cyathea dealbata*, *Cydonia oblonga*, *Cryptomeria*
 - 15 *japonica*, *Cymbopogon* spp., *Cynthea dealbata*, *Cydonia oblonga*, *Dalbergia monetaria*, *Davallia divaricata*, *Desmodium* spp., *Dicksonia squarrosa*, *Diheteropogon amplexans*, *Dioclea* spp., *Dolichos* spp., *Dorycnium rectum*, *Echinochloa pyramidalis*, *Ehrartia* spp., *Eleusine coracana*, *Eragrostis* spp., *Erythrina* spp., *Eucalyptus* spp., *Euclea schimperi*, *Eulalia villosa*, *Fagopyrum* spp., *Feijoa sellowiana*, *Fragaria* spp., *Flemingia* spp.,
 - 20 *Freycinetia banksii*, *Geranium thunbergii*, *Ginkgo biloba*, *Glycine javanica*, *Gliricidia* spp., *Gossypium hirsutum*, *Grevillea* spp., *Guibourtia coleosperma*, *Hedysarum* spp., *Hemarthia altissima*, *Heteropogon contortus*, *Hordeum vulgare*, *Hyparrhenia rufa*, *Hypericum erectum*, *Hyperthelia dissoluta*, *Indigo incarnata*, *Iris* spp., *Leptarrhena pyrolifolia*, *Lespedeza* spp., *Lettuca* spp., *Leucaena leucocephala*, *Loudetia simplex*,
 - 25 *Lotonous bainesii*, *Lotus* spp., *Macrotyloma axillare*, *Malus* spp., *Manihot esculenta*, *Medicago sativa*, *Metasequoia glyptostroboides*, *Musa sapientum*, *Nicotianum* spp., *Onobrychis* spp., *Ornithopus* spp., *Oryza* spp., *Peltophorum africanum*, *Pennisetum* spp., *Persea gratissima*, *Petunia* spp., *Phaseolus* spp., *Phoenix canariensis*, *Phormium cookianum*, *Photinia* spp., *Picea glauca*, *Pinus* spp., *Pisum sativum*, *Podocarpus totara*,
 - 30 *Pogonarthria fleckii*, *Pogonarthria squarrosa*, *Populus* spp., *Prosopis cineraria*, *Pseudotsuga menziesii*, *Pterolobium stellatum*, *Pyrus communis*, *Quercus* spp., *Rhaphiolepis umbellata*, *Rhopalostylis sapida*, *Rhus natalensis*, *Ribes grossularia*, *Ribes* spp., *Robinia pseudoacacia*, *Rosa* spp., *Rubus* spp., *Salix* spp., *Schyzachyrium sanguineum*, *Sciadopitys verticillata*, *Sequoia sempervirens*, *Sequoiadendron*
 - 35 *giganteum*, *Sorghum bicolor*, *Spinacia* spp., *Sporobolus fimbriatus*, *Stiburus alopecuroides*, *Stylosanthos humilis*, *Tadehagi* spp., *Taxodium distichum*, *Themeda triandra*, *Trifolium* spp., *Triticum* spp., *Tsuga heterophylla*, *Vaccinium* spp., *Vicia* spp., *Vitis vinifera*, *Watsonia pyramidata*, *Zantedeschia aethiopica*, *Zea mays*, amaranth,

artichoke, asparagus, broccoli, brussel sprout, cabbage, canola, carrot, cauliflower, celery, collard greens, flax, kale, lentil, oilseed rape, okra, onion, potato, rice, soybean, straw, sugarbeet, sugar cane, sunflower, tomato, squash, and tea, amongst others, or the seeds of any plant specifically named above or a tissue, cell or organ culture of any of the above species.

The term "plant cell", as used herein includes seeds, *e.g.*, seed suspension cultures, embryos, cells from meristematic regions, cells from callus tissue, cells from leaves, cells from roots, cells from shoots, gametophytes, sporophytes, pollen, and microspores.

The ICK molecules of the present invention are involved in cell cycle regulation in plants. Accordingly, the ICK molecules of the present invention, or derivatives thereof, may be used to modulate the cell cycle in a plant by, for example, modulating the activity or level of expression of ICK; altering the rate of the cell cycle or phases of the cell cycle; or altering entry into and out of the various cell cycle phases. In plants, the ICK molecules of the present invention may be used in agriculture to, for example, improve the growth characteristics of a plant such as the growth rate of a plant; the size of specific tissues or organs in a plant; or the architecture or morphology of a plant. The ICK molecules of the present invention may also be used in agriculture to increase crop yield, improve tolerance to environmental stress conditions (such as drought, salt, temperature, or nutrient deprivation), improve tolerance to plant pathogens that abuse the cell cycle, or as targets to facilitate the identification of inhibitors or activators of ICKs that may be useful as herbicides or plant growth regulators.

As used herein, the term "cell cycle associated disorders" includes a disorder, disease or condition which is caused or characterized by a misregulation (*e.g.*, downregulation or upregulation), abuse, arrest, or modification of the cell cycle. In plants cell cycle associated disorders include endomitosis, acytokinesis, polyploidy, polyteny, and endoreduplication which may be caused by external factors such as pathogens (nematodes, viruses, fungi, or insects), chemicals, environmental stress (*e.g.*, drought, temperature, nutrients, or UV light) resulting in, for example, neoplastic tissue (*e.g.*, galls, root knots) or inhibition of cell division/proliferation (*e.g.*, stunted growth).

The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as ICK protein and nucleic acid molecules, which comprise a family of molecules having certain conserved structural and functional features. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family

can contain a first protein of plant, *e.g.*, rice, origin, as well as other, distinct proteins of plant, *e.g.*, rice, origin or alternatively, can contain homologues of other plant, *e.g.* wheat or maize, or of non-plant origin. Members of a family may also have common functional characteristics.

- 5 In one embodiment of the invention, an ICK protein of the present invention, *e.g.*, an ICK protein from a monocot plant such as rice, is identified based on the presence of at least one or more of the following motifs:

- 10 **Motif 1:** FXXKYNFD (SEQ ID NO:18), wherein X is any amino acid
Motif 2: [P/L]LXGRYEW (SEQ ID NO:19), wherein X is any amino acid and [P/L] means that either a proline or a leucine appear at the indicated position
Motif 3: EXE[D/E]FFXXXE (SEQ ID NO:20), wherein X is any amino acid and [D/E] means that either an aspartate or a glutamate appear at the indicated position
15 **Motif 4:** YXQLRSRR (SEQ ID NO:21), wherein X is any amino acid
Motif 5: MGKY[M/I][K/R]KX[K/R] (SEQ ID NO:22), wherein X is any amino acid, [M/I] means that either a methionine or an isoleucine appear at the indicated position, and [K/R] means that either a lysine or an arginine appear at the indicated position
20 **Motif 6:** SXGVRTRA (SEQ ID NO:23), wherein X is any amino acid

(The foregoing motifs are summarized in Table 1 and graphically represented in Figure 4).

- 25 In a preferred embodiment, an ICK molecule of the present invention, *e.g.*, an ICK molecule from a monocot plant such as rice, contains two, three, four, five, or, more preferably, all six of the foregoing motifs. All six motifs are present in the full-length OsICK2 (SEQ ID NO:10), full-length OsICK4 (SEQ ID NO:44) and predicted full-length OsICK5 (SEQ ID NO:55) proteins of the present invention. Although motifs 2 and 5 are present in the predicted full-length OsICK5 protein, they deviate from the
30 consensus sequences.

- Motifs 1, 2, and 3 are typically found in the carboxyl-terminal region of plant ICK proteins. This region is believed to be involved in the interaction of ICKs with both CDKs and cyclins (Chen *et al.* (1996) *Mol. Cell Biol* 16, 4673-4682, Matsuoka *et al.* (1995) *Genes Dev.* 9, 650-662, and Nakayama and Nakayama (1998) *Bioessays* 20,
35 1020-1029). Motifs 4, 5, and 6 are typically found in the amino-terminal region of plant ICK proteins.

Table 1. Conserved motifs in plant ICK proteins. ICK1 to ICK7 denote the *Arabidopsis thaliana* ICKs.

	Motif 1	Motif 2	Motif 3	Motif 4	Motif 5	Motif 6
Alfalfa ICK	198- FMEKYNFD	211- PLPGRYET	182- EFEEFCAKHE	74 - YLQLRSRR	1- MGKYMKKLK	45- SDGVRTRA
ICK1 AC003040	167- FKKKYNFD	180- PLEGRYEW	151- EIEDFFVEAE	20 - YMQLRSRR		
ICK2 AL132979	183- CSMKYNFD	197- LGGGRYEW	164- ELEDFFQVAE			
ICK3 AB012242	197- FMEKYNFD	210- PLSGRYEW	181- EMEEFFAYAE	58 - YLQLRSRR	1- MGKYMKKSK	26- SPGVRTRA
ICK4 AC003974	264- FIEKYNFD	277- PLPGRFEW	248- EMDEFFSGAE	102- YLQLRSRR	1- MGKYIRKSK	44- SLGVLTRA
ICK5 AB028609	164- FIQKYNFD	177- PLPGRYEW	148- EIEDFFASAE	54- YLQLRSRR	1- MGKYIKKSK	24- ALGFRTRA
ICK6 AP000419	173- FIEKYNFD	186- PLEGRYKW	155- ETEDLFSELE			
ICK7 AC011807	170- FTEKYNFD	183- PLEGRYQW	154- ELDDFFSAAE			
Chenopodium ICK AJ002173	171- FSEKYNFD	184- PLKGRYDW	155- EIEEFFAVAE	25- IPQLRSRR		
OsICK2	233- FAAKYNFD	247- LDAGRFEW	217- EIEAFFAAAE	75- YLQLRSRM	1- MGKYMRRFR	24- VVGVRTRS
OsICK1	----YNYD	PLQGRYEW				
OsICK3	FAEKY---		EIEAFFAAAE			
OsICK4	170- FIDKYNFD	183- PLPGRFEW	154- ELEAFFAAEE	48- YLELRSRR	1- MGKYMRRKAK	28- PLGVRTRA
OsICK5	196- FAAKYNFD	209- PLDAGGAGRF EW	180- EIEEFFLAAAE	63- YLRLRSRR	1- MGKKKKRDG	20- VGGVRTRA
ZmICK1	FASKYNFD	LDAGRFEW	EIQEFFAAAE			
ZmICK2	FIDKYNFD	PLPGRFEW	EMNEYFAAEQ			
SbICK	FAEAYNYD	PLEGRFEW	EIEAFFAAAE			
CONSENSUS	FX ₂ KYNFD	[P/L]LXGR[Y/F]EW	EXE[D/E]FFX ₂ E	YXQLRSRR	MGKY[W/I][K/ R]KX[K/R]	SXGVRTRA

- 5 The ICK proteins of the present invention from a monocot plant such as rice, in particular, are characterized by extensive α -helical stretches especially in between motifs 5 and 6 and in between motifs 6 and 4. Furthermore, in the ICK proteins of the present invention from a monocot plant such as rice, the region between motifs 4 and 3, only contains predicted α -helical segments and no extended β -sheets. These secondary

structure characteristics of the ICK proteins from a monocot plant such as rice, are different from those found in alfalfa ICK and *Arabidopsis* ICKs ICK3, ICK4 and ICK5.

In another embodiment of the invention, an ICK protein of the present invention, *e.g.*, an ICK protein from a monocot plant such as rice, is identified based on the presence of a "Cy-box." As used herein, the term "Cy-Box" includes an amino acid sequence of about 5 amino acid residues in length having the consensus sequence RXHuF (SEQ ID NO:24), wherein X is any amino acid and Hu is a hydrophobic uncharged amino acid, such as M, I, L or V (see Figure 5). Cy-boxes are typically involved in the interaction of ICKs with cyclins. Amino acid residues 81-84 of the OsICK2 protein (SEQ ID NO:10) are predicted to comprise a Cy-box (RMLF).

In another embodiment of the invention, an ICK protein of the present invention, *e.g.*, an ICK protein from a monocot plant such as rice, is identified based on the presence of a "nuclear localization sequence." As used herein, the term "nuclear localization sequence" includes an amino acid sequence of about 4-20 amino acid residues in length, which serves to direct a protein to the nucleus. Typically, the nuclear localization sequence is rich in basic amino acids, such as arginine (R) and lysine (K). A nuclear localization signal may have one or more of the sequences depicted in Table 2. Nuclear localization signals are described in, for example, Gorlich D. (1998) EMBO 5.17:2721-7, the contents of which are incorporated herein by reference. Amino acid residues 54-57 of the OsICK2 protein (SEQ ID NO:10) comprise a nuclear localization sequence. The Os ICK4 protein (SEQ ID NO:44) comprises multiple nuclear localization sequences as indicated in Table 2. Also the predicted full-length OsICK5 (SEQ ID NO:55) protein comprises an amino-terminal nuclear localization region (see Table 2).

Table 2: Potential nuclear localization sequences (NLSs) identified in plant ICKs using the PSORT/Prediction of protein localization sites software (<http://psort.nibb.ac.jp>).

	NLS type	
ICK	4-residue pattern	Robbins & Dingwall consensus
Alfalfa ICK		80 ^a -RRLKRPLIRQHSAKRNK
Chenopodium ICK		15-KKVSKSSYNIPQLRSRR
ICK2	23-KRRK	
ICK4	123-KRRK 240-HRRR 241-RRRP	108-RRLQKKPPIVVIRSTKR 112-KKPPIVVIRSTKRRKQQ
ICK5		60-RRLVKLPLLTNTRKQQK

ICK7	5-KPKR 142-KKKK	
OsICK2 ^b	54-RRRK	
OsICK5	3-KKKK 4-KKKR	

^aPosition of the first amino acid of the site in the amino acid sequence of the indicated ICK.

^bIdentification of the OsICK2 NLSs was done manually, i.e., the protein sequence was not analyzed using the public PSORT software on the indicated Website.

- 5 PSORT uses the following two rules to detect it: 4 residue pattern composed of basic amino acids (K or R), or composed of three basic amino acids (K or R) and H or P; a pattern starting with P and followed within 3 residues by a basic segment containing 3 K or R residues out of 4 residues. Another type of nuclear targeting signal is the type of Xenopus nucleoplasmin proposed by Robbins et al. (J. Robbins, S. M. Dilworth, R. A. Laskey, and C. Dingwall, Cell, 64, 615, 1991). The pattern is: 2 basic residues, 10 residue spacer, and another basic region consisting of at least 3 basic residues out of 5 residues.

In a further embodiment of the invention, an ICK protein of the present invention, e.g., an ICK protein from a monocot plant such as rice, is identified based on the presence of a "PEST sequence." As used herein, the term "PEST sequence" includes an amino acid sequence which is enriched in the amino acid residues proline (P), glutamate (E), serine (S) and threonine (T) and which is present in proteins with a high proteolytic turnover rate. PEST sequences are described in, for example, Rogers *et al.* (1986) *Science* 234, 364-368, the contents of which are incorporated herein by reference. Amino acid residues 167-191 of the OsICK2 protein, amino acid residues 117-131 of the OsICK4 protein and amino acid residues 128-145 of the predicted full-length OsICK5 protein comprise potential PEST sequences (see Table 3).

Table 3: Potential PEST sequences identified in the plant ICKs using the PESTFIND software downloaded from <http://www.ebi.ac.uk> and run on a local server.

ICK	Potential PEST sequences	PEST score
Alfalfa ICK	11 ^a - KSESPSPNSTPTPSPSPSPTPITTNSPPPTTPNSSDGVR	+24.12
Chenopodium ICK	105-RTADPEVESGEASSK	+11.43

ICK2	71-RDSPPVEEQCQIEEDSSVSCCSTSEEK	+15.46
ICK4	243-RPTTPMEMDEFFSGAEEQK	+9.21
ICK5	100-KLEPDTTTEEACGDNER	+13.68
ICK6	24-KLNDSSDSSPDSH	+12.76
	118-KETSPVSEGLGETTTEMESSATK	+15.73
	149-KTPTAAEIEDLFSELESQDDK	+8.59
OsICK2	167-RETPSSFLPGEVSDLESFLAGGQK	+4.75
OsICK4	117-RDPDTISTPGSTTR	+13.74
OsICK5	128-RPPGDADSSDAESNQEAK	+13.12

^aPosition of the first amino acid of the site in the amino acid sequence of the indicated ICK.

Isolated ICK proteins of the present invention, *e.g.*, ICK proteins from a monocot plant such as rice, have an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44 or 55, or are encoded by a nucleotide sequence sufficiently identical to SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (*e.g.*, an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%, or 50% identity, preferably 60% identity, more preferably 70%-80%, and even more preferably 90-95% identity across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently identical. Furthermore, amino acid or nucleotide sequences which share at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% identity and share a common functional activity are defined herein as sufficiently identical.

As used interchangeably herein, an "ICK activity", "biological activity of ICK" or "functional activity of ICK", refers to an activity exerted by an ICK protein, polypeptide or nucleic acid molecule on an ICK responsive cell or tissue, or on an ICK protein substrate, as determined *in vivo*, or *in vitro*, according to standard techniques. In one embodiment, an ICK activity is a direct activity, such as an association with an ICK-target molecule, *e.g.*, a CDK or a cyclin molecule. Such interactions have been experimentally demonstrated in the current invention. As used herein, a "target molecule" or "binding partner" is a molecule with which an ICK protein binds or interacts in nature, such that ICK-mediated function is achieved. An ICK target molecule can be a non-ICK molecule, *e.g.*, a CDK or a cyclin molecule, or an ICK

protein or polypeptide of the present invention. In an exemplary embodiment, an ICK target molecule is an ICK ligand. Alternatively, an ICK activity is an indirect activity, such as a cellular signaling activity mediated by interaction of the ICK protein with an ICK ligand. The biological activities of ICK are described herein. For example, the

- 5 ICK proteins of the present invention can have one or more of the following activities: (1) they may inhibit CDK activity (*e.g.*, cyclin-CDK activity); (2) they may regulate cyclin-CDK complex assembly; (3) they may regulate the commitment of cells to divide, *e.g.*, by integrating mitogenic and antimitogenic signals; (4) they may regulate cell cycle progression; (5) they may regulate DNA replication and/or DNA repair; (6) 10 they may regulate gene transcription; (7) they may regulate cyclin degradation; (8) they may be involved in cell cycle withdrawal and/or cell differentiation; (9) they may regulate cell death, *e.g.*, apoptosis; (10) they may control organ (*e.g.*, plant organ) and/or organism (*e.g.*, plant organism) size; and (11) they may regulate endoreduplication.

Accordingly, another embodiment of the invention features isolated ICK proteins 15 and polypeptides having an ICK activity. Preferred proteins are ICK proteins, *e.g.*, ICK proteins from a monocot plant such as rice, having at least one or more of the following domains: a motif 1, a motif 2, a motif 3, a motif 4, a motif 5, a motif 6, a Cy-box, a nuclear localization sequence, or a PEST sequence, extensive α -helical stretches, *e.g.*, in between motifs 5 and 6, in between motifs 6 and 4, and in between motifs 4 and 3, and, 20 preferably, an ICK activity.

Additional preferred proteins, *e.g.*, ICK proteins from a monocot plant such as rice, have at least one or more of the following domains: a motif 1, a motif 2, a motif 3, a motif 4, a motif 5, a motif 6, a Cy-box, a nuclear localization sequence, or a PEST sequence, extensive α -helical stretches, *e.g.*, in between motifs 5 and 6, in between 25 motifs 6 and 4, and in between motifs 4 and 3, and are, preferably, encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56.

30 The sequences of the present invention are summarized below, in Table 4.

Table 4

CLONE	ORGANISM	DNA SEQUENCE	PROTEIN SEQUENCE
OsICK1 (AQ574895)	<i>Oryza sativa</i>	2	11
OsICK2	<i>Oryza sativa</i>	1 (partial length) 9	10

		(full length)	
OsICK3 (AQ365042)	<i>Oryza sativa</i>	3	12
OsICK4 (AC069145)	<i>Oryza sativa</i>	4 (partial length) 43 (full length) 45 (genomic fragment)	13 (partial length) 44 (full length)
OsICK5 (AP003525)	<i>Oryza sativa</i>	54 (predicted cDNA) 56 (genomic fragment)	55 (predicted protein)
ZmICK1 (AI737717)	<i>Zea mays</i>	5	14
ZmICK2 (AW267370)	<i>Zea mays</i>	6	15
SbICK (AF061282)	<i>Sorghum bicolor</i>	7	16
PtICK (AA556411)	<i>Pinus taeda</i>	8	17

Various aspects of the invention are described in further detail in the following subsections:

5

I. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in agricultural methods and screening assays. The isolated nucleic acid molecules of the invention can be used, for example, to express an ICK protein (e.g., via a recombinant expression vector in a host cell), to detect ICK mRNA (e.g., in a biological sample) or a genetic alteration in an ICK gene, and to modulate ICK activity, as described further below. The ICK proteins can be used to treat disorders characterized by insufficient or excessive production of an ICK substrate or production of ICK inhibitors. In addition, the ICK proteins can be used to screen for naturally occurring ICK substrates, to screen for drugs or compounds which modulate ICK activity, as well as to treat disorders characterized by insufficient or excessive production of ICK protein or production of ICK protein forms which have decreased or

aberrant activity compared to ICK wild type protein. Moreover, the anti-ICK antibodies of the invention can be used to detect and isolate ICK proteins, regulate the bioavailability of ICK proteins, and modulate ICK activity.

5 A. Agricultural Uses:

In another embodiment of the invention, a method is provided for modifying cell fate and/or plant development and/or plant morphology and/or biochemistry and/or physiology comprising the modification of expression in particular cells, tissues or organs of a plant, of a genetic sequence encoding an ICK, *e.g.*, an ICK operably
10 connected with a plant-operable promoter sequence.

Modulation of the expression in a plant of an ICK or a homologue, analogue or derivative thereof as defined in the present invention can produce a range of desirable phenotypes in plants, such as, for example, the modification of one or more morphological, biochemical, or physiological characteristics including: (i) modification
15 of the length of the G1 and/or the S and/or the G2 and/or the M phase of the cell cycle of a plant; (ii) modification of the G1/S and/or S/G2 and/or G2/M and/or M/G1 phase transition of a plant cell; (iii) modification of the initiation, promotion, stimulation or enhancement of cell division; (iv) modification of the initiation, promotion, stimulation or enhancement of DNA replication; (v) modification of the initiation, promotion,
20 stimulation or enhancement of seed set and/or seed size and/or seed development; (vi) modification of the initiation, promotion, stimulation or enhancement of tuber formation; (vii) modification of the initiation, promotion, stimulation or enhancement of fruit formation; (viii) modification of the initiation, promotion, stimulation or enhancement of leaf formation; (ix) modification of the initiation, promotion,
25 stimulation or enhancement of shoot initiation and/or development; (x) modification of the initiation, promotion, stimulation or enhancement of root initiation and/or development; (xi) modification of the initiation, promotion, stimulation or enhancement of lateral root initiation and/or development; (xii) modification of the initiation, promotion, stimulation or enhancement of nodule formation and/or nodule function;
30 (xiii) modification of the initiation, promotion, stimulation or enhancement of the bushiness of the plant; (xiv) modification of the initiation, promotion, stimulation or enhancement of dwarfism in the plant; (xv) modification of the initiation, promotion, stimulation or enhancement of senescence; (xvi) modification of stem thickness and/or strength characteristics and/or wind-resistance of the stem and/or stem length; (xvii)
35 modification of tolerance and/or resistance to biotic stresses such as pathogen infection; and (xviii) modification of tolerance and/or resistance to abiotic stresses such as drought stress or salt stress.

Methods to effect expression of an ICK or a homologue, analogue or derivative thereof as defined in the present invention in a plant cell, tissue or organ, include either the introduction of the protein directly to a cell, tissue or organ such as by microinjection of ballistic means or, alternatively, introduction of an isolated nucleic acid molecule encoding the protein into the cell, tissue or organ in an expressible format. Methods to effect expression of an ICK or a homologue, analogue or derivative thereof as defined in the current invention in whole plants include regeneration of whole plants from the transformed cells in which an isolated nucleic acid molecule encoding the protein was introduced in an expressible format.

10 The present invention clearly extends to any plant produced by the inventive method described herein, and any and all plant parts and propagules thereof. The present invention extends further to encompass the progeny derived from a primary transformed or transfected cell, tissue, organ or whole plant that has been produced by the inventive method, the only requirement being that the progeny exhibits the same
15 genotypic and/or phenotypic characteristic(s) as those characteristic(s) that (have) been produced in the parent by the performance of the inventive method.

Exploiting plant ICK functions to regulate plant growth and development can depend on methods comprising enhancing ICK gene expression or ectopic expression of ICK genes. For example, a method for exploiting plant ICK function comprises
20 suppression of ICK gene expression, thus, relieving negative control on cell cycle progression and positive control on cell differentiation.

In a preferred embodiment of the invention the cell cycle progression rate is modified by downregulation of expression of a plant ICK protein or a homologue or derivative thereof as defined in the present invention. ICK molecules interact with and
25 inhibit the activity of cell cycle control molecules, *e.g.*, Cdc2-related protein kinases or cyclins. Accordingly, decreased levels of ICK molecules result in a significant acceleration of the cell cycle progression. Downregulation of the expression of ICK can promote and extend cell division activity in cells that normally become quiescent during the course of development and/or as a consequence of adverse growth conditions and/or
30 as a consequence of stress conditions. Downregulation of expression of ICK can, thus, be expected to increase the frequency of the formation of lateral organs including leaves (resulting in increased bushiness), flowers (resulting in increased numbers of seeds or seed pods) and roots (resulting in increased numbers of lateral roots). The timing of lateral organ formation can also be altered, *e.g.*, resulting in earlier flowering. Another
35 expected effect of delaying cells to become quiescent is the delayed occurrence of senescence. Downregulation of expression of ICK is furthermore expected to enhance growth under conditions of, *e.g.*, salt or drought stress.

When downregulation of expression of ICK is occurring at the whole plant level, an overall growth enhancing effect is to be expected, i.e., recombinant plants will grow faster and/or will reach a larger size. This is particularly useful to increase the yield of, e.g., fodder plants, forage plants, leguminous plants, and wood-producing plants.

- 5 Alternatively, downregulation of expression of ICK at the whole plant level may result in local growth enhancing effects, e.g., due to local and specific expression of the plant cellular proteins specifically targeted by said ICK. When downregulation of expression of ICK is confined to single cells, tissues, or organs of a plant, the growth enhancing effect will be confined to the single cells, tissues or organs of the plant. Particularly
10 useful are restrictions of downregulation of expression of ICK to tissues or organs including seeds, fruits, tubers, roots, shoots, stems, and nodules to increase yield and/or size of these tissues or organs.

- Thus, a preferred embodiment of the present invention involves downregulation of expression of an ICK protein or a homologue or derivative thereof as defined herein,
15 in a plant cell and/or tissue and/or organ to obtain enhanced growth and/or delayed senescence of the plant cell and/or tissue and/or organ, or to obtain enhanced formation of lateral organs from the plant tissue and/or organ.

- In another preferred embodiment downregulation of expression of an ICK protein or a homologue or derivative thereof as defined herein, in a whole plant results
20 in enhanced growth and/or in increased frequency of lateral organ formation and/or delayed senescence of the plant.

- Plant cells in which expression of an ICK is downregulated are furthermore expected to be stimulated to go through endoreduplication cycles, i.e., passage through consecutive cell cycles including DNA replication but without intervening cytokinesis.
25 Cells undergoing endoreduplication, thus, become polyploid.

- Downregulation of expression of ICK can further be used to increase seed yield and/or seed size. Grain yield in crop plants is largely a function of the amount of starch produced in the endosperm of the seed. The amount of protein produced in the endosperm is also a contributing factor to grain yield (Traas *et al.* (1998) *Current Opin.*
30 *Plant Biol.* 1, 498-503). In contrast, the embryo and aleurone layers contribute little in terms of the total weight of the mature grain. By virtue of being linked to cell expansion and metabolic activity, endoreduplication is generally considered to be an important factor for increasing yield. As grain endosperm development initially includes extensive endoreduplication (Olsen *et al.* (1999) *Trends Plant Sci.* 4, 253-257),
35 enhancing, promoting or stimulating this process is likely to result in increased grain yield. Enhancing, promoting or stimulating cell division during seed development as described *supra* is an alternative way to increase grain yield. In another aspect, the present invention also features a method for the production of SiO₂ from the peels or

husks of larger rice seeds. Methods for extraction and/or production of pure SiO₂ from rice seed peels or husks are known in the art (e.g. Gorthy and Pudukottah 1999) and units for production of SiO₂ from rice seed peels are being set up (visit e.g. <http://bisnis.doc.gov/bisnis/leads/990604sp.htm>). SiO₂ has many applications including electronics, perfume industry and pharmacology and silicone production.

Another embodiment of the current invention comprises cell cycle stage-specific, developmental stage-specific and/or tissue-specific downregulation of expression of an ICK protein or a homologue or derivative thereof as defined herein. Downregulation of ICK expression can be obtained by using nucleotide sequences distinguishing alternatively polyadenylated transcripts of ICK (see Example 4). This approach has potential advantages such as, e.g., the fact that a constitutive promoter can be used to downregulate expression of ICK instead of a cell cycle phase-specific, developmental stage-specific or tissue-specific promoter.

In yet another preferred embodiment of the invention the cell cycle progression rate is significantly modified by ectopic expression of an ICK protein or a homologue or derivative thereof as defined herein. As ICK molecules interact with and inhibit the activity of cell cycle control, e.g., CDK, molecules, elevated levels of ICK result in a significant inhibition of the cell cycle progression. Thus, effects opposite to those obtainable as described for downregulation of expression of ICK can be expected. These opposite effects have useful applications as described *infra*. Ectopic expression of ICK at the whole plant level can, e.g., create dwarfism. Ectopic expression of ICK in specific cells, tissues or organs can be used to inhibit side shoot formation in crops such as tomato. Ectopic expression of ICK may also confer enhanced resistance to pathogens causing neoplastic plant growth, such as plant pathogenic bacteria including *Agrobacterium tumefaciens*, *Rhodococcus fascians*, *Pseudomonas savastnoi*, *Xanthomonas campestris pv citri* and *Erwinia herbicola*, plant pathogenic fungi including *Plasmodiophora brassicae*, *Crinipellis pernicioso*, *Pucciniastrum geoppertianum*, *Taphrina wiesneri*, *Ustilaga maydis*, *Exobasidium vaccinii*, *E. camelliae*, *Entorrhiza casparyana* and *Apiosporina morbosum*.

Ectopic expression of an ICK molecule may also confer enhanced resistance or tolerance against pathogens which rely on endoreduplication events in the infected host cells to survive. The ectopic expression of ICK is expected to inhibit endoreduplication events. Pathogens relying on host cell endoreduplication to, for example, establish a feeding structure, include nematodes such as *Heterodera* species and *Meloidogyne* species.

As used herein, the terms "ectopic expression" or "ectopic overexpression" of a gene or a protein refer to expression patterns and/or expression levels of the gene or protein normally not occurring under natural conditions.

By "cell fate and/or plant development and/or plant morphology and/or biochemistry and/or physiology" is meant that one or more developmental and/or morphological and/or biochemical and/or physiological characteristics of a plant is altered by the performance of one or more steps pertaining to the invention described
5 herein.

"Cell fate" includes the cell-type or cellular characteristics of a particular cell that are produced during plant development or a cellular process therefor, in particular during the cell cycle or as a consequence of a cell cycle process.

The term "plant development" or the term "plant developmental characteristic" or similar terms shall, when used herein, be taken to mean any cellular process of a plant
10 that is involved in determining the developmental fate of a plant cell, in particular the specific tissue or organ type into which a progenitor cell will develop. Cellular processes relevant to plant development will be known to those skilled in the art. Such processes include, for example, morphogenesis, photomorphogenesis, shoot development, root
15 development, vegetative development, reproductive development, stem elongation, flowering, and regulatory mechanisms involved in determining cell fate, in particular a process or regulatory process involving the cell cycle.

The term "plant morphology" or the term "plant morphological characteristic" or similar term will, when used herein, be understood by those skilled in the art to include
20 the external appearance of a plant, including any one or more structural features or combination of structural features thereof. Such structural features include the shape, size, number, position, color, texture, arrangement, and patterning of any cell, tissue or organ or groups of cells, tissues or organs of a plant, including the root, stem, leaf, shoot, petiole, trichome, flower, petal, stigma, style, stamen, pollen, ovule, seed,
25 embryo, endosperm, seed coat, aleurone, fiber, fruit, cambium, wood, heartwood, parenchyma, aerenchyma, sieve element, phloem or vascular tissue.

The term "plant biochemistry" or the term "plant biochemical characteristic" or similar term will, when used herein, be understood by those skilled in the art to include the metabolic and catalytic processes of a plant, including primary and secondary
30 metabolism and the products thereof, including any small molecules, macromolecules or chemical compounds, such as but not limited to starches, sugars, proteins, peptides, enzymes, hormones, growth factors, nucleic acid molecules, celluloses, hemicelluloses, calloses, lectins, fibbers, pigments such as anthocyanins, vitamins, minerals, micronutrients, or macronutrients, that are produced by plants.

35 The term "plant physiology" or the term "plant physiological characteristic" or similar term will, when used herein, be understood to include the functional processes of a plant, including developmental processes such as growth, expansion and differentiation, sexual development, sexual reproduction, seed set, seed development, grain filling,

asexual reproduction, cell division, dormancy, germination, light adaptation, photosynthesis, leaf expansion, fiber production, secondary growth or wood production, amongst others; responses of a plant to externally-applied factors such as metals, chemicals, hormones, growth factors, environment and environmental stress

5 factors (*e.g.*, anoxia, hypoxia, high temperature, low temperature, dehydration, light, day length, flooding, salt, heavy metals, amongst others), including adaptive responses of plants to said externally-applied factors.

The ICK molecules of the present invention are useful in agriculture. The nucleic acid molecules, proteins, protein homologues, and antibodies described herein

10 can be used to modulate the protein levels or activity of a protein involved in the cell cycle, *e.g.*, proteins involved in the G1/S and/or the G2/M transition in the cell cycle.

Thus, the ICK molecules of the present invention may be used to modulate, *e.g.*, enhance, crop yields; modulate, *e.g.*, attenuate, stress, *e.g.*, heat or nutrient deprivation, tolerance; modulate tolerance to pests and diseases; modulate plant architecture;

15 modulate plant quality traits; or modulate plant reproduction and seed development.

The ICK molecules of the present invention may also be used to modulate endoreduplication in storage cells, storage tissues, and/or storage organs of plants or parts thereof. The term "endoreduplication" includes recurrent DNA replication without consequent mitosis and cytokinesis. Preferred target storage organs and parts thereof for

20 the modulation of endoreduplication are, for example, seeds (such as from cereals, oilseed crops), roots (such as in sugar beet), tubers (such as in potatoes) and fruits (such as in vegetables and fruit species). Increased endoreduplication in storage organs, and parts thereof, correlates with enhanced storage capacity and, thus, with improved yield. In another embodiment of the invention, the endoreduplication of a whole plant is

25 modulated.

B. Screening Assays:

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides,

30 peptidomimetics, small molecules or other drugs) which bind to ICK proteins, have a stimulatory or inhibitory effect on, for example, ICK expression or ICK activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of an ICK substrate.

In one embodiment, the invention provides assays for screening candidate or test

35 compounds which are substrates of an ICK protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of an ICK protein or polypeptide or biologically active portion thereof, *e.g.*, modulate the ability of ICK to

interact with its cognate ligand. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*).

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing an ICK target molecule (*e.g.*, a plant cyclin dependent kinase) with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the ICK target molecule. Determining the ability of the test compound to modulate the activity of an ICK target molecule can be accomplished, for example, by determining the ability of the ICK protein to bind to or interact with the ICK target molecule, or by determining the ability of the target molecule, *e.g.*, the plant cyclin dependent kinase, to phosphorylate a protein.

The ability of the target molecule, *e.g.*, the plant cyclin dependent kinase, to phosphorylate a protein can be determined by, for example, an *in vitro* kinase assay. Briefly, a protein can be incubated with the target molecule, *e.g.*, the plant cyclin dependent kinase, and radioactive ATP, *e.g.*, [γ -³²P] ATP, in a buffer containing MgCl₂ and MnCl₂, *e.g.*, 10 mM MgCl₂ and 5 mM MnCl₂. Following the incubation, the immunoprecipitated protein can be separated by SDS-polyacrylamide gel electrophoresis under reducing conditions, transferred to a membrane, *e.g.*, a PVDF membrane, and autoradiographed. The appearance of detectable bands on the

autoradiograph indicates that the protein has been phosphorylated. Phosphoaminoacid analysis of the phosphorylated substrate can also be performed in order to determine which residues on the protein are phosphorylated. Briefly, the radiophosphorylated protein band can be excised from the SDS gel and subjected to partial acid hydrolysis.

- 5 The products can then be separated by one-dimensional electrophoresis and analyzed on, for example, a phosphoimager and compared to ninhydrin-stained phosphoaminoacid standards.

- Determining the ability of the ICK protein to bind to or interact with an ICK target molecule can be accomplished by determining direct binding. Determining the ability of the ICK protein to bind to or interact with an ICK target molecule can be accomplished, for example, by coupling the ICK protein with a radioisotope or enzymatic label such that binding of the ICK protein to an ICK target molecule can be determined by detecting the labeled ICK protein in a complex. For example, ICK molecules, *e.g.*, ICK proteins, can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, ICK molecules can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

- 20 It is also within the scope of this invention to determine the ability of a compound to modulate the interaction between ICK and its target molecule, without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of ICK with its target molecule without the labeling of either ICK or the target molecule. McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between compound and receptor.

- In a preferred embodiment, determining the ability of the ICK protein to bind to or interact with an ICK target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target, detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, chloramphenicol acetyl transferase), or detecting a target-regulated cellular response.

In yet another embodiment, an assay of the present invention is a cell-free assay in which an ICK protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the ICK protein or biologically active portion thereof is determined. Binding of the test compound to the ICK protein
5 can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the ICK protein or biologically active portion thereof with a known compound which binds ICK to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an ICK protein, wherein determining the ability of the test
10 compound to interact with an ICK protein comprises determining the ability of the test compound to preferentially bind to ICK or biologically active portion thereof as compared to the known compound.

In another embodiment, the assay is a cell-free assay in which an ICK protein or biologically active portion thereof is contacted with a test compound and the ability of
15 the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the ICK protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of an ICK protein can be accomplished, for example, by determining the ability of the ICK protein to bind to an ICK target molecule by one of the methods described above for determining direct binding. Determining the ability
20 of the ICK protein to bind to an ICK target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*,
25 BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of an ICK protein can be accomplished by determining the ability of the ICK protein to further modulate the activity of an ICK target molecule (*e.g.*, an
30 ICK mediated signal transduction pathway component). For example, the activity of the effector molecule on an appropriate target can be determined, or the binding of the effector to an appropriate target can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting an ICK protein or biologically active portion thereof with a known compound which binds the
35 ICK protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the ICK protein, wherein determining the ability of the test compound to interact with the ICK

protein comprises determining the ability of the ICK protein to preferentially bind to or modulate the activity of an ICK target molecule.

The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of proteins (*e.g.*, ICK proteins or biologically active portions thereof). In the case of cell-free assays in which a membrane-bound form a protein is used it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either ICK or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to an ICK protein, or interaction of an ICK protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ ICK fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or ICK protein, and the mixture incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of ICK binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either an ICK protein or an ICK target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated ICK protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit,

Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with ICK protein or target molecules but which do not interfere with binding of the ICK protein to its target molecule can be derivatized to the wells of the plate, and unbound target or ICK protein
5 trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the ICK protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the ICK protein or target molecule.

10 In another embodiment, modulators of ICK expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of ICK mRNA or protein in the cell is determined. The level of expression of ICK mRNA or protein in the presence of the candidate compound is compared to the level of expression of ICK mRNA or protein in the absence of the candidate compound. The
15 candidate compound can then be identified as a modulator of ICK expression based on this comparison. For example, when expression of ICK mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of ICK mRNA or protein expression. Alternatively, when expression of ICK mRNA or protein is less
20 (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of ICK mRNA or protein expression. The level of ICK mRNA or protein expression in the cells can be determined by methods described herein for detecting ICK mRNA or protein.

In yet another aspect of the invention, the ICK proteins can be used as "bait
25 proteins" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with ICK ("ICK-binding proteins" or "ICK-bp") and are
30 involved in ICK activity. Such ICK-binding proteins are also likely to be involved in the propagation of signals by the ICK proteins or ICK targets as, for example, downstream elements of an ICK-mediated signaling pathway. Alternatively, such ICK-binding proteins are likely to be ICK inhibitors.

The two-hybrid system is based on the modular nature of most transcription
35 factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for an ICK protein is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a

library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an ICK-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the ICK protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate plant or animal model. For example, an agent identified as described herein (e.g., an ICK modulating agent, an antisense ICK nucleic acid molecule, an ICK-specific antibody, or an ICK-binding partner) can be used in a plant or animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in a plant or animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for the agricultural and therapeutic uses described herein.

C. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; identify an individual from a minute biological sample (tissue typing); and aid in forensic identification of a biological sample. Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the ICK nucleotide sequences, described herein, can be used to map the location of the ICK genes on a chromosome. The mapping of the ICK sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, ICK genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the ICK nucleotide sequences. Computer analysis of the ICK sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers

can then be used for PCR screening of cell hybrids containing individual plant or human chromosomes. Only those hybrids containing the plant or human gene corresponding to the ICK sequences will yield an amplified fragment.

Other mapping strategies which can similarly be used to map an ICK sequence to its chromosome include *in situ* hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between plants affected and unaffected with a disease associated with the ICK gene, can be determined. If a mutation is observed in some or all of the affected plants but not in any unaffected plants, then the mutation is likely to be the causative agent of the particular disease.

Comparison of affected and unaffected plants generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several plants can be performed to
5 confirm the presence of a mutation and to distinguish mutations from polymorphisms.

II. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode ICK proteins or biologically active portions thereof, as well as nucleic acid
10 fragments sufficient for use as hybridization probes to identify ICK-encoding nucleic acids (*e.g.*, ICK mRNA) and fragments for use as PCR primers for the amplification or mutation of ICK nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA), chimeric RNA/DNA oligonucleotides, and analogs of
15 the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated" includes nucleic acid molecules
20 which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated ICK nucleic acid molecule can contain less than
25 about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or
30 other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, using all or portion of the nucleic
35 acid sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, as a hybridization probe, ICK nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T.

Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56 can be isolated by the polymerase chain
5 reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, respectively.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can
10 be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to ICK nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45,
15 54 or 56.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to
20 the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, respectively, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, respectively, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ ID NO:1,
25 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or a portion of any of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an ICK protein. The nucleotide sequence determined from the cloning of the ICK gene allows for the generation of probes and
30 primers designed for use in identifying and/or cloning other ICK family members, as well as ICK homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or

15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56. In an exemplary embodiment, a nucleic acid molecule
5 of the present invention comprises a nucleotide sequence which is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or 800 nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56.

Probes based on the ICK nucleotide sequences can be used to detect transcripts
10 or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which misexpress an ICK protein, such as by measuring a level of an ICK-
15 encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting ICK mRNA levels or determining whether a genomic ICK gene has been mutated or deleted.

A nucleic acid fragment encoding a "biologically active portion of an ICK protein" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, which encodes a polypeptide having an ICK
20 biological activity (the biological activities of the ICK proteins are described herein), expressing the encoded portion of the ICK protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the ICK protein.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, due
25 to the degeneracy of the genetic code and, thus, encode the same ICK proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding an ICK protein.

In addition to the ICK nucleotide sequences shown in SEQ ID NO:1, 2, 3, 4, 5,
30 6, 7, 8, 9, 43, 45, 54 or 56, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the ICK proteins may exist within a population (*e.g.*, a rice plant population). Such genetic polymorphism in the ICK genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer
35 to nucleic acid molecules which include an open reading frame encoding an ICK protein, preferably a plant ICK protein, and can further include non-coding regulatory sequences, and introns. Such natural allelic variations include both functional and non-functional ICK proteins and can typically result in 1-5% variance in the nucleotide

sequence of an ICK gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in ICK genes that are the result of natural allelic variation and that do not alter the functional activity of an ICK protein are intended to be within the scope of the invention.

- 5 Natural allelic variants are further include molecules that comprise single nucleotide polymorphisms (SNPs) as well as small insertion/deletion polymorphisms (INDELs; the size of INDELs is usually less than about 100 bp). SNPs and INDELs form the largest set of sequence variants in naturally occurring polymorphic strains of most organisms. They are helpful in mapping genes and in discovery of genes and gene
- 10 functions. They are furthermore helpful in the identification of genetic loci, *e.g.*, plant genes, involved in determining processes such as growth rate, plant size and plant yield, plant vigor, disease resistance, stress tolerance and the like. Many techniques are nowadays available to identify SNPs and/or INDELs including (i) PCR followed by denaturing high performance liquid chromatography (DHPLC; *e.g.*, Cho *et al.* (1999)
- 15 *Nature Genet* 23, 203-207); (ii) constant denaturant capillary electrophoresis (CDCE) combined with high-fidelity PCR (*e.g.*, Li-Sucholeiki *et al.* (1999) *Electrophoresis* 20, 1224-1232); (iii) denaturing gradient gel electrophoresis (Fischer and Lerman (1983) *Proc. Natl. Acad. Sci. USA* 80, 1579-1583); (iv) matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; *e.g.*, Ross *et al.* (2000) *Biotechniques* 29, 620-629); (v) real-time fluorescence monitoring PCR assays
- 20 (Tapp *et al.* (2000) *Biotechniques* 28, 732-738); (vi) AcryditeTM gel technology (Kenney *et al.* (1998) *Biotechniques* 25, 516-521); (vii) cycle dideoxy fingerprinting (CddF; Langemeier *et al.* (1994) *Biotechniques* 17, 484-490); (viii) single-strand conformation polymorphism (SSCP) analysis (Vidal-Puig and Moller (1994)
- 25 *Biotechniques* 17, 490-496) and (ix) mini-sequencing primer extension reaction (Syvanen (1999) *Hum Mutat* 13, 1-10). The technique of 'Targeting Induced Local Lesions in Genomes' (TILLING; McCallum *et al.* (2000) *Nat. Biotechnol* 18, 455-457; *Plant Physiol* 123, 439-442), which is a variant of (i) *supra*, can also be applied to rapidly identify an altered gene in, *e.g.*, chemically mutagenized plant individuals
- 30 showing interesting phenotypes.

Differences in preferred codon usage are illustrated below for *Agrobacterium tumefaciens* (a bacterium), *A. thaliana*, *M. sativa* (two dicotyledonous plants) and *Oryza sativa* (a monocotyledonous plant). For example, the codon GGC (for glycine) is the most frequently used codon in *A. tumefaciens* (36.2 %), is the second most frequently

35 used codon in *O. sativa* but is used at much lower frequencies in *A. thaliana* and *M. sativa* (9 % and 8.4 %, respectively). Of the four possible codons encoding glycine the GGC codon is most preferably used in *A. tumefaciens* and *O. sativa*. However, in *A.*

thaliana the GGA (and GGU) codon is most preferably used, whereas in *M. sativa* the GGU (and GGA) codon is most preferably used.

Moreover, nucleic acid molecules encoding other ICK family members and, thus, which have a nucleotide sequence which differs from the ICK sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56 are intended to be within the scope of the invention. For example, another ICK cDNA can be identified based on the nucleotide sequence of the plant ICK molecules described herein. Moreover, nucleic acid molecules encoding ICK proteins from different species and, thus, which have a nucleotide sequence which differs from the ICK sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56 are intended to be within the scope of the invention. For example, a corn ICK cDNA can be identified based on the nucleotide sequence of a rice ICK.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the ICK cDNAs of the invention can be isolated based on their homology to the ICK nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56. In other embodiment, the nucleic acid is at least 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or 600 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 30%, 40%, 50%, or 60% identical to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°C, and even more preferably at 65°C. Ranges intermediate to the above-recited values, *e.g.*, at 60-65 °C or at 55-60 °C are also intended to be encompassed by the present invention. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56 corresponds to a

naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In addition to naturally-occurring allelic variants of the ICK sequences that may exist in nature, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, thereby leading to changes in the amino acid sequence of the encoded ICK proteins, without altering the functional ability of the ICK proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of an ICK protein. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of ICK without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the ICK proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, additional amino acid residues that are conserved between the ICK proteins of the present invention and other ICK family members are not likely to be amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding ICK proteins that contain changes in amino acid residues that are not essential for activity.

An isolated nucleic acid molecule encoding an ICK protein homologous to the ICK proteins of the present invention can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an ICK

protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an ICK coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for ICK biological activity to identify mutants that
5 retain activity. Following mutagenesis of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, the encoded protein can be expressed recombinantly and the activity of the protein can be determined. Another alternative embodiment comprises targeted *in vivo* gene correction or modification which can be achieved by chimeric RNA/DNA oligonucleotides (*e.g.* Yoon *et al.* (1996), *Proc. Natl. Acad. Sci. USA* 93, 2071-2076).

10 In a preferred embodiment, a mutant ICK protein can be assayed for the ability to: (1) inhibit CDK activity (*e.g.*, cyclin-CDK activity); (2) regulate cyclin-CDK complex assembly; (3) regulate the commitment of cells to divide, *e.g.*, by integrating mitogenic and antimitogenic signals; (4) regulate cell cycle progression; (5) regulate DNA replication and/or DNA repair; (6) regulate gene transcription; (7) regulate cyclin
15 degradation; (8) modulate cell cycle withdrawal and/or cell differentiation; (9) regulate cell death, *e.g.*, apoptosis; (10) control organ (*e.g.*, plant organ) and/or organism (*e.g.*, plant organism) size; and (11) regulate endoreduplication.

In addition to the nucleic acid molecules encoding ICK proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are
20 antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire ICK coding strand,
25 or only to a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding ICK. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of
30 the coding strand of a nucleotide sequence encoding ICK. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding ICK disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and
35 Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of ICK mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of ICK mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding

the translation start site of ICK mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). Preferably, production of antisense nucleic acids in plants occurs by means of a stably integrated transgene comprising a promoter operative in plants, an antisense oligonucleotide, and a terminator.

Other known nucleotide modifications include methylation, cyclization and 'caps' and substitution of one or more of the naturally occurring nucleotides with an analog such as inosine. Modifications of nucleotides include the addition of acridine, amine, biotin, cascade blue, cholesterol, Cy3[®], Cy5[®], Cy5.5[®] Dabcyl, digoxigenin, dinitrophenyl, Edans, 6-FAM, fluorescein, 3'-glyceryl, HEX, IRD-700, IRD-800, JOE, phosphate psoralen, rhodamine, ROX, thiol (SH), spacers, TAMRA, TET, AMCA-S[®], SE, BODIPY[®], Marina Blue[®], Pacific Blue[®], Oregon Green[®], Rhodamine Green[®], Rhodamine Red[®], Rhodol Green[®] and Texas Red[®]. Polynucleotide backbone modifications include methylphosphonate, 2'-OMe-methylphosphonate RNA,

phosphorothiorate, RNA, 2'-OMeRNA. Base modifications include 2-amino-dA, 2-aminopurine, 3'-(ddA), 3'dA(cordycepin), 7-deaza-dA, 8-Br-dA, 8-oxo-dA, N⁶-Me-dA, abasic site (dSpacer), biotin dT, 2'-OMe-5Me-C, 2'-OMe-propynyl-C, 3'-(5-Me-dC), 3'-(ddC), 5-Br-dC, 5-I-dC, 5-Me-dC, 5-F-dC, carboxy-dT, convertible dA, convertible dC, 5 convertible dG, convertible dT, convertible dU, 7-deaza-dG, 8-Br-dG, 8-oxo-dG, O⁶-Me-dG, S6-DNP-dG, 4-methyl-indole, 5-nitroindole, 2'-OMe-inosine, 2'-dI, O⁶-phenyl-dI, 4-methyl-indole, 2'-deoxynebularine, 5-nitroindole, 2-aminopurine, dP(purine analogue), dK(pyrimidine analogue), 3-nitropyrrole, 2-thio-dT, 4-thio-dT, biotin-dT, carboxy-dT, O⁴-Me-dT, O⁴-triazol dT, 2'-OMe-propynyl-U, 5-Br-dU, 2'-dU, 5-F-dU, 5-10 I-dU, O⁴-triazol dU.

The antisense nucleic acid molecules of the invention are typically introduced into a plant or administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an ICK protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or 15 translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of introduction or administration of antisense nucleic acid molecules of the invention include transformation in a plant or direct 20 injection at a tissue site in a subject. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell 25 surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a constitutive promoter or a strong pol II or pol III promoter are preferred.

30 In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o- 35 methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330). In another embodiment, the antisense nucleic acid molecule further comprises a sense nucleic acid molecule complementary to the antisense nucleic acid molecule. Gene silencing

methods based on such nucleic acid molecules are well known to the skilled artisan (e.g., Grierson *et al.* (1998) WO 98/53083; Waterhouse *et al.* (1999) WO 99/53050).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave ICK mRNA transcripts to thereby inhibit translation of ICK mRNA. A ribozyme having specificity for an ICK-encoding nucleic acid can be designed based upon the nucleotide sequence of an ICK cDNA disclosed herein (*i.e.*, SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an ICK-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, ICK mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418. The use of ribozymes for gene silencing in plants is known in the art (*e.g.*, Atkins *et al.* (1994) WO 94/00012; Lenne *et al.* (1995) WO 95/03404; Lutziger *et al.* (2000) WO 00/00619; Prinsen *et al.* (1997) WO 97/13865 and Scott *et al.* (1997) WO/ 97/38116).

Alternatively, ICK gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the ICK (*e.g.*, the ICK promoter and/or enhancers) to form triple helical structures that prevent transcription of the ICK gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

In yet another embodiment, the ICK nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide

synthesis protocols as described in Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of ICK nucleic acid molecules can be used for increasing crop yield in plants or in therapeutic and diagnostic applications. For example, PNAs can be used as
5 antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of ICK nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (*e.g.*, by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (*e.g.*, S1 nucleases (Hyrup B. (1996) *supra*));
10 or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of ICK can be modified, (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of
15 drug delivery known in the art. For example, PNA-DNA chimeras of ICK nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of
20 appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) *supra* and Finn P.J. *et al.* (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and
25 modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be
30 synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. US.* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652;
35 PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or

intercalating agents. (See, e.g., Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

5 III. Isolated ICK Proteins and Anti-ICK Antibodies

One aspect of the invention pertains to isolated ICK proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-ICK antibodies. In one embodiment, native ICK proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein
10 purification techniques. In another embodiment, ICK proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an ICK protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is
15 substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the ICK protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of ICK protein in which the protein is separated from cellular components of the cells from which it is isolated or
20 recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of ICK protein having less than about 30% (by dry weight) of non-ICK protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-ICK protein, still more preferably less than about 10% of non-ICK protein, and most preferably less than about 5% non-ICK
25 protein. When the ICK protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals"
30 includes preparations of ICK protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of ICK protein having less than about 30% (by dry weight) of chemical precursors or non-ICK chemicals, more preferably less than about 20%
35 chemical precursors or non-ICK chemicals, still more preferably less than about 10% chemical precursors or non-ICK chemicals, and most preferably less than about 5% chemical precursors or non-ICK chemicals.

Biologically active portions of an ICK protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the ICK protein, which include less amino acids than the full length ICK proteins, and exhibit at least one activity of an ICK protein. Typically, biologically
5 active portions comprise a domain or motif with at least one activity of the ICK protein. A biologically active portion of an ICK protein can be a polypeptide which is, for example, at least 10, 25, 50, 100 or more amino acids in length.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps
10 can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at
15 least 70%, 80%, or 90% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid
20 "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two
25 sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet
30 another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

The nucleic acid and protein sequences of the present invention can further be
35 used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the

NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to ICK nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to ICK protein molecules of the invention. To obtain
5 gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

The invention also provides ICK chimeric or fusion proteins. As used herein, an
10 ICK "chimeric protein" or "fusion protein" comprises an ICK polypeptide operatively linked to a non-ICK polypeptide. An "ICK polypeptide" refers to a polypeptide having an amino acid sequence corresponding to ICK, whereas a "non-ICK polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the ICK protein, *e.g.*, a protein which is different from the
15 ICK protein and which is derived from the same or a different organism. The non-ICK polypeptide can, for example, be (histidine)₆-tag, glutathione S-transferase, protein A, maltose-binding protein, dihydrofolate reductase, Tag•100 epitope (EETARFQPGYRS; SEQ ID NO:37), c-myc epitope (EQKLISEEDL; SEQ ID NO:38), FLAG[®]-epitope (DYKDDDDK; SEQ ID NO:39), lacZ, CMP (calmodulin-binding peptide), HA epitope
20 (YPYDVDPDYA; SEQ ID NO:40), protein C epitope (EDQVDPRLIDGK; SEQ ID NO:41) or VSV epitope (YTDIEMNRLGK; SEQ ID NO:42).

Within an ICK fusion protein the ICK polypeptide can correspond to all or a portion of an ICK protein. In a preferred embodiment, an ICK fusion protein comprises at least one biologically active portion of an ICK protein. In another preferred
25 embodiment, an ICK fusion protein comprises at least two biologically active portions of an ICK protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the ICK polypeptide and the non-ICK polypeptide are fused in-frame to each other. The non-ICK polypeptide can be fused to the N-terminus or C-terminus of the ICK polypeptide.

30 For example, in one embodiment, the fusion protein is a GST-ICK fusion protein in which the ICK sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant ICK.

In another embodiment, the fusion protein is an ICK protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, plant or
35 mammalian host cells), expression and/or secretion of ICK can be increased through use of a heterologous signal sequence.

The ICK fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a plant or a subject *in vivo*. The ICK fusion proteins can be used to affect the bioavailability of an ICK substrate. Use of ICK fusion proteins may be useful agriculturally for the increase of crop yields or therapeutically for the treatment of cellular growth related disorders, *e.g.*, cancer. Moreover, the ICK-fusion proteins of the invention can be used as immunogens to produce anti-ICK antibodies in a subject, to purify ICK ligands and in screening assays to identify molecules which modulate the interaction of ICK with an ICK substrate, *e.g.*, a CDK molecule or a cyclin molecule.

Preferably, an ICK chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A ICK-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the ICK protein.

The present invention also pertains to variants of the ICK proteins which function as either ICK agonists (mimetics) or as ICK antagonists. Variants of the ICK proteins can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of an ICK protein. An agonist of the ICK proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of an ICK protein. An antagonist of an ICK protein can inhibit one or more of the activities of the naturally occurring form of the ICK protein by, for example, competitively modulating a cellular activity of an ICK protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the ICK protein.

In one embodiment, variants of an ICK protein which function as either ICK agonists (mimetics) or as ICK antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of an ICK protein for ICK protein agonist or antagonist activity. In one embodiment, a variegated library of ICK variants is
5 generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of ICK variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential ICK sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for
10 phage display) containing the set of ICK sequences therein. There are a variety of methods which can be used to produce libraries of potential ICK variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes
15 allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential ICK sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

20 In addition, libraries of fragments of an ICK protein coding sequence can be used to generate a variegated population of ICK fragments for screening and subsequent selection of variants of an ICK protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an ICK coding sequence with a nuclease under conditions wherein nicking occurs only
25 about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal,
30 C-terminal and internal fragments of various sizes of the ICK protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of ICK
35 proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a

desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify ICK variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

In one embodiment, cell based assays can be exploited to analyze a variegated ICK library. For example, a library of expression vectors can be transfected into a cell line which ordinarily synthesizes and secretes ICK. The transfected cells are then cultured such that ICK and a particular mutant ICK are secreted and the effect of expression of the mutant on ICK activity in cell supernatants can be detected, *e.g.*, by any of a number of enzymatic assays. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of ICK activity, and the individual clones further characterized.

An isolated ICK protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind ICK using standard techniques for polyclonal and monoclonal antibody preparation. A full-length ICK protein can be used or, alternatively, the invention provides antigenic peptide fragments of ICK for use as immunogens. The antigenic peptide of ICK comprises at least 8 amino acid residues and encompasses an epitope of ICK such that an antibody raised against the peptide forms a specific immune complex with ICK. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of ICK that are located on the surface of the protein, *e.g.*, hydrophilic regions.

An ICK immunogen typically is used to prepare antibodies by immunizing a suitable subject, (*e.g.*, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed ICK protein or a chemically synthesized ICK polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic ICK preparation induces a polyclonal anti-ICK antibody response.

Accordingly, another aspect of the invention pertains to anti-ICK antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as ICK. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the

antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind ICK. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of ICK. A monoclonal antibody composition thus typically displays a single binding affinity for a particular ICK protein with which it immunoreacts.

Polyclonal anti-ICK antibodies can be prepared as described above by immunizing a suitable subject with an ICK immunogen. The anti-ICK antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized ICK. If desired, the antibody molecules directed against ICK can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the anti-ICK antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an ICK immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds ICK.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-ICK monoclonal antibody (see, *e.g.*, G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al.* *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (*e.g.*, a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made

by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind ICK, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-ICK antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with ICK to thereby isolate immunoglobulin library members that bind ICK. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

Additionally, recombinant anti-ICK antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the

- invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496;
- 5 Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA*
- 10 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.
- 15 An anti-ICK antibody (*e.g.*, monoclonal antibody) can be used to isolate ICK by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-ICK antibody can facilitate the purification of natural ICK from cells and of recombinantly produced ICK expressed in host cells. Moreover, an anti-ICK antibody can be used to detect ICK protein (*e.g.*, in a cellular lysate or cell supernatant) in order
- 20 to evaluate the abundance and pattern of expression of the ICK protein. These antibodies can also be used, for example, for the immunoprecipitation and immunolocalization of proteins according to the invention as well as for the monitoring of the synthesis of such proteins, for example, in recombinant organisms, and for the identification of compounds interacting with the protein according to the invention.
- 25 Anti-ICK antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent
- 30 materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,
- 35 dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

IV. Computer Readable Means

The nucleotide or amino acid sequences of the invention are also provided in a variety of mediums to facilitate use thereof. As used herein, "provided" refers to a manufacture, other than an isolated nucleic acid or amino acid molecule, which contains a nucleotide or amino acid sequences of the present invention. Such a manufacture provides the nucleotide or amino acid sequences, or a subset thereof (*e.g.*, a subset of open reading frames (ORI's)) in a form which allows a skilled artisan to examine the manufacture using means not directly applicable to examining the nucleotide or amino acid sequences, or a subset thereof, as they exist in nature or in purified form.

In one application of this embodiment, a nucleotide or amino acid sequence of the present invention can be recorded on computer readable media. As used herein "computer readable media" includes any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as a CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. The skilled artisan will readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention.

As used herein "recorded" refers to a process of storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising the nucleotide or amino acid sequence information of the present invention.

A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase Oracle, or the like. The skilled artisan can readily adapt any number of dataprocessor structuring formats (*e.g.*, text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

By providing the nucleotide or amino acid sequences of the invention in computer readable form, the skilled artisan can routinely access the sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the invention in computer readable form to
5 compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identity fragments or regions of the sequences of the invention which match a particular target sequence or target motif.

As used herein, a "target sequence" can be any DNA or amino acid sequence of
10 six or more nucleotide or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues. However, it is well recognized that commercially important
15 fragments, such as sequence fragments involved in gene expression and protein processing, may be shorter length.

As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of
20 the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

Computer software is publicly available which allows a skilled artisan to access
25 sequence information provided in a computer readable medium for analysis and comparison to other sequences. A variety of known algorithms are disclosed publicly and a variety of commercially available software of conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software include, but are not limited to, MacPatter (EMBL), BLASTN and BASTX
30 (NCBIA).

For example, software which implements the BLAST (Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410) and BLAZE (Brutlag *et al.* (1993) *Comp. Chem.* 17:203-207) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) of the sequences of the invention which contain homology to ORFs or proteins
35 from other libraries. Such ORFs are protein encoding fragments and are useful in producing commercially important proteins such as enzyme used in various reactions and in the production of commercially useful metabolites.

Furthermore, folding simulations and computer redesign of structural motifs of the protein of the invention can be performed using appropriate computer programs (Olszewski et al. 1996, Hoffman et al. 1995). Computer modeling of protein folding can be used for the conformational and energetic analysis of detailed peptide and protein models (Monge et al. 1995, Renouf and Hounsell 1995). In particular, the appropriate programs can be used for the identification of interactive sites of the ICK and cyclin-dependent kinases, its ligand or other interacting proteins by computer assisted searches for complementary peptide sequences (Fassina and Melli 1994). Further appropriate computer systems for the design of protein and peptides are described in the prior art, for example in Berry and Brenner (1994), Wodak (1987), Pabo and Suchanek (1986). The results obtained from the above-described computer analysis can be used for, *e.g.* the preparation of peptidomimetics of the proteins of the invention or fragments thereof.

Furthermore, a three-dimensional and/or crystallographic structure of the protein of the invention can be used for the design of peptidomimetic inhibitors of the biological activity of the protein of the invention (Rose et al. 1996, Rutenber et al. 1996).

V. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an ICK protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, *e.g.*, a plant cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, ICK proteins, mutant forms of ICK proteins, fusion proteins, and the like).

The vectors of the invention comprise a selectable and/or scorable marker. Selectable marker genes useful for the selection of transformed plant cells, callus, plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for *dhfr*, which confers resistance to methotrexate (Reiss, *Plant Physiol. (Life Sci. Adv.)* 13 (1994), 143-149); *npt*, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin (Herrera-Estrella, *EMBO J.* 2 (1983), 987-995) and *hygro*, which confers resistance to hygromycin (Marsh, *Gene* 32 (1984), 481-485). Additional selectable genes have been described, namely *trpB*, which allow cells to utilize indole in place of tryptophan; *hisD*, which allows cells to utilize histinol in place of histidine (Hartman, *Proc. Natl. Acad. Sci. USA* 85 (1988), 8047); mannose-6-phosphate isomerase which allows cells to utilize mannose (WO 94/20627) and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: *Current Communications in Molecular Biology*, Cold Spring Harbor Laboratory ed.) or deaminase from *Aspergillus terreus* which confers resistance to Blasticidin S (Tamura, *Biosci. Biotechnol. Biochem.* 59 (1995), 2336-2338).

Useful scorable markers are also known to those skilled in the art and are commercially available. Advantageously, the marker is a gene encoding luciferase (Giacomin, *Pl. Sci.* 116 (1996), 59-72; Scikantha, *J. Bact.* 178 (1996), 121), green fluorescent protein (Gerdes, *FEBS Lett.* 389 (1996), 44-47) or β -glucuronidase (Jefferson, *EMBO J.* 6 (1987), 3901-3907). This embodiment is particularly useful for simple and rapid screening of cells, tissues and organisms containing a vector of the invention.

A "plant promoter" is a promoter capable of initiating transcription in plant cells. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria. Preferred promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression and/or to alter the spatial expression and/or temporal expression of a nucleic acid molecule to which it is operably connected. For example, copper-responsive, glucocorticoid-responsive or dexamethasone-responsive regulatory elements may be placed adjacent to a heterologous promoter sequence driving expression of a nucleic acid molecule to confer copper inducible, glucocorticoid-inducible, or dexamethasone-inducible expression respectively, on said nucleic acid molecule. Examples of promoters under developmental control include promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, seeds, endosperm, embryos, fibers, xylem vessels, tracheids, or sclerenchyma. Such promoters are referred to as "tissue preferred." Promoters which initiate transcription only in certain tissue are referred to as "tissue specific." A "cell type" specific promoter primarily drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" promoter is a promoter which is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue specific, tissue preferred, cell type specific, and inducible promoters constitute the class of "non-constitutive" promoters. A "constitutive" promoter is a promoter which is active under most environmental conditions.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, an ICK protein can be expressed in plant cells, bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including
10 calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

Means for introducing a recombinant expression vector of this invention into
15 plant tissue or cells include, but are not limited to, transformation using CaCl_2 and variations thereof, in particular the method described by Hanahan (*J. Mol. Biol.* 166, 557-560, 1983), direct DNA uptake into protoplasts (Krens *et al.*, *Nature* 296: 72-74, 1982; Paszkowski *et al.*, *EMBO J.* 3:2717-2722, 1984), PEG-mediated uptake to protoplasts (Armstrong *et al.*, *Plant Cell Reports* 9: 335-339, 1990) microparticle
20 bombardment, electroporation (Fromm *et al.*, *Proc. Natl. Acad. Sci. (USA)* 82:5824-5828, 1985), microinjection of DNA (Crossway *et al.*, *Mol. Gen. Genet.* 202:179-185, 1986), microparticle bombardment of tissue explants or cells (Christou *et al.*, *Plant Physiol* 87: 671-674, 1988; Klein *et al.* (1992) *Biotechnology* 24, 384-386), vacuum-infiltration of tissue with nucleic acid, or in the case of plants, T-DNA-mediated transfer
25 from *Agrobacterium* to the plant tissue as described essentially by An *et al.* (*EMBO J.* 4:277-284, 1985), Herrera-Estrella *et al.* (*Nature* 303: 209-213, 1983a; *EMBO J.* 2: 987-995, 1983b; In: *Plant Genetic Engineering*, Cambridge University Press, N.Y., pp 63-93, 1985), or *in planta* method using *Agrobacterium tumefaciens* such as that described by Bechtold *et al.*, (*C.R. Acad. Sci. (Paris, Sciences de la vie/ Life Sciences)* 316: 1194-
30 1199, 1993) or Clough *et al.* (*Plant J.* 16: 735-743, 1998). Methods for transformation of monocotyledonous plants are well known in the art and include *Agrobacterium*-mediated transformation (Cheng *et al.* (1997) WO 97/48814; Hansen (1998) WO 98/54961; Hiei *et al.* (1994) WO 94/00977; Hiei *et al.* (1998) WO 98/17813; Rikiishi *et al.* (1999) WO 99/04618; Saito *et al.* (1995) WO 95/06722), microprojectile
35 bombardment (Adams *et al.* (1999) US 5,969,213; Bowen *et al.* (1998) US 5,736,369; Chang *et al.* (1994) WO 94/13822; Lundquist *et al.* (1999) US 5,874,265/US 5,990,390; Vasil and Vasil (1995) US 5,405,765; Walker *et al.* (1999) US 5,955,362), DNA uptake (Eval *et al.* (1993) WO 93/181,168), microinjection of *Agrobacterium* cells (von Holt

1994 DE 4309203) and sonication (Finer *et al.* (1997) US 5,693,512). The vector DNA may further comprise a selectable marker gene to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct. Suitable selectable marker genes contemplated herein include the ampicillin resistance (Amp^r),
5 tetracycline resistance gene (Tc^r), bacterial kanamycin resistance gene (Kan^r), phosphinothricin resistance gene, neomycin phosphotransferase gene (*npII*), hygromycin resistance gene, β -glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, green fluorescent protein (*gfp*) gene (Haseloff *et al.*, 1997), and luciferase gene.

10 For microparticle bombardment of cells, a microparticle is propelled into a cell to produce a transformed cell. Any suitable ballistic cell transformation methodology and apparatus can be used in performing the present invention. Exemplary apparatus and procedures are disclosed by Stomp *et al.* (U.S. Patent No. 5,122,466) and Sanford and Wolf (U.S. Patent No. 4,945,050). When using ballistic transformation procedures,
15 the gene construct may incorporate a plasmid capable of replicating in the cell to be transformed. Examples of microparticles suitable for use in such systems include 1 to 5 μ m gold spheres. The DNA construct may be deposited on the microparticle by any suitable technique, such as by precipitation.

A whole plant may be regenerated from the transformed or transfected cell, in
20 accordance with procedures well known in the art. Plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a gene construct of the present invention and a whole plant regenerated therefrom. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary
25 tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (*e.g.*, apical meristem, axillary buds, and root meristems), and induced meristem tissue (*e.g.*, cotyledon meristem and hypocotyl meristem).

The term "organogenesis", as used herein, includes a process by which shoots
30 and roots are developed sequentially from meristematic centres.

The term "embryogenesis", as used herein, includes a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes.

Preferably, the plant is produced according to the methods of the invention by
35 transfecting or transforming the plant with a genetic sequence, or by introducing to the plant a protein, by any art-recognized means, such as microprojectile bombardment, microinjection, *Agrobacterium*-mediated transformation (including *in planta*

transformation), protoplast fusion, or electroporation, amongst others. Most preferably the plant is produced by *Agrobacterium*-mediated transformation.

Agrobacterium-mediated transformation or agrolistic transformation of plants, yeast, moulds or filamentous fungi is based on the transfer of part of the transformation vector sequences, called the T-DNA, to the nucleus and on integration of said T-DNA in the genome of said eukaryote.

The term "*Agrobacterium*" as used herein, includes a member of the *Agrobacteriaceae*, more preferably *Agrobacterium* or *Rhizobacterium* and most preferably *Agrobacterium tumefaciens*.

The term "T-DNA", or "transferred DNA", as used herein, includes the transformation vector flanked by T-DNA borders which is, after activation of the *Agrobacterium vir* genes, nicked at the T-DNA borders and is transferred as a single stranded DNA to the nucleus of an eukaryotic cell.

As used herein, the terms "T-DNA borders", "T-DNA border region", or "border region" include either right T-DNA borders (RB) or left T-DNA borders (LB), which comprise a core sequence flanked by a border inner region as part of the T-DNA flanking the border and/or a border outer region as part of the vector backbone flanking the border. The core sequences comprise 22 bp in case of octopine-type vectors and 25 bp in case of nopaline-type vectors. The core sequences in the right border region and left border region form imperfect repeats. Border core sequences are indispensable for recognition and processing by the *Agrobacterium* nicking complex consisting of at least VirD1 and VirD2. Core sequences flanking a T-DNA are sufficient to promote transfer of the T-DNA

As used herein, the term "T-DNA transformation vector" or "T-DNA vector" includes any vector encompassing a T-DNA sequence flanked by a right and left T-DNA border consisting of at least the right and left border core sequences, respectively, and used for transformation of any eukaryotic cell.

As used herein, the term "T-DNA vector backbone sequence" or "T-DNA vector backbone sequences" includes all DNA of a T-DNA containing vector that lies outside of the T-DNA borders and, more specifically, outside the nicking sites of the border core imperfect repeats.

The present invention includes optimized T-DNA vectors such that vector backbone integration in the genome of a eukaryotic cell is minimized or absent. The term "optimized T-DNA vector" as used herein includes a T-DNA vector designed either to decrease or abolish transfer of vector backbone sequences to the genome of a eukaryotic cell. Such T-DNA vectors are known to the one of skill in the art and include

those described by Hanson *et al.* (1999) *Plant J.* **19**:727-734, by Stuiiver *et al.* (1999 - WO9901563) and by Depicker *et al.* (2001 - WO0144482).

The current invention clearly considers the inclusion of a DNA sequence encoding an ICK, homologue, analogue, derivative or immunologically active fragment thereof as defined supra, in any T-DNA vector comprising binary transformation
5 vectors, super-binary transformation vectors, co-integrate transformation vectors, Ri-derived transformation vectors as well as in T-DNA carrying vectors used in agrolistic transformation.

As used herein, the term "binary transformation vector" includes a T-DNA
10 transformation vector comprising: a T-DNA region comprising at least one gene of interest and/or at least one selectable marker active in the eukaryotic cell to be transformed; and
a vector backbone region comprising at least origins of replication active in *E. coli* and *Agrobacterium* and markers for selection in *E. coli* and *Agrobacterium*.

15 The T-DNA borders of a binary transformation vector can be derived from octopine-type or nopaline-type Ti plasmids or from both. The T-DNA of a binary vector is only transferred to a eukaryotic cell in conjunction with a helper plasmid. As used herein, the term "helper plasmid" includes a plasmid that is stably maintained in *Agrobacterium* and is at least carrying the set of *vir* genes necessary for enabling
20 transfer of the T-DNA. The set of *vir* genes can be derived from either octopine-type or nopaline-type Ti plasmids or from both.

As used herein, the term "super-binary transformation vector" includes a binary transformation vector additionally carrying in the vector backbone region a *vir* region of the Ti plasmid pTiBo542 of the super-virulent *A. tumefaciens* strain A281 (EP0604662,
25 EP0687730). Super-binary transformation vectors are used in conjunction with a helper plasmid.

As used herein, the term "co-integrate transformation vector" includes a T-DNA vector at least comprising: a T-DNA region comprising at least one gene of interest and/or at least one selectable marker active in plants; and a vector backbone region
30 comprising at least origins of replication active in *Escherichia coli* and *Agrobacterium*, and markers for selection in *E. coli* and *Agrobacterium*, and a set of *vir* genes necessary for enabling transfer of the T-DNA. The T-DNA borders and the set of *vir* genes of the T-DNA vector can be derived from either octopine-type or nopaline-type Ti plasmids or from both.

The term "Ri-derived plant transformation vector" includes a binary transformation vector in which the T-DNA borders are derived from a Ti plasmid and the binary transformation vector being used in conjunction with a 'helper' Ri-plasmid carrying the necessary set of *vir* genes.

- 5 The terms "agrolistics", "agrolistic transformation" or "agrolistic transfer" include a transformation method combining features of *Agrobacterium*-mediated transformation and of biolistic DNA delivery. As such, a T-DNA containing target plasmid is co-delivered with DNA/RNA enabling in planta production of VirD1 and VirD2 with or without VirE2 (Hansen and Chilton (1996) *Proc.Natl.Acad.Sci.U.S.A* 93:14978-14983 ; Hansen *et al.* (1997) *Proc.Natl.Acad.Sci.U.S.A* 94:11726-11730; 10 Hansen and Chilton (1997) - WO9712046).

- A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) an ICK protein. Accordingly, the invention further provides methods for producing an ICK protein using the host cells of 15 the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an ICK protein has been introduced) in a suitable medium such that an ICK protein is produced. In another embodiment, the method further comprises isolating an ICK protein from the medium or the host cell.

- 20 The host cells of the invention can also be used to produce transgenic plant or non-human transgenic animals in which exogenous ICK sequences have been introduced into their genome or homologous recombinant plants or animals in which endogenous ICK sequences have been altered. Such plants and animals are useful for studying the function and/or activity of an ICK and for identifying and/or evaluating 25 modulators of ICK activity.

Trangenic Plants

- As used herein, "transgenic plant" includes a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is 30 stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those 35 transgenics initially so altered as well as those created by sexual crosses as asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring event such as random

cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.

- A transgenic plant of the invention can be created by introducing an ICK-encoding nucleic acid into the plant by placing it under the control of regulatory elements which ensure the expression in plant cells. These regulatory elements may be heterologous or homologous with respect to the nucleic acid molecule to be expressed as well with respect to the plant species to be transformed. In general, such regulatory elements comprise a promoter active in plant cells. These promoters can be used to modulate (*e.g.* increase or decrease) ICK content and/or composition in a desired tissue.
- To obtain expression in all tissues of a transgenic plant, preferably constitutive promoters are used, such as the 35 S promoter of CaMV (Odell, *Nature* 313 (1985), 810-812) or promoters from such genes as rice actin (McElroy *et al.* (1990) *Plant Cell* 2:163-171) maize H3 histone (Lepetit *et al.* (1992) *Mol. Gen. Genet* 231:276-285) or promoters of the polyubiquitin genes of maize (Christensen, *Plant Mol. Biol.* 18 (1982), 675-689). In order to achieve expression in specific tissues of a transgenic plant it is possible to use tissue specific promoters (see, *e.g.*, Stockhaus, *EMBO J.* 8 (1989), 2245-2251 or Table 5, below).

Table 5:

I: CELL-SPECIFIC, TISSUE-SPECIFIC, AND ORGAN-SPECIFIC PROMOTERS		
GENE SOURCE	EXPRESSION PATTERN	REFERENCE
α -amylase (<i>Amy32b</i>)	aleurone	Lanahan et al, <i>Plant Cell</i> 4:203-211, 1992; Skriver et al, <i>Proc Natl Acad Sci USA</i> 88:7266-7270, 1991
cathepsin β -like gene	aleurone	Cejudo et al, <i>Plant Mol Biol</i> 20:849-856, 1992
<i>Agrobacterium rhizogenes</i> <i>rolB</i>	cambium	Nilsson et al, <i>Physiol Plant</i> 100:456-462, 1997
<i>AtPRP4</i>	flowers	http://salus.mediam.edu/mmg/tierney/html
chalcone synthase (<i>chsA</i>)	flowers	Van der Meer et al, <i>Plant Mol Biol</i> 15:95-109, 1990
<i>LAT52</i>	anther	Twiss et al, <i>Mol Gen Genet</i> 217:240-245, 1989
<i>apetala-3</i>	flowers	
chitinase	fruit (berries, grapes, etc)	Thomas et al, CSIRO Plant Industry, Urrbrae, South Australia, Australia; http://winetitles.com.au/gwrdc/csh95-1.html
<i>rbcs-3A</i>	green tissue (eg leaf)	Lam et al, <i>Plant Cell</i> 2:857-866, 1990; Tucker et al., <i>Plant Physiol</i> 113:1303-1308, 1992
leaf-specific genes	leaf	Baszczynski et al, <i>Nucl Acid Res</i> 16:4732, 1988
<i>AtPRP4</i>	leaf	http://salus.mediam.edu/mmg/tierney/html
chlorella virus adenine methyltransferase gene promoter	leaf	Mitra and Higgins, <i>Plant Mol Biol</i> 26:85-93, 1994
aldP gene promoter from rice	leaf	Kagaya et al, <i>Mol Gen Genet</i> 248:668-674, 1995
<i>rbcs</i> promoter from rice or tomato	leaf	Kyozuka et al, <i>Plant Physiol</i> 102:991-1000, 1993
<i>Pinus cab-6</i>	leaf	Yamamoto et al, <i>Plant Cell Physiol</i> 35:773-778, 1994

rubisco promoter	leaf	
cab (chlorophyll a/b-binding protein)	leaf	
pea Blec4 gene	vegetative and floral epidermal tissues	Mandaci and Dobres, Plant Mol Biol 34:961-965
SAM22	senescent leaf	Crowell et al, Plant Mol Biol 18:459-466, 1992
<i>ltp</i> gene (lipid transfer gene)		Fleming et al, Plant J 2:855-862, 1992
<i>R. japonicum nif</i> gene	nodule	United States Patent No 4 803165
<i>B. japonicum nifH</i> gene	nodule	United States Patent No 5008194
GmENOD40	nodule	Yang et al, Plant J 3:573-585, 1993
PEP carboxylase (PEPC)	nodule	Pathirana et al, Plant Mol Biol 20:437-450, 1992
leghaemoglobin (Lb)	nodule	Gordon et al, J Exp Bot 44:1453-1465, 1993
<i>Tungro bacilliform virus</i> gene	phloem	Bhattacharyya-Pakrasi et al, Plant J 4:71-79, 1992
pollen-specific genes	pollen; microspore	Albani et al, Plant Mol Biol 15:605, 1990; Albani et al, Plant Mol Biol 16:501, 1991
Zm13	pollen	Guerrero et al, Mol Gen Genet 224:161-168, 1993
apg gene	microspore	Twel et al, Sex Plant Reprod 6:217-224, 1993
maize pollen-specific gene	pollen	Hamilton et al, Plant Mol Biol 18:211-218, 1992
sunflower pollen-expressed gene	pollen	Baltz et al, Plant J 2:713-721, 1992
<i>B. napus</i> pollen-specific gene	pollen; anther; tapetum	Arnoldo et al, J Cell Biochem, Abstract No. Y101, 204, 1992
root-expressible genes	roots	Tingey et al, EMBO J 6:1, 1987
tobacco auxin-inducible gene	root tip	Van der Zaal et al, Plant Mol Biol 16:983, 1991
β -tubulin	root	Oppenheimer et al, Gene 63:87, 1988
tobacco root-specific genes	root	Conkling et al, Plant Physiol 93:1203, 1990
<i>B. napus</i> G1-3b gene	root	United States Patent No 5401836
SbPRP1	roots	Suzuki et al, Plant Mol Biol 21:109-119, 1993
AtPRP1; AtPRP3	roots; root hairs	http://salus.mediam.edu/mmg/tierney/html
RD2 gene	root cortex	http://www2.cnsu.edu/ncsu/research
TobRB7 gene	root vasculature	http://www2.cnsu.edu/ncsu/research
AtPRP4	leaves; flowers; lateral root primordia	http://salus.mediam.edu/mmg/tierney/html
seed-specific genes	seed	Simon et al, Plant Mol Biol 5:191, 1985; Scofield et al, J Biol Chem 262:12202, 1987; Baszczynski et al, Plant Mol Biol 14:633, 1990
Brazil Nut albumin	seed	Pearson et al, Plant Mol Biol 18:235-245, 1992
legumin	seed	Ellis et al, Plant Mol Biol 10:203-214, 1988
glutelin (rice)	seed	Takaiwa et al, Mol Gen Genet 208:15-22, 1986; Takaiwa et al, FEBS Lett 221:43-47, 1987
zein	seed	Matzke et al, Plant Mol Biol 14:323-32, 1990
napA	seed	Stalberg et al, Planta 199:515-519, 1996
wheat LMW and HMW glutenin-1	endosperm	Mol Gen Genet 216:81-90, 1989; Nucl Acids Res 17:461-462, 1989
wheat SPA	seed	Albani et al, Plant Cell 9:171-184, 1997
cZ19B1, maize 19 kDa zein	seed	WO0011177
mi1ps, maize myoinositol-1-Pi synthase	seed	WO0011177
wheat α , β , γ -gliadins	endosperm	EMBO J 3:1409-1415, 1984
barley <i>ltr1</i> promoter	endosperm	

barley B1, C, D, hordein	endosperm	Theor Appl Gen 98:1253-1262, 1999; Plant J 4:343-355, 1993; Mol Gen Genet 250:750-60, 1996
barley DOF	endosperm	Mena et al, Plant J 116:53-62, 1998
blz2	endosperm	EP99106056.7
synthetic promoter	endosperm	Vicente-Carbajosa et al, Plant J 13:629-640, 1998
rice prolamin NRP33	endosperm	Wu et al, Plant Cell Physiol 39: 885-889, 1998
rice α -globulin Glb-1	endosperm	Wu et al, Plant Cell Physiol 39:885-889, 1998
maize END genes	endosperm	WO0012733
barley END1	endosperm	WO9808961
barley NUC1	nucellus	WO9808961
rice OSH1	embryo	Sato et al, Proc Natl Acad Sci USA 93:8117-8122, 1996
rice α -globulin REB/OHP-1	endosperm	Nakase et al, Plant Mol Biol 33:513-522, 1997
rice ADP-glucose PP	endosperm	Trans Res 6:157-168, 1997
maize ESR gene family	endosperm	Plant J 12:235-246, 1997
sorghum γ -kafirin	endosperm	Plant Mol Biol 32:1029-1035, 1996
KNOX	embryo	Postma-Haarsma et al, Plant Mol Biol 39:257-271, 1999
rice oleosin	embryo and aleuron	Wu et al, J Biochem 123:386, 1998
sunflower oleosin	seed (embryo and dry seed)	Cummins et al, Plant Mol Biol 19:873-876, 1992
LEAFY	shoot meristem	Weigel et al, Cell 69:843-859, 1992
<i>Arabidopsis thaliana knat1</i>	shoot meristem	Accession number AJ131822
<i>Malus domestica kn1</i>	shoot meristem	Accession number Z71981
CLAVATA1	shoot meristem	Accession number AF049870
stigma-specific genes	stigma	Nasrallah et al, Proc Natl Acad Sci USA 85:5551, 1988; Trick et al, Plant Mol Biol 15:203, 1990
class I patatin gene	tuber	Liu et al, Plant Mol Biol 153:386-395, 1991
PCNA rice	meristem	Kosugi et al, Nucl Acids Res 19:1571-1576, 1991; Kosugi and Ohashi, Plant Cell 9:1607-1619, 1997
Pea TubA1 tubulin	Dividing cells	Stotz and Long, Plant Mol Biol 41:601-614, 1999
<i>Arabidopsis cdc2a</i>	cycling cells	Chung and Parish, FEBS Lett 362:215-219, 1995
<i>Arabidopsis Rop1A</i>	Anthers; mature pollen + pollen tubes	Li et al, Plant Physiol 118:407-417, 1998
<i>Arabidopsis AtDMC1</i>	Meiosis-associated	Klimyuk and Jones, Plant J 11:1-14, 1997
Pea PS-IAA4/5 and PS-IAA6	Auxin-inducible	Wong et al, Plant J 9:587-599, 1996
Pea farnesyltransferase	Meristematic tissues; phloem near growing tissues; light- and sugar-repressed	Zhou et al, Plant J 12:921-930, 1997
Tobacco (<i>N. sylvestris</i>) cyclin B1;1	Dividing cells / meristematic tissue	Trehin et al, Plant Mol Biol. 35:667-672, 1997
<i>Catharanthus roseus</i> Mitotic cyclins CYS (A-type) and CYM (B-type)	Dividing cells / meristematic tissue	Ito et al, Plant J 11:983-992, 1997
<i>Arabidopsis cyc1At</i> (=cyc B1;1) and <i>cyc3aAt</i> (A-type)	Dividing cells / meristematic tissue	Shaul et al, Proc Natl Acad Sci USA 93:4868-4872, 1996
<i>Arabidopsis tef1</i> promoter box	Dividing cells / meristematic tissue	Regad et al, Mol Gen Genet 248:703-711, 1995
<i>Catharanthus roseus cyc07</i>	Dividing cells / meristematic tissue	Ito et al, Plant Mol Biol 24:863-878, 1994
II: CONSTITUTIVE PROMOTERS		
Actin	constitutive	McElroy et al, Plant Cell 2:163-171, 1990
CAMV 35S	constitutive	Odell et al, Nature 313:810-812, 1985

CaMV 19S	constitutive	Nilsson et al, <i>Physiol Plant</i> 100:456-462, 1997
GOS2	constitutive	de Pater et al, <i>Plant J</i> 2:837-844, 1992
ubiquitin	constitutive	Christensen et al, <i>Plant Mol Biol</i> 18:675-689, 1992
rice cyclophilin	constitutive	Buchholz et al, <i>Plant Mol Biol</i> 25:837-843, 1994
maize histone H3	constitutive	Lepetit et al, <i>Mol Gen Genet</i> 231:276-285, 1992
alfalfa histone H3	constitutive	Wu et al, <i>Nucleic Acids Res</i> 17:3057-3063, 1989; Wu et al, <i>Plant Mol Biol</i> 11:641-649, 1988
actin 2	constitutive	An et al, <i>Plant J</i> 10:107-121, 1996
III: STRESS-INDUCIBLE PROMOTERS		
P5CS (delta(1)-pyrroline-5-carboxylate synthase)	salt, water	Zhang et al, <i>Plant Sci</i> 129:81-89, 1997
cor15a	cold	Hajela et al, <i>Plant Physiol</i> 93:1246-1252, 1990
cor15b	cold	Wijihelm et al, <i>Plant Mol Biol</i> 23:1073-1077, 1993
cor15a (-305 to +78 nt)	cold, drought	Baker et al, <i>Plant Mol Biol</i> 24: 01-713, 1994
rd29	salt, drought, cold	Kasuga et al, <i>Nature Biotechnol</i> 18:287-291, 1999
heat shock proteins, including artificial promoters containing the heat shock element (HSE)	heat	Barros et al, <i>Plant Mol Biol</i> 19 665-75, 1992. Marrs et al, <i>Dev Genet</i> 14:27-41, 1993. Schoff et al, <i>Mol Gen Genet</i> 217:246-53, 1989.
smHSP (small heat shock proteins)	heat	Waters et al, <i>J Exp Bot</i> 47:325-338, 1996
wcs120	cold	Ouellete et al, <i>FEBS Lett</i> 423:324-328, 1998
ci7	cold	Kirch et al, <i>Plant Mol Biol</i> 33:897-909, 1997
Adh	cold, drought, hypoxia	Dolferus et al, <i>Plant Physiol</i> 105:1075-87, 1994
pws18	water: salt and drought	Joshee et al, <i>Plant Cell Physiol</i> 39:64-72, 1998
ci21A	cold	Schneider et al, <i>Plant Physiol</i> 113:335-45, 1997
Trg-31	drought	Chaudhary et al, <i>Plant Mol Biol</i> 30:1247-57, 1996
Osmotin	osmotic	Raghothama et al, <i>Plant Mol Biol</i> 23:1117-28, 1993
LapA	wounding, environmental	WO99/03977 University of California/INRA
IV: PATHOGEN-INDUCIBLE PROMOTERS		
RB7	Root-knot nematodes (<i>Meloidogyne</i> spp.)	US5760386 - North Carolina State University; Opperman et al, <i>Science</i> 263:221-23, 1994
PR-1, 2, 3, 4, 5, 8, 11	fungal, viral, bacterial	Ward et al, <i>Plant Cell</i> 3:1085-1094, 1991; Reiss et al 1996; Lebel et al, <i>Plant J</i> 16:223-233, 1998; Melchers et al, <i>Plant J</i> 5:469-480, 1994; Lawton et al, <i>Plant Mol Biol</i> , 19:735-743, 1992
HMG2	nematodes	WO9503690 - Virginia Tech Intellectual Properties Inc.
Abi3	Cyst nematodes (<i>Heterodera</i> spp.)	unpublished
ARM1	nematodes	Barthels et al, <i>Plant Cell</i> 9:2119-2134, 1997 WO 98/31822 - Plant Genetic Systems
Att0728	nematodes	Barthels et al, <i>Plant Cell</i> 9: 2119-2134, 1997 PCT/EP98/07761
Att1712	nematodes	Barthels et al, <i>Plant Cell</i> 9, 2119-2134, 1997 PCT/EP98/07761
Gst1	Different types of pathogens	Strittmatter et al, <i>Mol Plant-Microbe Interact</i> 9:68-73, 1996
LEMMI	nematodes	WO 92/21757 - Plant Genetic Systems
CLE	geminivirus	PCT/EP99/03445 - CINESTAV
PDF1.2	Fungal including <i>Alternaria brassicicola</i> and <i>Botrytis cinerea</i>	Manners et al, <i>Plant Mol Biol</i> , 38:1071-1080, 1998
Thi2.1	Fungal - <i>Fusarium oxysporum f sp. matthiolae</i>	Vignutelli et al, <i>Plant J</i> 14:285-295, 1998
DB#226	nematodes	Bird and Wilson, <i>Mol Plant-Microbe Interact</i> 7:419-442, 1994 WO 95.322888

DB#280	nematodes	Bird and Wilson, Mol Plant-Microbe Interact 7:419-442, 1994 WO 95.322888
Cat2	nematodes	Niebel et al, Mol Plant-Microbe Interact 8:371-378, 1995
□Tub	nematodes	Aristizabal et al (1996), 8 th International Congress on Plant-Microbe Interaction, Knoxville US B-29
sHSP	nematodes	Fenoll et al (1997) In: Cellular and molecular aspects of plant-nematode interactions. Kluwer Academic, C. Fenoll, F.M.W. Grundler and S.A. Ohi (Eds.),
Tsw12	nematodes	Fenoll et al (1997) In: Cellular and molecular aspects of plant-nematode interactions. Kluwer Academic, C. Fenoll, F.M.W. Grundler and S.A. Ohi (Eds.)
Hs1(pro1)	nematodes	WO 98/122335 - Jung
nsLTP	viral, fungal, bacterial	Molina and Garcia-Olmedo FEBS Lett, 316:119-122, 1993
RIP	viral, fungal	Turner et al, Proc Natl Acad Sci USA 94:3866-3871, 1997

The promoters listed in the foregoing table are provided for the purposes of exemplification only and the present invention is not to be limited by the list provided therein. Those skilled in the art will readily be in a position to provide additional promoters that are useful in performing the present invention. The promoters listed may also be modified to provide specificity of expression as required.

Known are also promoters which are specifically active in tubers of potatoes or in seeds of different plants species, such as maize, Vicia, wheat, barley and the like. Inducible promoters may be used in order to be able to exactly control expression under certain environmental or developmental conditions such as pathogens, anaerobia, or light. Examples of inducible promoters include the promoters of genes encoding heat shock proteins or microspore-specific regulatory elements (WO96/16182). Furthermore, the chemically inducible Tet-system may be employed (Gatz, Mol. Gen. Genet. 227 (1991); 229-237). Further suitable promoters are known to the person skilled in the art and are described, *e.g.*, in Ward (Plant Mol. Biol. 22 (1993), 361-366). The regulatory elements may further comprise transcriptional and/or translational enhancers functional in plants cells. Furthermore, the regulatory elements may include transcription termination signals, such as a poly-A signal, which lead to the addition of a poly A tail to the transcript which may improve its stability.

In the case that a nucleic acid molecule according to the invention is expressed in the sense orientation, the coding sequence can be modified such that the protein is located in any desired compartment of the plant cell, *e.g.*, the nucleus, endoplasmatic reticulum, the vacuole, the mitochondria, the plastids, the apoplast, or the cytoplasm.

Methods for the introduction of foreign DNA into plants are also well known in the art. These include, for example, the transformation of plant cells or tissues with T-DNA using *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes*, the fusion of protoplasts, direct gene transfer (see, *e.g.*, EP-A 164 575), injection, electroporation, biolistic methods
5 like particle bombardment, pollen-mediated transformation, plant RNA virus-mediated transformation, liposome-mediated transformation, transformation using wounded or enzyme-degraded immature embryos, or wounded or enzyme-degraded embryogenic callus and other methods known in the art. The vectors used in the method of the invention may contain further functional elements, for example "left border"- and "right
10 border"-sequences of the T-DNA of *Agrobacterium* which allow for stably integration into the plant genome. Furthermore, methods and vectors are known to the person skilled in the art which permit the generation of marker free transgenic plants, *i.e.*, the selectable or scorable marker gene is lost at a certain stage of plant development or plant breeding. This can be achieved by, for example, cotransformation (Lyznik, Plant Mol.
15 Biol. 13 (1989), 151-161; Peng, Plant Mol. Biol. 27 (1995), 91-104) and/or by using systems which utilize enzymes capable of promoting homologous recombination in plants (see, *e.g.*, WO97/08331; Bayley, Plant Mol. Biol. 18 (1992), 353-361); Lloyd, Mol. Gen. Genet. 242 (1994), 653-657; Maeser, Mol. Gen. Genet. 230 (1991), 170-176; Onouchi, Nucl. Acids Res. 19 (1991), 6373-6378). Methods for the preparation of
20 appropriate vectors are described by, *e.g.*, Sambrook (Molecular Cloning; A Laboratory Manual, 2nd Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

Suitable strains of *Agrobacterium tumefaciens* and vectors, as well as transformation of *Agrobacteria*, and appropriate growth and selection media are
25 described in, for example, GV3101 (pMK90RK), Koncz, Mol. Gen. Genet. 204 (1986), 383-396; C58C1 (pGV 3850kan), Deblaere, Nucl. Acid Res. 13 (1985), 4777; Bevan, Nucleic. Acid Res. 12(1984), 8711; Koncz, Proc. Natl. Acad. Sci. USA 86 (1989), 8467-8471; Koncz, Plant Mol. Biol. 20 (1992), 963-976; Koncz, Specialized vectors for gene tagging and expression studies. In: Plant Molecular Biology Manual Vol 2, Gelvin and
30 Schilperoort (Eds.), Dordrecht, The Netherlands: Kluwer Academic Publ. (1994), 1-22; EP-A-120 516; Hoekema: The Binary Plant Vector System, Offsetdrukkerij Kanter B.V., Alblasterdam (1985), Chapter V, Fraley, Crit. Rev. Plant. Sci., 4, 1-46; An, EMBO J. 4 (1985), 277-287). Although the use of *Agrobacterium tumefaciens* is preferred in the method of the invention, other *Agrobacterium* strains, such as *Agrobacterium*
35 *rhizogenes*, may be used, for example, if a phenotype conferred by said strain is desired.

Methods for the transformation using biolistic methods are known to the person skilled in the art; see, *e.g.*, Wan, Plant Physiol. 104 (1994), 37-48; Vasil, Bio/Technology 11 (1993), 1553-1558 and Christou (1996) Trends in Plant Science 1, 423-431.

Microinjection can be performed as described in Potrykus and Spangenberg (eds.), *Gene Transfer To Plants*. Springer Verlag, Berlin, NY (1995).

The transformation of most dicotyledonous plants may be performed using the methods described above or using transformation via biolistic methods as, *e.g.*, described
5 above as well as protoplast transformation, electroporation of partially permeabilized cells, or introduction of DNA using glass fibers.

In general, the plants which are modified according to the invention may be derived from any desired plant species. They can be monocotyledonous plants or dicotyledonous plants, preferably they belong to plant species of interest in agriculture, wood culture or
10 horticulture interest, such as crop plants (*e.g.*, maize, rice, barley, wheat, rye, oats), potatoes, oil producing plants (*e.g.*, oilseed rape, sunflower, pea nut, soy bean), cotton, sugar beet, sugar cane, leguminous plants (*e.g.*, beans, peas), or wood producing plants, preferably trees.

The present invention also relates to a transgenic plant cell which contains
15 (preferably stably integrated into its genome) a nucleic acid molecule of the present invention linked to regulatory elements which allow expression of the nucleic acid molecule in plant cells. The presence and expression of the nucleic acid molecule in the transgenic plant cells leads to the synthesis of an ICK protein and may lead to physiological and phenotypic changes in plants containing such cells.

Transformed plant cells which are derived by any of the above transformation
20 techniques can be cultured to regenerate a whole plant which possesses the transformed genotype. Such regeneration techniques often rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced with a polynucleotide of the present
25 invention.

Plant cells transformed with a plant expression vector can be regenerated, *e.g.*, from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration
30 from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture*, *Handbook of Plant Cell Culture*, Macmillilan Publishing Company, New York, pp. 124-176 (1983); and *Binding, Regeneration of Plants, Plant Protoplasts*, CRC Press, Boca Raton, pp. 21-73 (1985).

Transformed plant cells, calli or explant can be cultured on regeneration medium
35 in the dark for several weeks, generally about 1 to 3 weeks to allow the somatic embryos to mature. Preferred regeneration media include media containing MS salts, such as PHI-E and PHI-F media. The plant cells, calli or explant are then typically cultured on rooting medium in a light/dark cycle until shoots and roots develop. Methods for plant

regeneration are known in the art and preferred methods are provided by Kamo *et al.*, (*Bot. Gaz.* 146(3):324-334, 1985), West *et al.*, (*The Plant Cell* 5:1361-1369, 1993), and Duncan *et al.* (*Planta* 165:322-332, 1985).

Small plantlets can then be transferred to tubes containing rooting medium and
5 allowed to grow and develop more roots for approximately another week. The plants can then be transplanted to soil mixture in pots in the greenhouse.

The regeneration of plants containing the foreign gene introduced by *Agrobacterium* from leaf explants can be achieved as described by Horsch *et al.*, *Science*, 227:1229-1231 (1985). In this procedure, transformants are grown in the
10 presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species being transformed as described by Fraley *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth.
15 Transgenic plants of the present invention may be fertile or sterile.

Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.*, 38:467-486(1987). The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, from example, *Methods for*
20 *Plant Molecular Biology*, A. Weissbach and H. Weissback, eds., Academic Press, Inc., San Diego, Calif. (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots, rooting ht transformant shoots and growth of the plantlets in soil. For maize cell culture and regeneration see generally, *The Maize Handbook*, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn*
25 *Improvement*, 3rd edition, Sprague and Dudley Eds., American Society of Agronomy, Madison, Wisconsin (1988).

One of skill will recognize that after the recombinant expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding
30 techniques can be used, depending upon the species to be crossed.

In vegetatively propagated crops, mature transgenic plants can be propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed propagated crops, mature transgenic plants can
35 be self crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants that would produce the selected phenotype, (*e.g.*, altered cell cycle content or composition).

Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit and the like are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid of the present invention. Progeny and variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.

Transgenic plants expressing the selectable marker can be screened for transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expression-positive plants. Standard techniques for RNA analysis can be employed and include PCR amplification assays using oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition, in situ hybridization and immunocytochemistry according to standard protocols can be done using heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Generally, a number of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.

A preferred embodiment of the invention is a transgenic plant that is homozygous for the added heterologous nucleic acid; *i.e.*, a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered cell division relative to a control plant (*i.e.*, native, non-transgenic). Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.

The present invention also relates to transgenic plants and plant tissue comprising transgenic plant cells according to the invention. Due to the (over)expression of an ICK molecule, *e.g.*, at developmental stages and/or in plant tissue in which they do not naturally occur, these transgenic plants may show various physiological, developmental and/or morphological modifications in comparison to wild-type plants.

Therefore, part of this invention is the use of the ICK molecules to modulate the cell cycle and/or plant cell division and/or growth in plant cells, plant tissues, plant organs and/or whole plants. To the scope of the invention also belongs a method for influencing the activity of cell cycle control proteins such as CDKs and cyclins in a plant cell by transforming the plant cell with a nucleic acid molecule according to the invention and/or manipulation of the expression of the molecule.

Furthermore, the invention also relates to a transgenic plant cell which contains (preferably stably integrated into its genome) a nucleic acid molecule of the invention or part thereof, wherein the transcription and/or expression of the nucleic acid molecule or part thereof leads to reduction of the synthesis of an ICK. In a preferred embodiment, the reduction is achieved by an anti-sense, sense, ribozyme, co-suppression and/or dominant mutant effect. The reduction of the synthesis of a protein according to the invention in the transgenic plant cells can result in an alteration in, *e.g.*, cell division. In transgenic plants comprising such cells this can lead to various physiological, developmental and/or morphological changes.

In yet another aspect, the invention relates to harvestable parts and to propagation material of the transgenic plants of the invention which either contain transgenic plant cells expressing a nucleic acid molecule according to the invention or which contain cells which show a reduced level of the described protein. Harvestable parts can be in principle any useful parts of a plant, for example, flowers, pollen, seedlings, tubers, leaves, stems, fruit, seeds, roots etc. Propagation material includes, for example, seeds, fruits, cuttings, seedlings, tubers, rootstocks, and the like.

VI. Agricultural Compositions

The ICK nucleic acid molecules, ICK proteins, and anti-ICK antibodies (also referred to herein as "active compounds") of the invention can be incorporated into compositions useful in agriculture and in plant cell and tissue culture. Plant protection compositions can be prepared by conventional means commonly used for the application of, for example, herbicides and pesticides. For example, certain additives known to those skilled in the art stabilizers or substances which facilitate the uptake by the plant cell, plant tissue or plant may be used.

The agricultural compositions can be included in a container, pack, or dispenser together with instructions for administration.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing are incorporated herein by reference.

EXAMPLES

Unless stated otherwise in the example, all recombinant DNA techniques are performed according to protocols as described in Sambrook *et al.* (1989), Molecular cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY or in Ausubel *et al.* (1999) Current Protocols in Molecular Biology, CD-ROM, John Wiley & Sons, Inc, NY. Standard material and methods for plant molecular work are described in Plant Molecular Biology Labfase (1993) by R.D.D. Croy, jointly published by BIOS Scientific Publications Ltd (UK) and Blackwell Scientific Publications (UK).

10 **EXAMPLE 1: CONSTRUCTION OF THE RICE TWO-HYBRID cDNA LIBRARY**

- For the identification of ICKs, a two-hybrid system based on Gal4 transcriptional activation was developed with the aim of identifying CDC2Os1-interacting proteins. Total RNA was extracted from cell suspension cultures harvested at 0, 3, 6, 9, and 12 days after subculturing in fresh medium. These timepoints correspond to cells in the lag phase following subculture, the exponential growth, and the late stationary phase. Equimolar amounts of total RNA (5 x 100 µg) from the different fractions were then pooled. The total RNA sample was used to purify 5 µg of polyA⁺ mRNA using the Poly(A) Quik mRNA Isolation kit (Stratagene), based on oligo(dT) cellulose columns.
- 20 Synthesis and subcloning of the cDNA into the HybriZAP-2.1 lambda vector were performed according to the manufacturer's guidelines (Stratagene). Approximately 2 million independent plaque-forming units were produced, with an average insert size of 1.0 kb. Bank amplification and mass excision to obtain phagemids used to transform yeast were done following the same instruction manual.
- 25 The rice Cdc2-Os1 gene was amplified using the following primers (sense: 5'-AGGGATGTTTAATACCACTAC-3', SEQ ID NO:33 and antisense primer: 5'-GCACAGTTGAAGTGAAGTTGC-3', SEQ ID NO:34) and the *Pfx* DNA polymerase (Promega). The PCR fragment was blunt end cloned into the *Sma*I site of pBD-Gal4 (Stratagene) bait vector in frame with the binding domain. The bait vector was
- 30 introduced in yeast PJ69-4a according to the "Quick and Easy TRAF0 Protocol" (Gietz, R.D. and R.A. Woods, (1994) High Efficiency transformation in Yeast (Invited Book Chapter) In: Molecular Genetics of Yeast: Practical Approaches, ed. J.A. Johnston, Oxford University Press pp. 121-134.) and the transformants selected on dropout medium lacking tryptophane. These transformants were confirmed by PCR using the
- 35 above mentioned primers.

Using the yeast two-hybrid assay, a number of Cdc2Os1-interacting clones were identified. Surprisingly, however, none of these clones was an ICK.

The lambdaHybriZAP-2.1 (Stratagene, La Jolla, CA) two-hybrid cDNA library made from the rice suspension culture as outlined above was deposited on October 27, 2000 with the 'Belgian co-ordinated collections of micro-organisms' (BCCM-LMBP, University Gent, Laboratorium voor Moleculaire Biologie, K.L. Ledeganckstraat 35, B-9000 Gent, Belgium) according to the regulations of the Budapest Treaty. BCCM is recognized by the WIPO as an IDA. The accession number of the deposit is LMBP4268).

EXAMPLE 2: MOLECULAR CLONING OF ICK FRAGMENTS

To overcome the aforementioned problem, public sequence databases (available at, for example, <http://www.ncbi.nlm.nih.gov>, <http://www.tigr.org>) were screened for the "GRYEW" amino acid motif located at the carboxy-termini of all known plant ICKs, using the advanced BLAST program with a high expect value (1000).

Using the foregoing database mining approach, four hits were obtained in *Oryza sativa*, one EST (partial cDNA, GenBank accession number AU075786, SEQ ID NO:1, termed **OsICK2**), two GSS (partial genomic sequences, GenBank accession number AQ574895, SEQ ID NO:2, termed **OsICK1** and GenBank accession number AQ365042, SEQ ID NO:3, termed **OsICK3**), and one HTGS (high throughput genomic sequences, GenBank accession number AC069145, SEQ ID NO:4, termed **OsICK4**), none of them annotated as encoding a putative ICK protein. Four additional unannotated clones, two *Zea mays* ESTs (GenBank accession number AI737717, SEQ ID NO:5, termed **ZmICK1**; and GenBank accession number AW267370, SEQ ID NO:6, termed **ZmICK2**) a *Sorghum bicolor* BAC genomic clone (GenBank accession number AF061282, SEQ ID NO:7, termed **SbICK**), and a *Pinus taeda* cDNA (GenBank accession number AA556411, SEQ ID NO:8, termed **PtICK**) were identified as plant ICKs.

The following Primers were designed to perform a PCR to amplify the identified fragments:

OsICK1 yielding a 178 bp DNA fragment:
5'-TAACTCGATCCCCAGCCTCTCCCA-3' (SEQ ID NO:25) and
5'-TACAATTACGACATTGCCCTCGAC-3' (SEQ ID NO:26)

OsICK2 yielding a 430 bp fragment:
5'-CCGCCGAGATCGAGGCGTTCTTCG-3' (SEQ ID NO:27) and
5'-AAACCTCTGATAAATACTGGGACG-3' (SEQ ID NO:28)

OsICK3 yielding a 200 bp fragment:

5'-CTGTCACACACTCACACTCACACT -3' (SEQ ID NO:29) and
5'-CGAAGAACGCCTCGATCTCC-3' (SEQ ID NO:30)

OsICK4 yielding a 271 bp fragment:

- 5 5'-GAATACCAGGGAGACGACACCTTGC-3' (SEQ ID NO:31)
5'-TCAGTCTAGCTTGACCCATTCAAAC-3' (SEQ ID NO:32)

The two-hybrid bank (in the form of plasmid) was used to amplify all of these fragments, which were then subcloned into the pUC18 SmaI site and transformed into *E. coli* following standard molecular biology techniques.

EXAMPLE 3: HYBRIDIZATION SCREENING OF THE RICE TWO-HYBRID cDNA LIBRARY AND MOLECULAR CLONING OF FULL-LENGTH OsICK2 cDNA

- 15 Following plasmid purification from *E. coli*, the four fragments were isolated by restriction and gel-purified following art known techniques. The respective fragments were radioactively labelled with the aim to identify, via homologous hybridisation, the corresponding cDNAs in the two-hybrid library. Serial dilutions of a plasmid preparation (6 µg/µl) of the library was used as template for PCR amplification.
- 20 For OsICK2, the 430 bp could be amplified until dilution 10⁻⁴. This dilution was used to transform XL-10 Gold (Stratagene) ultracompetent cells. Approximately 70,000 colonies were then screened with the labelled OsICK2 fragment. A number of putative positives colonies were re-screened via PCR using the OsICK2 primers. A total of 5 positive clones were finally obtained, one of which was further characterized.
- 25 Sequencing of the insert indicated that this clone was indeed the OsICK2 full length clone.

EXAMPLE 4: TWO-HYBRID SCREENING AND HYBRIDIZATION SCREENING OF THE RICE TWO-HYBRID cDNA LIBRARY AND MOLECULAR CLONING OF FULL-LENGTH OsICK4 cDNA

- 30 As described in Example 1, a first two-hybrid screening of the rice two-hybrid cDNA library using Cdc2-Os1 as bait did not yield any OsICKs as Cdc2-Os1 interactors. The two-hybrid screening was repeated in a second attempt to obtain OsICK clones via this methodology. In parallel, hybridization screening of the rice two-hybrid cDNA library was performed as described in Example 3 with the aim of obtaining a full-length OsICK4 cDNA.
- 35

Two-Hybrid screening

- Screening of a library prepared from an actively dividing rice cell suspension was accomplished by sequential transformation of yeast. PJ69-4a carrying pBD-*cdc2Os*-Gal4 was transformed with library DNA according to the protocol Matchmaker
- 5 Two-Hybrid System (protocol#PT1020-1, version#PR4Y411) from CLONTECH Laboratories, Inc. After a library scale transformation (efficiency 17268 clones / μ g DNA) a total number of 672 clones were recovered from selective medium (SD-TLH) lacking tryptophane, leucine and histidine. These clones were further selected on SD-TLA (lacking tryptophane, leucine and adenine) and SD-TLAH (lacking tryptophane,
- 10 leucine, adenine and histidine). Nine clones were finally selected and sequenced. Among the nine clones a CDK inhibitor was identified which was a putative partial OsICK4 cDNA sequence missing the 5' end.

Hybridization screening

- 15 The OsICK4 fragment cloned in pUC 18 as described in Example 2 was used to prepare a probe for the hybridization screening of the rice two-hybrid cDNA library. The primers with SEQ ID NO:31 and SEQ ID NO:32 (see Example 2) were used for this purpose. Approximately 750.000 plaque-forming units from the cell suspension two-hybrid cDNA library were screened. Plaques were transferred to Hybond N+
- 20 membranes (Amersham). The filters obtained were prehybridized in sodium phosphate 0.25M, (pH7.2), SDS 7% at 60°C for 4 hours. Hybridization was performed with the prehybridization buffer containing 50 ng of [α]³²P-dCTP-labelled probe at 60 °C overnight (protocol of Church G.M. and Gilbert W. *PNAS USA* 81:1991-1994). The filters were washed twice with 1XSSC, 0.1%SDS at 60 °C for 30 minutes and then once
- 25 with 0.1XSSC, 0.1%SDS at 60 °C for 30 minutes. The membranes were placed into a film cassette and exposed to film for 6 hours. Four clones were isolated. A second round of screening on these clones was performed. Pure positive plaques were isolated from which the phagemids were excised. Two clones were obtained for sequencing. One of them is a full length clone with a size of 1.1 kb. This clone contains an ORF of 585
- 30 bp encoding a protein of 194 amino acids. This ORF comprises the partial OsICK4 nucleotide sequence as identified in the two-hybrid screening (*supra*; see Figure 10).

- The nucleotide sequence of this full-length OsICK4 is depicted in Figure 1B and set forth as SEQ ID NO:43. The amino acid sequence of this full-length OsICK4 is depicted in Figure 11 and set forth as SEQ ID NO:44. The OsICK4 genomic sequence
- 35 was also determined as is set forth herein in SEQ ID NO:45 and depicted in Figure 18.

On September 30, 2000, the fifth version of GenBank Accession Number AC069145 was released in GenBank. GenBank Accession Number AC069145 was previously identified by the inventors as containing a putative OsICK sequence (see

Example 2). Contrary to previous versions, AC069145.5 now has the putative OsICK annotated as a putative cyclin-dependent kinase inhibitor identified by protein ID=AAG16867.1. The ORF prediction and, thus, the predicted protein sequence is, however, different from the cDNA and protein sequences experimentally determined by the present application. The OsICK protein predicted in GenBank (protein ID=AAG16867.1) contains an insertion of 48 superfluous amino acids and is, therefore, almost certainly functionally inactive. The comparison of the GenBank predicted protein and the currently experimentally obtained protein is set forth herein in Figure 11.

The current experiments also clearly demonstrate the physical interaction of the rice cyclin-dependent kinase Cdc2-Os1 with the rice cyclin-dependent kinase inhibitor OsICK4 as a partial clone of the latter was obtained via two-hybrid screening of a rice cDNA library. These data furthermore indicate that the NH₂-terminal 66 amino acids of the OsICK4 are apparently not required for interaction with Cdc2-Os1.

15 **EXAMPLE 5: CHARACTERIZATION OF OsICK2 AND OsICK4**

As described in the preceding example, screening of the rice two-hybrid cDNA library resulted in the identification of the full length OsICK2 cDNA (SEQ ID NO:9) encoding a full-length rice OsICK2 protein (SEQ ID NO:10) and of the full length OsICK4 cDNA (SEQ ID NO:43) encoding a full-length rice OsICK4 protein (SEQ ID NO:44). The partial open reading frame of SEQ ID NO:1 encodes, when taking into account a frame shift at nucleotide 52 of SEQ ID NO:1, the carboxy-terminal part of the OsICK2 protein. When comparing the nucleotide sequences SEQ ID NO:1 and SEQ ID NO:9, however, a stretch of 104 nucleotides (nucleotides 1121-1224 in SEQ ID NO:9) can be discerned in the 3' untranslated region of SEQ ID NO:9 which are not present in SEQ ID NO:1 (see Figure 1). This indicates that OsICK2 primary transcripts are prone to alternative polyadenylation site selection. A closer examination of the 3' untranslated region in SEQ ID NO:9 reveals the presence of two canonical mRNA polyadenylation sites (Edwards-Gilbert et al. 1997), namely AAUAAA (nucleotides 922-927 in SEQ ID NO:9) and AUUAAA (nucleotides 1156-1161 in SEQ ID NO:9). The second of these sites is not present in the 3' untranslated region of SEQ ID NO:1 which is consistent with the use of alternative polyadenylation sites in primary OsICK2 transcripts.

Another interesting feature of the 3' untranslated regions of the two different transcripts most likely derived from the same OsICK2 gene concerns class I AREs (AU-rich elements). Transcripts corresponding to SEQ ID NO:1 comprise one such ARE (AUUUA, nucleotides 419-423 in SEQ ID NO:1) whereas transcripts corresponding to SEQ ID NO:9 contain two AREs (AUUUA; nucleotides 1076-1080 and 1161-1165 in SEQ ID NO:9). A putative ARE is also present in the 3' untranslated region of OsICK4 (AUUUA; nucleotides 729-733 in SEQ ID NO:43). AREs are also present 3' relative to

the stop codons in OsICK1 (stop codon 'TGA': nucleotides 154-156 of SEQ ID NO:2; ARE 'ATTTA': nucleotides 596-600, 600-604, 616-620 and 634-638 of SEQ ID NO:2); in ZmICK1 (stop codon 'TGA': nucleotides 350-352 of SEQ ID NO:5; ARE 'ATTTA': nucleotides 545-549 of SEQ ID NO:5) and in PtICK (stop codon 'TGA': nucleotides 161-163 of SEQ ID NO:8; ARE 'ATTTA': nucleotides 284-288 of SEQ ID NO:8). AREs are known to confer instability to an mRNA (Brewer 1991, Chen and Shiyu 1995, Malter 1989). AREs are furthermore recognized by HuR proteins, *i.e.*, a ubiquitously expressed Elav protein family member.

Binding of HuR to AREs (and the poly-A-tail) enhances transcript stability (Fan and Steitz 1998). Interestingly, transcripts of the mammalian ICK p21Cip1 are stabilized upon UV-C irradiation of cells. Stabilization of p21Cip1 mRNA implies a HuR and increases p21Cip1 protein levels (Wang et al. 2000). p21Cip1 is known to enforce S-phase arrest upon the occurrence of DNA damage, *e.g.*, as a result of UV irradiation (Chen et al. 1995). AREs are the target of Rnase E which is conserved from bacteria to humans. Importantly, mRNAs containing more than one ARE are cleaved more efficiently by Rnase E (Wennborg et al. 1995). Thus, the transcript corresponding to SEQ ID NO:9 may be degraded faster than the transcript corresponding to SEQ ID NO:1. Without wishing to be bound by theory or mode of action, a double function can be envisaged for OsICK2: a first function related to cell cycle control and implying rapid turnover of an unstable transcript and a second function related to differentiation (*i.e.*, cell cycle withdrawal) and/or cell cycle arrest implying a transcript of higher stability. Alternatively, the opposite situation can be envisaged as transcript stability and translation efficiency can be positively or negatively correlated (Edwards-Gilbert et al. 1997 for review).

Another possibility for the regulation of OsICK2 function lies in the fact that alternative transcript polyadenylation can, as the skilled artisan will know, be tissue-specific and/or developmentally-specific and/or cell cycle-regulated (Edwards-Gilbert et al. 1997). Notable examples of cell cycle genes of which the transcripts are alternatively polyadenylated comprise dihydrofolate reductase (DHFR, required for DNA synthesis during S-phase and for DNA repair; Noé et al. 1999) and metazoan cyclin D1 (Kiyokawa et al. 1992, Xiong et al. 1991, Yarden et al. 1995). Alternation in DHFR transcript polyadenylation is moreover cell cycle-regulated (Noé et al. 1999). Changes in polyadenylation site usage in cyclin D1 occur during zebrafish embryonic development (Yarden et al. 1995). The polyadenylation process itself is also regulated by the cell cycle: the poly-A-polymerase (PAP) is inhibited by phosphorylation by mitosis-specific Cdc2-cyclin B complexes (Colgan et al. 1996) and PAP activity is increased in cells stimulated to enter the cell cycle (Benz et al. 1977, Coleman et al. 1997, Hauser et al.

1978). It will be clear to the skilled artisan that the above mentioned mechanisms of regulation of gene expression may also apply to OsICK4 gene expression.

The amino acid sequences of OsICK2 (SEQ ID NO:10) and OsICK4 (SEQ ID NO:44) were aligned with all full-length plant ICK amino acid sequences known in the art (see Figure 2). The amino acid sequences of OsICK2 (SEQ ID NO:10) and OsICK4 (SEQ ID NO:44) were also aligned with the partial amino acid sequences of the other plant ICKs identified in the present invention: the partial amino acid sequence of OsICK1 (SEQ ID NO:11, encoded by the nucleotide sequence of SEQ ID NO:2), the partial amino acid sequence of OsICK3 (SEQ ID NO:12 encoded by the nucleotide sequence of SEQ ID NO:3), the partial amino acid sequence of the *Zea mays* ICK1 (SEQ ID NO:14 encoded by the nucleotide sequence of SEQ ID NO:5), the partial amino acid sequence of the *Zea mays* ICK2 (SEQ ID NO:15 encoded by the nucleotide sequence of SEQ ID NO:6) the partial amino acid sequence of the *Sorghum bicolor* ICK (SEQ ID NO:16 encoded by the nucleotide sequence of SEQ ID NO:7) and the partial amino acid sequence of the *Pinus taeda* ICK (SEQ ID NO:17 encoded by the nucleotide sequence of SEQ ID NO:8) (see Figure 3).

Identities and similarities between the amino acid sequences of OsICK2 (SEQ ID NO:10) and OsICK4 (SEQ ID NO:44) and the amino acid sequences of other known plant ICKs are set forth in Table 6. The overall identity percentages between all listed ICKs range from 23 to 51% and the similarity percentages between 28 and 59 %.

Table 6. Percentage of identity (bold) and similarity (italics) between the indicated amino acid sequences. The GAP program belonging to the GCG software (Wisconsin Package version 10.1; Madison, Wisconsin) was used with default settings gap weight = 8 and length weight =2.

At1-7: *Arabidopsis thaliana* ICK1-7

Os2/4: *Oryza sativa* ICK2/4

Alf: *Medicago sativa* (alfalfa) ICK

Che: *Chenopodium rubrum* ICK

	At1	At2	At3	At4	At5	At6	At7	Os2	Os4	Alf	Che
At1	100	34	31	28	31	30	30	24	28	26	32
At2	44	100	30	23	23	35	28	24	23	29	27
At3	37	38	100	46	51	30	34	26	46	41	37
At4	38	36	55	100	34	26	26	31	38	39	27
At5	39	31	59	45	100	27	28	24	38	39	29
At6	37	46	34	36	34	100	49	30	34	24	30
At7	36	40	44	35	38	56	100	30	27	23	29

Os2	31	31	42	35	32	37	37	100	46	30	31
Os4	36	32	53	47	45	41	37	52	100	41	26
Alf	28	37	49	50	45	32	30	38	47	100	26
Che	39	37	42	35	38	37	38	38	36	34	100

Identities and similarities were calculated between the amino acid sequences of the relevant parts of the full-length OsICK2 amino acid sequence (SEQ ID NO:10) and the full-length OsICK4 amino acid sequence (SEQ ID NO:43) with the partial amino acid sequence of OsICK1 (SEQ ID NO:11), the partial amino acid sequence of OsICK3 (SEQ ID NO:12), the partial amino acid sequence of the *Zea mays* ICK1 (SEQ ID NO:14), the partial amino acid sequence of the *Zea mays* ICK2 (SEQ ID NO:15), the partial amino acid sequence of the *Sorghum bicolor* ICK (SEQ ID NO:16), and the partial amino acid sequence of the *Pinus taeda* ICK (SEQ ID NO:17). The results of this calculation are included in Table 7.

Table 7. Percentage of identity (**bold**) and similarity (*italics*) between the indicated amino acid sequences. The GAP program belonging to the GCG software (Wisconsin Package version 10.1; Madison, Wisconsin) was used with default settings gap weight = 8 en length weight = 2.

	OsICK1	OsICK2	OsICK3	OsICK4	ZmICK1	ZmICK2	SbICK	PtICK
OsICK1	100	50	15	48	52	48	71	55
OsICK2	64	100	40	36	64	33	41	38
OsICK3	35	44	100	29	25	24	43	47
OsICK4	57	42	36	100	37	75	30	56
ZmICK1	62	69	31	46	100	37	35	39
ZmICK2	57	38	31	81	41	100	37	50
SbICK	86	46	47	38	44	43	100	42
PtICK	55	49	53	67	49	63	46	100

All of the plant ICK protein sequences, including the OsICK2 (SEQ ID NO:10) sequence of the invention, were fed into the PHD secondary structure prediction software (Rost and Sander (1993) *J.Mol.Biol.* 232, 584-599 and Rost, B. and Sander, C. (1994) *Proteins* 19, 55-72). The results of this analysis are summarized in Figure 4. The conserved ICK motifs 1, 2 and 3 (SEQ ID NO:18, 19 and 20, respectively) present in all plant ICKs as described *supra* are not only conserved at the amino acid sequence level but also at the level of the predicted secondary structure with motif 2 being partially involved in an extended β -sheet and motifs 1 and 3 being (partially) α -helical. When present, motifs 4 and 6 (SEQ ID NO:21 and 23, respectively) are predicted to be (partially) α -helical. Motif 5 (SEQ ID NO:22) is, when present, predicted to be either

partially α -helical or partially an extended β -sheet. Outside the conserved motifs, however, the predicted secondary structures of all plant ICKs, including the OsICK2 protein (SEQ ID NO:10) of the present invention, are different and unique. This observation is clearly in line with the low overall homologies between plant ICKs. The

5 OsICK2 protein, in particular, is characterized by extensive α -helical stretches especially in between motifs 5 and 6 and in between motifs 6 and 4. The OsICK2 region between motifs 4 and 3, furthermore, only contains predicted α -helical segments and no extended β -sheets. These characteristics are different from those found in the plant ICKs belonging to the same family as OsICK2, namely alfalfa ICK and *Arabidopsis* ICKs

10 ICK3, ICK4 and ICK5. PHD secondary prediction was not performed for the OsICK4 (SEQ ID NO:44) protein.

The presented sequence and secondary structure data, thus, clearly distinguish OsICK2 from other plant ICKs and, more specifically, from plant ICKs belonging to the same family as OsICK2.

15

EXAMPLE 6: EXPRESSION ANALYSIS OF OsICK1, OsICK2 AND OsICK4

RNA isolation

Total RNA was extracted from 100-200 mg of immature seed, leave, root, shoot or fraction enriched apical meristems. Frozen tissues were ground with liquid nitrogen in an ice cold mortar. Two microliters of extraction buffer (1M Tris-HCl pH 9, 1%SDS, 5% β -mercaptoethanol) and an equal volume of phenol/chloroform/isoamyl alcohol (PCI 25/24/1) were added in the mortar and grinding continued until the paste thawed. The mixture was transferred to a tube and vortexed at 10,000 rpm for 10 minutes. The

20 aqueous layer was removed and re-extracted with an equal volume of PCI. After centrifugation (at 10,000 rpm for 10 minutes) the supernatant was precipitated at 4°C for 10 minutes with a 1/10 volume of 3M sodium acetate and 0.8 volumes of cold isopropanol. The pellet recovered after centrifugation was washed twice with 70% ethanol/0.1M sodium acetate (pH5.5) before resuspending in 0.5 ml of H₂O. RNA was

25 precipitated by adding an equal volume of 4M LiCl and incubating on ice overnight. The RNA was collected by centrifugation and the pellet washed twice with 70% ethanol/0.1M sodium acetate. The pellet was drained and dissolved in approximately 80 μ l of water.

35 cDNA synthesis

The cDNA synthesis was performed using the "Superscript preamplification system for first strand cDNA synthesis" kit from Gibco BRL. Three μ g of total RNA were mixed with 0.5 μ g of an anchored oligo (dT)₂₅ and 12 μ l of DEPC water. The

- mixture was incubated at 70°C for 10 minutes and then incubated on ice for at least 1 minute. The following solutions were then added: 2 µl of 10X PCR buffer, 2 µl of 25 mM MgCl₂, 1 µl of 10 mM dNTP mix, and 2 µl of 0.1 M DTT. After an incubation of the mixture at 42°C for 5 minutes, 1 µl of Superscript II RT was added and the
- 5 incubation at 42 °C was continues for 50 minutes. The reaction was terminated at 70°C for 15 minutes and then chilled on ice. One µl of RNase H was added and the reaction was incubated for 20 minutes at 37°C.

Amplification of the target cDNA

- 10 The first strand cDNA obtained as described in the previous paragraph was amplified using PCR, using the following reactants:

	10X PCR buffer	5 µl
	2 mM dNTP mix	5 µl
15	sense primer (10 µM)	1 µl
	antisense primer (10 µM)	1 µl
	Taq DNA polymerase (Boehringer)	0.5 µl
	cDNA	2 µl
	water	35.5 µl

- 20 The primers used for the RT-PCR amplifications were as described in Example 2: primers with SEQ ID NOs: 25 and 26 for OsICK1; primers with SEQ ID NOs: 27 and 28 for OsICK2; and primers with SEQ ID NOs: 31 and 32 for OsICK4.

The DNA amplification was carried out using the following conditions (for OsICK4 amplification, the primer annealing temperature was 58°C instead of 55°C):

- 25
- | | | |
|-----------------|-------------------------------|--|
| 94°C for 3 min | } 15 cycles for immature seed | |
| 94°C for 45 sec | | |
| 55°C for 45 sec | | |
| 72°C for 1 min | | |
| 30 | } 20 cycles for other tissues | |
| 94°C for 45 sec | | |
| 55°C for 45 sec | | |
| 72°C for 1 min | | |
| | 72°C for 5 min | |

35 Hybridization analysis

Fifty µl of the above-described PCR reaction were loaded on an 1.5% agarose gel. The DNA was blotted onto nylon membranes (Hybond N+, Amersham) and the membranes were baked at 80°C for 2 hours. The hybridization was performed using the

“North2South Chemiluminescent Nucleic Acid Hybridization and Detection” kit from Pierce. The DNA was prehybridized for 4 hours at 55°C in the hybridization buffer supplied by the kit and then hybridized overnight in the same buffer with a biotin-labelled OsICK2 or OsICK1 insert using the North2South Biotin Random Prime Kit (Pierce).

The membranes were washed twice for 20 minutes at room temperature in 2X SSC/0.1%SDS and twice in 0.5X SSC/0.1%SDS for 15 minutes at 55°C (at 60°C in the case of OsICK4). The probe detection and substrate development were performed according to the manufacturer’s instructions.

Probe detection and substrate development

The probe detection and substrate development were performed according to the manufacturer’s instructions. Briefly, after washing the membranes were blocked with the North2South Blocking buffer for 15 minutes at room temperature (RT). The Streptavidin-HRP conjugate was added to the North2South Blocking buffer at a 1:300 final dilution and incubated for 15 minutes at room temperature. The membranes were washed four times for 5 minutes each with North2South wash buffer at RT and then transferred in the North2South Substrate Equilibration buffer for 5 minutes at RT. The substrate development was carried out by covering the membranes with a mix of luminol/enhancer solution-peroxyde solution for 10 minutes. The membranes were placed into a film cassette and exposed to film for 1 minute. The film was developed by incubation for 5 minutes in the developer and for 5 minutes in the fixer solution.

Results

OsICK1 is predominantly expressed in stems. Lower levels of OsICK1 expression are apparent in roots, stem meristems, and seeds, whereas no or only very low expression of OsICK1 could be observed in the leaves (see Figure 6). OsICK2 is expressed in all rice plant tissues investigated including the leaves (Figure 6). OsICK4 is also expressed in all rice plant tissues investigated with a lower expression in roots and a higher expression in leaves and seeds (Figure 6).

Expression of OsICK1 rises very early during seed development with a peak at 2 days after pollination (DAP) and then slowly declines as seed development progresses. OsICK2 transcripts are abundantly present in seeds throughout their development with a peak at 8 DAP (see Figure 7). OsICK4 transcript levels are highly abundant in unpollinated flowers and during the first 3 days of seed development (*i.e.*, the first 3

days after pollination). Thereafter, OsICK4 expression gradually declines during the remaining period of seed development (see Figure 7).

EXAMPLE 7: *IN SITU* HYBRIDIZATION OF OsICK2 IN RICE IMMATURE SEEDS

In situ hybridization was performed according to the protocol of de Almeida-Engler *et al.* (2000) (Methods, in press) with slight modifications. Fixation was performed using 4% formaldehyde, 2.5% glutaraldehyde in 0.1M cacodilate buffer and a 1 hour incubation under vacuum. The fixative was refreshed and treatment continued for 4-5 hours up to overnight at 4 °C. The samples were then dehydrated using ethanol, transferred to xylene and embedded in paraplast. Subsequently, 10 µm sections were cut and placed on Vectabond coated slides. *In vitro* transcription and radioactive labelling (S^{35}) was performed using a transcription kit from Boehringer-Mannheim according to the manufacturer's instructions. For this OsICK2 was cloned in a pSP6 vector (Roche Diagnostic) in sense and antisense orientation behind the T7 promoter. Hybridization and developing of the slides were performed according to de Almeida-Engler *et al.*, *supra*.

In situ hybridization analysis of OsICK2 expression in rice seeds revealed that OsICK2 transcripts are spatially confined to the cell layers between the seed coat and the developing endosperm and display a patchy pattern in the developing embryo in seeds collected at 7 DAP (Figure 8). In seeds collected at 20 DAP, OsICK2 expression is still strong in the cell layers between the seed coat and the developing endosperm, as well as in the scutellum (Figure 9).

EXAMPLE 8: TRANSFORMATION OF *ARABIDOPSIS THALIANA* WITH A. *THALIANA* ICKs ICK2, ICK3 AND ICK4

The full-length coding regions of the A. thaliana ICKs ICK2, ICK3 and ICK4 were amplified by polymerase chain reaction using the appropriate primers introducing different restriction sites. The amplified fragments were digested with the corresponding restriction enzymes and cloned in the corresponding sites of pH35S (Hemerly *et al.* (1995) *EMBO J.* 14, 3925-3936) containing the CaMV35S promoter and NOS terminator. The expression cassettes were subcloned in pGSV4 (Hérouart *et al.* (1994) *Plant Physiol* 104, 873-880). The resulting vectors were mobilized by the helper plasmid pRK2013 into *Agrobacterium tumefaciens* C58C1Rif^R harboring plasmid pMP90. A. thaliana plants of the Col-0 ecotype were transformed by the floral dip method (Clough and Bent (1998) *Plant J.* 16, 735-743). Transgenic plants were obtained on kanamycin-containing media and later transferred to soil for optimal seed production.

A total of 39 and 5 transgenic *A. thaliana* lines were generated from the transformations with ICK2 and ICK3, respectively.

EXAMPLE 9: TRANSGENIC RICE PLANTS GENERATED WITH DIFFERENT EXPRESSION PATTERNS FOR OsICK4

A number of different constructs have been produced to either overexpress or down-regulate OsICK4 expression. The binary vector backbone is pCAMBIA1301. Constructs for modulating OsICK4 expression are outlined below.

OsICK4 Overexpression

The binary vector backbone is a proprietary vector, pCDV3 (pCAMBIA1301 derivative), into which the Gateway system (Life Technologies, Inc) has been introduced. Gateway primers have been designed to amplify OsICK4 following the instructions of the manufacturer. The construct for overexpression of OsICK4 under the control of the GOS2 promoter (de Pater *et al.* (1992) *Plant J.* 2, 837-844) is designated p0428 ICK4 and is depicted in Figure 12.

OsICK4 Co-suppression

To down-regulate gene expression, an inverted repeat conformation with a hairpin structure has been produced. The two inverted fragments from OsICK4 are separated by a matrix attachment region (MAR) from *Nicotiana tabacum* (GenBank accession number U67919). The MAR fragment of 315 bp has been PCR-amplified from tobacco genomic DNA using primers sense 5'-CGTTGTCAATATCCTGGAAATTTTGC-3' (SEQ ID NO:35) and antisense 5'-CTGCCATTCTTTAGAGGGGATGCTTG-3' (SEQ ID NO:36), and blunt-end subcloned into a *Sma*I-CIP pUC18.

A first OsICK4 fragment (893 bp) cut out from pAD-OsICK4 (full length) with *Ecl*136II-*Hinc*II is blunt ligated into pUC18-MAR cut with *Ecl*136 II (blunt). The orientation in which *Ecl*136 II has been restored is chosen to allow the excision of the whole inverted repeat (IR) cassette in a later stage. The second OsICK4 fragment (921 bp) is cut out from pAD-OsICK4 (full length) with *Pst*I-*Hinc*II (*Ecl*136II is included in the sequence) and subcloned into pUC18-Mars-OsICK4 restricted with *Pst*I-*Hinc*II in a sticky-blunt ligation. The vector pUC18-Mars-OsICK4 is depicted in Figure 13. The final inverted repeat cassette (2,129 bp ; termed OsICK4 IR) can be taken out using *Ecl*136II for subcloning in, for exampl, a plant transformation vector.

OsICK4 IR with GOS2 promoter

The pCAMBIA vector 1301 containing a 35SCaMV promoter driving GUS expression has been restricted with *Xba*I and *Nco*I to replace the 35SCaMV promoter with the GOS2 promoter *Xba*I-*Nco*I fragment from rice (de Pater *et al.* (1992) *Plant J.* 2(6) : 837-844).

This vector is then restricted with *Nco*I and *Pml*I, and these sites filled-in to produce blunt ends. The final inverted repeat cassette (OsICK4 IR) from pUC18 is taken out using *Ecl*136II and ligated into the binary vector. The resulting vector is termed p0490 and depicted in Figure 14.

OsICK4 IR with prolamine promoter

The 13kDa prolamine promoter (654 bp) from rice (Wu *et al.* (1998) *Plant Cell Physiol.* 39 :885) has been PCR-amplified using primers sense 5'-GAATTCCTTCTACATCGGCTTAGGTGTAGC-3' (SEQ ID NO:46) and antisense 5'-CCATGGTGTGTTGGATTCTACTACTATGC-3' (SEQ ID NO:47) and the subsp. Japonica genomic DNA. The fragment was further subcloned in pUC18 *Sma*I CIP. An *Xba*I and *Nco*I restriction produced a promoter fragment that was subcloned into the pCAMBIA 1301 35SCaMV-GUS vector also restricted with *Xba*I and *Nco*I. This led to the replacement of the CaMV promoter by the prolamine promoter. This prolamine-GUS binary vector was then restricted with *Nco*I and *Pml*I to introduce the IR cassette. After filling-in these sites to produce blunt ends, the *Ecl*136II final IR cassette (OsICK4 IR) was taken from the pUC18 and ligated into the binary vector. The resulting vector is termed p0489 and depicted in Figure 15.

OsICK4 IR with oleosin promoter

The 18kDa oleosin promoter (1236 bp) from rice (Wu *et al.* (1998) *Plant Cell Physiol.* 39 :885) has been PCR-amplified using primers sense 5'-GAACAAAGATGGTCAGCCAATACATTGATC-3' (SEQ ID NO:48) and antisense 5'-GGCCATGGCTAAGCTAGCTAGCAAGATGAA-3' (SEQ ID NO:49) and the subsp. Indica genomic DNA. The fragment was further subcloned into pUC18 *Sma*I CIP. An *Xba*I and *Nco*I restriction produced a promoter fragment that was subcloned into the pCAMBIA 1301 35SCaMV-GUS vector also restricted with *Xba*I and *Nco*I. This led to the replacement of the CaMV promoter by the oleosin promoter. This oleosin-GUS binary vector was then restricted with *Nco*I and *Pml*I to introduce the IR cassette. After filling-in these sites to produce blunt ends, the *Ecl*136II final IR cassette (OsICK4 IR) was taken from the pUC18 and ligated into the binary vector. The resulting vector is termed p0488 and depicted in Figure 16.

OsICK4 IR with glutelin promoter

The glutelin 3A promoter (984 bp) from rice (Wu *et al.* (1998) *J. Biochem.* 123: 386) has been PCR-amplified using primers sense 5'-

AGAAGAAAGATAAATAACCGAAACTATTTG-3' (SEQ ID NO:50) and antisense

5'-GGACATGTTTTTGTGGGACTGAACTCAATG-3' (SEQ ID NO:51) and the

subsp. Indica genomic DNA. The amplified fragment was further subcloned into pUC18 *Sma*I CIP. A *Sma*I and *Afl*III restriction produced a promoter fragment that was subcloned into the pCAMBIA 1301 35SCaMV-GUS vector restricted with *Sma*I and *Nco*I. This led to the replacement of the CaMV promoter by the glutelin promoter.

This glutelin-GUS binary vector was then restricted with *Bgl*II and *Pml*I to introduce the IR cassette. After filling-in these sites to produce blunt ends, the *Ecl*136II final IR cassette (OsICK4 IR) was taken from the pUC18 and ligated into the binary vector. The resulting vector is termed p0559 and depicted in Figure 17.

EXAMPLE 10: AGROBACTERIUM-MEDIATED RICE TRANSFORMATION

Mature dry seeds of the rice japonica cultivars Nipponbare or Taipei 309 are dehusked, sterilised and germinated on a medium containing 2,4-D (2,4-dichlorophenoxyacetic acid). After incubation in the dark for four weeks, embryogenic, scutellum-derived calli are excised and propagated on the same medium. Selected

embryogenic callus is then co-cultivated with *Agrobacterium*. Widely used *Agrobacterium* strains such as LBA4404 or C58 harbouring binary T-DNA vectors can be used. The hpt gene in combination with hygromycin is suitable as a selectable marker system but other systems can be used. Co-cultivated callus is grown on 2,4-D-containing medium for 4 to 5 weeks in the dark in the presence of a suitable concentration of the selective agent. During this period, rapidly growing resistant callus islands develop. After transfer of this material to a medium with a reduced concentration of 2,4-D and incubation in the light, the embryogenic potential is released and shoots develop in the next four to five weeks. Shoots are excised from the callus and incubated for one week on an auxin-containing medium from which they can be transferred to the soil. Hardened shoots are grown under high humidity and short days in a phytotron. Seeds can be harvested three to five months after transplanting. The method yields single locus transformants at a rate of over 50 % (Aldemita and Hodges (1996), Chan *et al.* 1993, Hiei *et al.* 1994).

**EXAMPLE 11: TWO-HYBRID INTERACTION OF OsICK2 AND OsICK4
WITH CDC2-Os1 AND CYCD3Os**

The interactions of OsICK2 and OsICK4 with Cdc2-Os1 and CycD3-Os (the rice cyclin D3) were verified using a yeast two hybrid approach. In a preliminary step, yeast strain PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4(deleted) gal80(deleted) LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) was transformed with Cdc2-Os1 in bait vector pBDGal4 (Stratagene), using the lithium acetate method, well known to those skilled in the art. The rice Cdc2-Os1 was previously obtained by PCR as described in Example 1. The Cdc2-Os1 was also cloned in the pADGal4 prey vector. The junctions between the pBDGal4 binding domain and the pADGal4 activation domain and the Cdc2-Os1 fragment were sequenced to verify correct in-frame fusion.

The full-length OsICK2 and OsICK4 cDNA clones in the pADGal4 vector were obtained as described in Examples 3 and 4. These cDNAs were also cloned in the pBDGal4 vector. The public databases were screened for conserved motifs found in all D-type cyclins. This search yielded a hit consisting of a rice EST clone (GenBank accession number AU082424). PCR was performed to amplify a part of this clone using the following primers: antisense 5'-ACTCCTTGTCCTATCGACACACC-3' (SEQ ID NO:52) and sense 5'-CCATGGGGGACGCCTCGGCATCCA-3' (SEQ ID NO:53). The amplified fragment was cloned in pUC18 and used as a radioactive probe for the two-hybrid cDNA library screening.

Approximately 750,000 plaque-forming units from the cell suspension two-hybrid cDNA library were screened. Plaques were transferred to Hybond N+ membranes (Amersham). The filters obtained were prehybridized in sodium phosphate 0.25M, (pH7.2), SDS 7% at 60°C for 4 hours. Hybridization was performed with the prehybridization buffer containing 50 ng of [α]³²P-dCTP-labelled probe at 60 °C overnight (protocol of Church G.M. and Gilbert W. *PNAS USA* 81:1991-1994). The filters were washed twice with 1XSSC, 0.1%SDS at 60 °C for 30 minutes and then once with 0.1XSSC, 0.1%SDS at 60 °C for 30 minutes. The membranes were placed into a film cassette and exposed to film for 6 hours.

Two putative positive clones were identified. A second round of screening on these clones was performed. Pure positive plaques were isolated and phagemids were excised therefrom. Sequencing of the two clones revealed that the clones were identical with a full length size of 1.7 kb. The clones contain an ORF of 1140 bp encoding a protein of 380 amino acids. This protein is designated cyclin D3 from rice (CycD3-Os). The yeast strain PJ69-4a containing the bait vector pBDGal4 with Cdc2-Os1 was retransformed with the prey vector pADGal4 containing the in-frame OsICK2 or CycD3-Os, and plated on selective Leu- Trp- His- to select for growth. The yeast

expressing both proteins could effectively grow, illustrating the interaction of Cdc2-Os1 with OsICK2 and CycD3-Os, respectively.

As positive controls, growth was assessed in yeast containing the prey vector pADGal4 with Cdc2-Os1 and retransformed with the bait vector pBDGal4 containing
5 OsICK2 or CycD3-Os. In all cases, yeast growth did occur. Appropriate negative controls were incorporated in which any of the described bait pBDGal4 or prey pADGal4 vectors containing either Cdc2-Os1, OsICK2 or CycD3-Os were combined with the empty prey pADGal4 or pBDGal4 vectors, respectively. None of these combinations was able to sustain yeast growth on selective medium.

10 From the molecular cloning of OsICK4 (see Example 4), it is evident that OsICK4 interacts physically with Cdc2-Os1.

In further experiments, the interaction between OsICK2 and OsICK4 with CycD3-Os, respectively, was assessed. Both OsICK2 and OsICK4 were shown to interact with CycD3-Os in a yeast two-hybrid system as described above.

15

EXAMPLE 13: EXPRESSION OF RECOMBINANT ICK PROTEINS IN BACTERIAL CELLS

In this example, the ICK molecules of the present invention are expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the
20 fusion polypeptide is isolated and characterized. Specifically, ICK molecules are fused to GST and this fusion polypeptide is expressed in *E. coli*, e.g., strain PEB199. Expression of the GST-ICK fusion protein in PEB199 is induced with IPTG. The recombinant fusion polypeptide is purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide
25 gel electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide is determined.

EXAMPLE 14: ISOLATION OF THE RICE OsICK5 GENOMIC CLONE AND PREDICTION OF THE OsICK5 cDNA AND PROTEIN SEQUENCES.

30 The public databases were screened for the "GRYEW" amino acid motif located at the carboxy-termini of all ICKs. This research yielded a hit with a non annotated HTGS full length clone (GenBank accession number AP003525). PCR was performed to amplify this genomic clone using the following primers :

-sense: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACAATGGGGAAGAA

35 GAAGAAGCGCGACG -3' (SEQ ID NO:57); and

-antisense: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGCCGCTGCCCCAC

CGCGG -3' (SEQ ID NO:58).

The amplified fragment was cloned in the pDON201 (Gateway system; Life Technologies).

5 Said sense and antisense primers (SEQ ID NO:57 and SEQ ID NO:58, respectively) are subsequently used to isolate the full-length OsICK5 cDNA by RT-PCR (see, e.g., Example 6).

10 The isolated OsICK5 genomic clone (SEQ ID NO:56; Figure 19) is part of the HTGS clone with GenBank accession number AP003525 (version 1) but no open reading frame or protein annotation is presented. Therefore, the open reading frame and protein deduced thereof were predicted. The predicted full-length OsICK5 cDNA is defined by SEQ ID NO:54 and the OsICK5 protein sequence deduced thereof is defined by SEQ ID NO:55. During the prediction process, difficulties arose in defining the correct exon-intron borders. These uncertainties are reflected in the OsICK5 cDNA sequence (SEQ ID NO:54; Figure 20A) by two 'N' nucleotides (i.e. may be any nucleotide (A, T, C or G) or a stretch of such nucleotide residues) at the positions 355 and 356 of SEQ ID NO:54. As defined in SEQ ID NO:54, the stretch of uncertain nucleotides may have a length of zero to 265 nucleotides, i.e. the maximum length between the intron involved. Said uncertain nucleotides being translated into an uncertain amino acid residue X (i.e. may be any amino acid residue or a stretch of such amino acid residues) at the position 119 of SEQ ID NO:55. As defined in SEQ ID NO:55, the stretch of uncertain amino acids may have a length of zero to 88 amino acids, i.e. the maximum protein sequence deducible from the whole intron involved.

25 **Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed:

1. A method for modulating the cell cycle in a plant, comprising introducing into the plant an ICK modulator, such that the cell cycle in the plant is modulated.
2. The method of claim 1, wherein the plant is a monocot plant.
3. The method of claim 1, wherein the plant is a dicot plant.
4. The method of claim 1, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.
5. A method for modulating plant growth, comprising introducing into a plant an ICK modulator, such that plant growth is modulated.
6. The method of claim 5, wherein the plant is a monocot plant.
7. The method of claim 5, wherein the plant is a dicot plant.
8. The method of claim 5, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.
9. A method for treating a cell cycle disorder in a plant, comprising introducing into the plant an ICK modulator, such that a cell cycle disorder in the plant is treated.
10. The method of claim 9, wherein the cell cycle disorder is selected from the group consisting of endomitosis, acytokinesis, polyploidy, polyteny, and endoreduplication.
11. The method of claim 9, wherein the plant is a monocot plant.
12. The method of claim 9, wherein the plant is a dicot plant.
13. The method of claim 9, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.

14. A method for improving tolerance to an environmental stress condition in a plant, comprising introducing into the plant an ICK modulator, such that tolerance to an environmental stress condition in the plant is improved.
- 5 15. The method of claim 14, wherein the environmental stress condition is selected from the group consisting of drought stress, salt stress, temperature stress, and nutrient deprivation.
- 10 16. The method of claim 14, wherein the plant is a monocot plant.
17. The method of claim 14, wherein the plant is a dicot plant.
18. The method of claim 14, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, 15 alfalfa, oilseed rape, soybean, sunflower, and canola.
19. A method for improving tolerance to a plant pathogen that abuses the cell cycle in a plant, comprising introducing into the plant an ICK modulator, such that tolerance to a plant pathogen that abuses the cell cycle in the plant is improved.
- 20 20. The method of claim 19, wherein said plant pathogen is a pathogenic bacterium selected from the group consisting of *Agrobacterium tumefaciens*, *Rhodococcus fascians*, *Pseudomonas savastnoi*, *Xanthomonas campestris pv citri* and *Erwinia herbicola*, plant pathogenic fungi including *Plasmodiophora brassicae*, 25 *Crinipellis pernicioso*, *Pucciniastrum geoppertianum*, *Taphrina wiesneri*, *Ustilaga maydis*, *Exobasidium vaccinii*, *E. camelliae*, *Entorrhiza casparyana* and *Apiosporina morbosum* and plant pathogenic gall-inducing insects including the midge *Mayetiola poae*.
- 30 21. The method of claim 20, wherein the plant is a monocot plant.
22. The method of claim 20, wherein the plant is a dicot plant.
23. The method of claim 20, wherein the plant is selected from the group 35 consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.

24. A method for modulating ICK activity in a plant, comprising introducing into the plant an ICK modulator, such that ICK activity in the plant is modulated.
25. The method of claim 24, wherein the plant is a monocot plant.
26. The method of claim 24, wherein the plant is a dicot plant.
27. The method of claim 24, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.
28. A method for modulating the cell cycle in a plant cell, comprising contacting the plant cell with an ICK modulator, such that the cell cycle in the plant cell is modulated.
29. A method for modulating plant cell growth, comprising contacting a plant cell with an ICK modulator, such that plant cell growth is modulated.
30. A method for treating a cell cycle disorder in a plant cell, comprising contacting the plant cell with an ICK modulator, such that a cell cycle disorder in the plant cell is treated.
31. A method for improving tolerance to an environmental stress condition in a plant cell, comprising contacting the plant cell with an ICK modulator, such that tolerance to an environmental stress condition in the plant cell is improved.
32. A method for improving tolerance to a plant pathogen that abuses the cell cycle in a plant cell, comprising contacting the plant cell with an ICK modulator, such that tolerance to a plant pathogen that abuses the cell cycle in the plant cell is improved.
33. A method for modulating ICK activity in a plant cell, comprising contacting the plant cell with an ICK modulator, such that ICK activity in the plant cell is modulated.
34. The method of any one of claims 1, 5, 9, 14, 19, 24, 28, 29, 30, 31, 32, or 33, wherein the ICK modulator is a small molecule.

35. The method of any one of claims 1, 5, 9, 14, 19, 24, 28, 29, 30, 31, 32, or 33, wherein the ICK modulator is capable of modulating ICK polypeptide activity.
36. The method of claim 35, wherein the ICK modulator is an anti-ICK
5 antibody.
37. The method of claim 35, wherein the ICK modulator is an ICK polypeptide comprising the amino acid sequence of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44, or 55, or a fragment thereof.
10
38. The method of any one of claims 1, 5, 9, 14, 19, 24, 28, 29, 30, 31, 32, or 33, wherein the ICK modulator is capable of modulating ICK nucleic acid expression.
39. The method of claim 38, wherein the ICK modulator is an antisense ICK
15 nucleic acid molecule.
40. The method of claim 38, wherein the ICK modulator is a ribozyme.
41. The method of claim 38, wherein the ICK modulator comprises the
20 nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 43, 45, 54 or 56, or a fragment thereof.
42. A transgenic plant comprising the nucleotide sequence set forth in SEQ ID NO:9, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:54 or SEQ ID NO:56.
25
43. The transgenic plant of claim 42, wherein the plant is a monocot plant.
44. The transgenic plant of claim 42, wherein the plant is a dicot plant.
- 30 45. The transgenic plant of claim 42, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, rice, wheat, barley, sorghum, tomato, potato, cotton, alfalfa, oilseed rape, soybean, sunflower, and canola.
- 35 46. An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 9, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:54, or SEQ ID NO:56.

47. An isolated nucleic acid molecule which encodes an ICK polypeptide comprising the amino acid sequence set forth in SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44 or 55.

5 48. An isolated ICK polypeptide comprising the amino acid sequence of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 44 or 55.

49. The ICK polypeptide of claim 48, further comprising heterologous amino acid sequences.

10

50. An antibody which selectively binds to a polypeptide of claim 48.

51. A method for identifying a compound which binds to a polypeptide of claim 48 comprising:

15

- a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

20 52. The method of claim 51, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detection of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay; and
- c) detection of binding using an assay for ICK activity.

25

53. A method for modulating the activity of a polypeptide of claim 48 comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

30

54. A method for identifying a compound which modulates the activity of a polypeptide of claim 48 comprising:

- a) contacting a polypeptide of claim 48 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

35

55. A method for modulating plant morphology, comprising introducing into a plant an ICK modulator, such that plant morphology is modulated.

56. A method for modulating plant cell fate, comprising introducing into a plant an ICK modulator, such that plant cell fate is modulated.
- 5 57. A method for modulating plant physiology, comprising introducing into a plant an ICK modulator, such that plant physiology is modulated.
58. A method for modulating plant biochemistry, comprising introducing into a plant an ICK modulator, such that plant biochemistry is modulated.
- 10 59. A method for modulating ICK levels in a plant, comprising introducing into the plant an ICK modulator, such that ICK levels in the plant is modulated.
60. A method for modulating plant cell fate, comprising contacting a plant
15 cell with an ICK modulator, such that plant cell fate is modulated.
61. A method for modulating plant morphology, comprising contacting a plant cell with an ICK modulator, such that plant morphology is modulated.
- 20 62. A method for modulating plant physiology, comprising contacting a plant cell with an ICK modulator, such that plant physiology is modulated.
63. A method for modulating plant biochemistry, comprising contacting a plant cell with an ICK modulator, such that plant biochemistry is modulated.
- 25 64. A method for modulating ICK level in a plant cell, comprising contacting the plant cell with an ICK modulator, such that ICK level in the plant cell is modulated.
65. An isolated nucleic acid molecule encoding a monocot ICK polypeptide
30 comprising a motif 1, a motif 2, a motif 3, a motif 4, a motif 5, a motif 6, a Cy-box, a nuclear localization sequence, a PEST sequence, and an α -helical stretch in between motifs 5 and 6 and in between motifs 6 and 4.
66. An isolated nucleic acid molecule encoding a monocot ICK polypeptide
35 comprising a motif 1, a motif 2, a motif 3, a motif 4, a motif 5, a motif 6, and a PEST sequence, and having an amino acid sequence which is at least 90 percent identical to the amino acid sequence of SEQ ID NO:10, SEQ ID NO:44 or SEQ ID NO:55.

67. An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with BCCM-LMBP as Accession Number LMBP4268.

1/24

```
1      GGCACGAGGC GGC GCAG (ATGGGCAAGTACA TGAGGAAGTT CAGGGGGGCC
51     ACGGGGGAGG AGTTGGCCGC CATGGAGGTC ACGCAGGTGG TTGGCGTCCG
101    GACGAGGTCG AGGTCGGCAG CGGCGGCGGG CGCGACGACG ACGAAGGTGC
151    AGGCGGCGTC GGC GGCCTCC ACCAGGAGGA GGAAGGCGCT GCTGCCGACG
201    GCGGTCGTGG GGA CTACTCG CCGTGACGGC GGGAGCTGCT ACCTCCAGCT
251    GAGGAGCCGC ATGCTGTTCA TGGCCCCGCC GAGGCCGGCG CCGGCCGCGA
301    GGGCTCCGGT TGTAGCGGAG GCGGCGGGTT CCGGGAACGG AGCGGCGGCG
351    CATGCGGCGG CTGGCTCTC GCGTTGCTCC AGCACGGCGT CGTCCGTGGA
401    CGCGGCGGCT CAGGACAGGA GCCTCGCGTG CCGCTCCGAC GTCGCGGAGG
451    CAGGCAGCGA GCATGTCCCG GAGGGCTCCG CGAGCGACTC GGCGAGCGGC
501    CGTGACCGCG AGAGGAGAGA AACAACTCCA TCAAGCTTTC TCCCCGGCGA
551    GGTGAGCGAT CTGGAGTCGG ATCTGGCTGG AGGACAGAAG CGCAGCCGTC
601    CACTACCTTC TGC GGCAACA GCCTCAGCAC AGCAAGCCAC GCGGCCGAAG
651    ATTCCGCCGG CCGCCGAGAT CGAGGCGTTC TTCGCGGCGG CCGAGGAGGC
701    TGAGGCCAAG CGCTTCGCCG CCAAGTACAA CTTTCGACGTC GTTCGCGGCG
751    TGCCCCTCGA CGCCGGTCGG TTCGAGTGGA CTCCGGTGGT CAGCAGCCGA
801    AGCTGA) AGCGAGCGTG CAGA TTAAGCGGAA GCTAGAAAGG AAGGTACAGG
851    GGGGCGCCGT GTAGAAAGGG AAGGCGAGCT AGAGAGAGGA GAAGAAGAAG
901    AAAAGATGCT CATCAAAGG GAATAAACGG GAAAAGTGGG AGACTACAAA
951    AAAAGAAGCA TTATAGCCTA ACAACCACCG ATTCGACTCT TTTTCTTTC
1001   ACATTTTCTT TGCATTTTTA CTCTTACTGT GTACTAGAAA GTAGTAGCAG
1051   TAGTAAACTA GTAATTCGTC CCAGTATTTA TCAGAGGTTT ATCTCGATAG
1101   GAATAGATAT ATTATCCCCT [TACTGTAATT GCCTCCATCT TGTATTTGGA
1151   TGGAAATTAA ATTTACTGTA CAGCAGCAGC AGCTGTTCTG CAAGTTTAAG
1201   TTAACCATCA CCGTTTTATT ACTT]AAAAAAAAAAAAAAAA AA
```

FIGURE 1

```
1  GAAACCCTAG  CCCCCTCCCA  TCCCGAGTCC  CGACCGCC (ATGGGCAAGTAC
51  ATGCGCAAGG  CCAAGGTGGT  GGTCTCCGGC  GAGGTGGTGG  CCGCCGCCGT
101 CATGGAGCTC  GCCGCGGCGC  CGCTCGGGGT  GCGCACCCGC  GCCCGCTCCC
151 TCGCGCTGCA  GAAGAGGCAG  GGCGGGGAGT  ACCTCGAGCT  CAGGAGCCGC
201 AGGCTCGAGA  AGCTCCCTCC  TCCCCGCCG  CCGCCGCCGA  GGAGGAGGGC
251 GACGGCTGCG  GCTGCGACTG  CTGATGCGAC  GGCGACGGAG  AGCGCGGAGG
301 CGGAGGTGTC  GTTCGGGGGG  GAGAACGTCC  TCGAGCTGGA  GGCCATGGAA
351 AGGAATACCA  GGGAGACGAC  ACCTTGCAGC  TTGATCAGGG  ACCCCGATAC
401 GATTAGCACC  CCTGGATCTA  CCACAAGGCG  CAGCCACTCG  AGTTCTCATT
451 GCAAGGTGCA  AACACCCGTG  CGCCACAACA  TTATTCCAGC  ATCAGCAGAG
501 CTGGAAGCGT  TCTTCGCGYC  CGAAGAGCAA  CGGCAACGAC  AGGCTTTCAT
551 CGACAAGTAT  AACTTTGATC  CTGTGAATGA  CTGCCCTCTT  CCCGGCCGRT
601 TTGAATGGGT  CAAGCTAGAC  TGA) TAGATTTTCAGGAAAAG  AAGGGCACCA
651 TGGACCTCTC  TGCTCCCTCC  ACAGTAGTAG  CGTGGCAGAG  GCGCTTACCG
701 TCAAGTTAGC  TTTGATCCTG  TTGTAAAAAT  TTAGGGTTAG  CCTGTAGACT
751 CAATGGTCAA  TGTGAACATA  CAGAACTGAT  GCTGAGTTAC  AACCCTAATC
801 CCTCAACTAC  AATGTAACCC  TTAACAGCTC  ATTCTGTAAG  GAACCACCTC
851 CTCCTCTAGG  GCCTAGCTAG  CCTTATCATC  TGTTATTACC  AGTTGCTGGA
901 TTAATGAAGT  TAGATCTAGA  TATTGTGTCA  CAGTTTAACC  TGTTGTGTGT
951 GTGGTGGTAG  CATTGGCATT  GGCAATGGGG  TATGGCAGTG  TGTGTGTGGT
1001 GCTGCACTGC  ACCTCCCGAA  GTGCTGTAAT  TTTTGTCTAT  ACTTCTGCTA
1051 AAAAAAAAAA  AAAAAAA
```

FIGURE 2

		1	40
ALFALFA ICK	(1)	MGKYMKKLKSSESPPNSTPTSPSPSPPTPITTNSPPPT	
AtICK1	(1)	MVRKYRKAKGIVEAGVSS-----TVMQL	
AtICK2	(1)	MAAVRRRRERDVVEENGVTTTTVK-----RRK	
AtICK3	(1)	MGKYMKKSKITGDISVME-----VSKA	
AtICK4	(1)	MGKYIRKSKIDGAGAGAGGGGGGGGGESSIALMDVVSPS	
AtICK5	(1)	MGKYIKKSKVAGAVSVKD-----KSH	
AtICK6	(1)	MSERKRELAEEASSTSFSP-----LKKTK	
AtICK7	(1)	----MSETKPKRDSEYEGS-----NIKRMR	
CHENOPOD ICK	(1)	MAAAATPTSSPAKKIKKVS-----KSS	
OsICK2	(1)	MGKYMRRKFRGATGEELAAMEVTQVVGVRTR-----SRSA	
OsICK4	(1)	MGKYMRRKAKVVVSGEVVA---A-----AVMEL	
OsICK5	(1)	MGKKKKRDGAAARRQARVVVG-----VRTR	
		41	80
ALFALFA ICK	(41)	TPNSSDGVRTTRATLALENSNN-----	
AtICK1	(24)	RSRRIVYVRSEKSSSVSVVGDN-----	
AtICK2	(27)	MEEVDLVESRIILSPCVQATN-----	
AtICK3	(23)	TA-PSPGVRTRAAKTLALKRLN-----	
AtICK4	(41)	SS-SSLGVLTRAKSLALQQQQQRCLLQKPSSPSSLPPTSA	
AtICK5	(22)	P--PALGFRTRAATAAKNLALHR-----	
AtICK6	(25)	LNDSSDSSPDSDHDVIVFAVSSS-----	
AtICK7	(22)	LDDDDDVLRSPTRLSSSSSSSS-----	
CHENOPOD ICK	(23)	YN--IPQLRSRRKNLSAP--EN-----	
OsICK2	(35)	AAAGATTTTKVOAASAASTRRRK-----	
OsICK4	(25)	AA-APLGVRTTRARSLALQKRQG-----	
OsICK5	(27)	AAVTARRVVASAEEGCGLVGRG-----	
		81	120
ALFALFA ICK	(63)	-----QNQNLSVSSDSYQLRNRRLKR-----P	
AtICK1	(46)	-----GVSSSCSGSNEYKK-----KEL	
AtICK2	(49)	-----RGGIVARNSAGASETSVMIVRRRDSPP	
AtICK3	(44)	-----SSAADSALPNDSSCYQLRSRRLKPPSSLIEP	
AtICK4	(80)	SPNPPSKQKMKKKQQQMNDGCSYQLRSRRLQK----KPP	
AtICK5	(42)	-----LRSHSDEADSFNYQLRSRRLVK----LPL	
AtICK6	(47)	-----SVASSAALASDECSVTIG-GEE	
AtICK7	(44)	-----LAYSVSDSGGFCSVALSE----EED	
CHENOPOD ICK	(41)	-----FAELETTPLEVAAVVEEE	
OsICK2	(57)	----ALLPTAVVGTTTRDGGSCYQLRSRRLFMAPPAP	
OsICK4	(46)	-----GEYLELRSRRLK-----LPP	
OsICK5	(49)	-----GGGGSGDDGEGGCYQLRSRRLPFVAAAVVS	

FIGURE 3

		121		160	
ALFALFA ICK	(86)	LIRQHS	AKRNKGHDGNPKS-----	PIGDSIAE EKT VQK	
AtICK1	(63)	IHLEED	KDG-----	DTETSTYRRG TKRK	
AtICK2	(76)	VEEQCQ	IEEEDS-----	SVSCCSTSEEKSKR	
AtICK3	(76)	KQPPRV	HRS GIKESGSRSRVDSVNSVPVAQSS	NEDEC FDN	
AtICK4	(116)	IVVIRST	KRRKQQRNETCGRNPNPRSNLDS	SIRGDGSRSD	
AtICK5	(68)	LTNTRK	QQKQ-----	QLIPSVNQ CQTK--	
AtICK6	(68)	SDQSSS	ISSSGCFTS-E-----	SKEIAKNSSSFGVD	
AtICK7	(65)	DHLSSS	ISSSGCS-----	SSETNEIATRLP	
CHENOPOD ICK	(59)	EVANCSS	SEVITTARSDFP-----	PSCCSSNYDQLS--	
OsICK2	(93)	AARAPV	VAAEAGSGNG-----	AAAHAAAGLSRCSST	
OsICK4	(62)	PPPPPP	PR-RR-----	ATAAAATADATATE	
OsICK5	(81)	SRREEA	LGDSVAEAAAS-----	SSSSRAVELLGC	
		161		200	
ALFALFA ICK	(119)	SP	EPENAEFKEN-----	AED-TE	
AtICK1	(87)	LF	ENLREEEKEE-----	LSKSM	
AtICK2	(102)	RI	FVDLEENNG-----	DDR	
AtICK3	(116)	FVSVQV	SCGENS-----	LGFESR	
AtICK4	(156)	SVSES	VVFGDKDKLISEINKDPTFGQNF	FDLEEEHTQSFN	
AtICK5	(90)	--NPR	ASSGPAK-----	K--LE	
AtICK6	(97)	LEDHQI	ETETET-----	S-TFIT	
AtICK7	(89)	FSDLEA	HEISET-----	EISTLLT	
CHENOPOD ICK	(90)	SS	EPVVKDDG-----	LGNRTA	
OsICK2	(124)	ASSVDA	AAQDRSLACRS DVAEAGSEHVPEGSASDSASGRD		
OsICK4	(85)	SAAE	VSFGGEN-----	VLELEAME	
OsICK5	(109)	SG	EEEMA EKXS-----	ATTPSS	
		201		240	
ALFALFA ICK	(136)	RSAR	ETTPVHLIM-RADVLRPPRPIT	RRRTFPTEAN----	
AtICK1	(104)	ENYSSE	FESAVKE-SLDCCCSGRKTMEETV	TAE EEE----	
AtICK2	(117)	ETETSW	IYDDLNK-SESSNMDS	SSSVAVEDVESRR----	
AtICK3	(134)	HSTRES	TPCNFVE-DMELMVT	PGSSSTRSMCRAT----	
AtICK4	(196)	RTTRES	TPCSLIR-RPEIM	TPGSSSTKLNICVSES	NQRED
AtICK5	(103)	PDTTTE	EACGDNE-RISRSDCN	FGDKGFDLESE----	
AtICK6	(114)	SNFRKE	SPVSEG-LGETT	TEMESSSATKRKQP----	
AtICK7	(108)	NNFRKQ	GISSSEN-LGETAEMDSAT	TEMRDQRKTE----	
CHENOPOD ICK	(108)	DPEVES	SGEASSKQ-KE	SHRTEAREATKLDDQDYP----	
OsICK2	(164)	RERRET	TPSSFLPGEVSDLES	DLAGGQKRSRPLPSA	ATAS
OsICK4	(105)	RNTRET	TPCSLIR-DPDTL	STPGST	RRSHSSS---HCKV
OsICK5	(127)	RRPPGD	ADSSDAESNOEAKQOMCRRSSTTSAAAF	HAGATT	

FIGURE 3 (cont'd)

		241	280
ALFALFA ICK	(170)	PKTEQP-TIPISREFEEFCAKHEAEQQRE---	FMEKYNFD
AtICK1	(138)	EKAKLMTEMPTESEIEDFFVEAEKQLKEK---	EKKRYNFD
AtICK2	(151)	RLRKSLEHTVKEAELEDFQVAEKDLRNKLLC	SMKYNFD
AtICK3	(168)	YTREQDNVITPTTSEMEEFFAYAEQQQORL---	FMEKYNFD
AtICK4	(235)	SLSRSHRRRPTTPEMDEFFSGAEQQQOKQ---	FIEKYNFD
AtICK5	(135)	NRSMISDSKSIQSEIEDEFFASAEQQQORF---	FIQKYNFD
AtICK6	(146)	----GVRKTPTAAEIEDLSELESQDDKKK-Q	FIEKYNFD
AtICK7	(142)	-KKKKMEKSPTOAELDDFFSAAERYEQKR---	FTEKYNFD
CHENOPOD ICK	(142)	TKSTVQIKMPSDSEIEEFFAVAEKDLOKR---	FSEKYNFD
OsICK2	(204)	AQQATRPKIPPAAEIEAFFAAEEAEAKR---	FAAKYNFD
OsICK4	(141)	QTPVRHNTIPASAELEAFFAAEQQRQQA---	FIDKYNFD
OsICK5	(167)	RSFRMMAPPAAAAEIEEFFLAAERSEAER---	FAAKYNFD
		281	305
ALFALFA ICK	(206)	PVTEQPLPG----	RYETEKVSP---
AtICK1	(175)	FEKEKPLEG----	RYEWVKLE---
AtICK2	(191)	FEKDEPLGGG----	RYEWVKLNP---
AtICK3	(205)	IVNDIPLSG----	RYEWVQVKP---
AtICK4	(272)	PVNEQPLPG----	RFEWTKVDD---
AtICK5	(172)	IVSDNPLPG----	RYEWVKVMP---
AtICK6	(181)	IVNDEPLEG----	RYKWDRL---
AtICK7	(178)	IVNDTPLEG----	RYQWVSLKP---
CHENOPOD ICK	(179)	IVKDVPLKG----	RYDWVPINE---
OsICK2	(241)	VVRGVPLDAG----	RFEWTPVVSSRS
OsICK4	(178)	PVNDCLPG----	RFEWVKLD---
OsICK5	(204)	VVRGVPLDAGGAGRFEWTAVGSG--	

FIGURE 3 (cont'd)

OsICK2	(121)	SSTASSVDAAAQDRSLACRSDVAEAGSEHVPEGS-ASDSA
OsICK3 partial	(1)	-----LITLSVC
OsICK4	(61)	PPPPPPRRRRATAAAATADATATESAAEVSFGGENVLEL
OsICK5	(73)	FVAAAVVSSRREEALGDSVAEAASSSSSRVELLGCSGEE
PtICK	(1)	-----
SbICK partial	(1)	-----VFNAFKSCLY
ZmICK1 partial	(1)	-----GYGDHVPDVVXASNSG
ZmICK2 partial	(1)	-----ES
OsICK2	(160)	SGRDRERRETTPSS--FLPGEVSDLES SD LAGGQKRSRPLP
OsICK3 partial	(8)	HTLTTLTLINSCFYSLQFRKSLKPNSCSREVA AE HAGEHKH
OsICK4	(101)	EAMERNTRRETTPCSLIRDPDTISTPGSTTRSHSS---SH
OsICK5	(113)	EAMAEKXSATTPSSRRPPGDADSSDAESNQEAKQMCRRS
PtICK	(1)	-----
SbICK partial	(11)	IYIYKQTKDAPDDRRRLRRGRGESEGETREREPLQ---GP
ZmICK1 partial	(17)	SVPDRERRETTPSSSRAHGGE LS DLSDLVGRQK---TGC
ZmICK2 partial	(3)	EAMGRNTRRETTPCSLINS-EMISTPGSTTRSHSS---HR
OsICK2	(198)	SAATA SA QQA-----TRPKIPPAEIEAFFAAAEFAE
OsICK3 partial	(48)	NPAAAAAAGR-----RPPLSPPEAEIEAFFAAAEFAE
OsICK4	(138)	CKVQTPVRHN-----I---IPASAEIEAFFAAAEQRO
OsICK5	(153)	STTSAAAFHAGATTRSFRMMAPPAAAAEIEEFLAAAEERSE
PtICK	(1)	---QNEGRS-----APTSEMEEEFFAGAEQQQ
SbICK partial	(48)	RRRQTPSPPP-----PPPPPTAEIEAFFAAAEFAE
ZmICK1 partial	(54)	SSSPATTTSA-----AELIVPPAQETIOEFFAAAEFAH
ZmICK2 partial	(39)	RVKAPFVHA-----IPSSTEMNEYFAAEQORRO
OsICK2	(230)	AKRFAAKYNFDVVRGVPLDAG---RFEWTPVVSSRS
OsICK3 partial	(80)	RRRFAEKY-----
OsICK4	(167)	RQAFIDKYNFDPVND CPL PG---RFEWVKLD---
OsICK5	(193)	AERFAAKYNFDVVRGVPLDAGGAGRFEWTA V GSG--
PtICK	(25)	QRLFIERYNDPVND LPL SG---RYEWVRLRP---
SbICK partial	(80)	RRRFAEAYNDVALD CPL EG---RFEWTPVNT---
ZmICK1 partial	(86)	AKRFAKYNFDVVRGVPLDAG---RFEWTPGVSI--
ZmICK2 partial	(66)	QQAFIDKYNFDPVND CPL PG---RFEWVKLD---

FIGURE 4







FIGURE 5


p21Cip1 - Cy-1	13	-	CGSKAC	RRL	FGPVDS
p21Cip1 - Cy-2	150	-	FYHSKRRL	IFSKRKP	
p27Kip1	24	-	PKPSACRN	LFGPVDH	
p57Kip2	25	-	VRTSACRS	LFGPVDH	
Cdc25A	5	-	PSPAPRR	LLFACSP	P
p107	652	-	TAGSAKRRL	FGEDPP	
E2F1	416	-	EEGEGIR	DLFDCDFG	
CONSENSUS				RXHF	

FIGURE 6

**FIGURE 7**

**FIGURE 8**

**FIGURE 9**

**FIGURE 10**

(A)

1 GAAACCCTAG CCCCCTCCCA TCCCAGATCC CGACCGCC (ATGGGCAAGTAC
 51 ATGCGCAAGG CCAAGGTGGT GGTCTCCGGC GAGGTGGTGG CCGCCGCCGT
 101 CATGGAGCTC GCCGCGGCGC CGCTCGGGGT GCGCACCCGC GCCCGCTCCC
 151 TCGCGCTGCA GAAGAGGCAG GCGGGGGAGT ACCTCGAGCT CAGGAGCCGC
 201 AGGCTCGAGA AGCTCCCTCC TCCCCCGCCG CCGCCGCCGA GGAGGAGGGC
 251 GACGGCTGCG GCTGCGACTG CTGATGCGAC GCGGACGGAG AGCGCGGAGG
 301 CGGAGGTGTC GTTCGGGGGG GAGAACGTCC TCGAGCTGGA GGCCATGGAA
 351 AGGAATACCA GGGAGACGAC ACCTTGACAGC TTGATCAGGG ACCCCGATAC
 401 GATTAGCACC CCTGGATCTA CCACAAGGCG CAGCCACTCG AGTTCTCATT
 451 GCAAGGTGCA AACACCCGTG CGCCACAACA TTATTCCAGC ATCAGCAGAG
 501 CTGGAAGCGT TCTTCGCGYC CGAAGAGCAA CGGCAACGAC AGGCTTTCAT
 551 CGACAAGTAT AACTTTGATC CTGTGAATGA CTGCCCTCTT CCCGGCCGRT
 601 TTGAATGGGT CAAGCTAGACTGA) TAGATTT TCAGGAAAAG AAGGGCACCA
 651 TGGACCTCTC TGCTCCCTCC ACAGTAGTAG CGTGGCAGAG GCGCTTACCG
 701 TCAAGTTAGC TTTGATCCTG TTGTAAAAAT TTAGGGTTAG CCTGTAGACT
 751 CAATGGTCAA TGTGAACATA CAGAACTGAT GCTGAGTTAC AACCCTAATC
 801 CCTCAACTAC AATGTAACCC TTAACAGCTC ATTCTGTAAG GAACCACCTC
 851 CTCCTCTAGG GCCTAGCTAG CCTTATCATC TGTTATTACC AGTTGCTGGA
 901 TTAATGAAGT TAGATCTAGA TATTGTGTCA CAGTTTAACC TGTGTGTGT
 951 GTGGTGGTAG CATTGGCATT GGCAATGGGG TATGGCAGTG TGTGTGTGGT
 1001 GCTGCACTGC ACCTCCCGAA GTGCTGTAAT TTTTGTCTAT ACTTCTGCTA
 1051 AAAAAAAAAA AAAAAA

(B)

		1	50
2-H ICK4	(1)	-----	
HYB ICK4	(1)	MGKYMRKAKVVVSGEVVAAAVMELAAAPLGVRTRARSLALQKRQGGEYLE	
		51	100
2-H ICK4	(1)	-----PRRRATAAAATADATATESAEAEVSFGGENVLEL	
HYB ICK4	(51)	LRSRRLEKLPPPPPPPPRRRATAAAATADATATESAEAEVSFGGENVLEL	
		101	150
2-H ICK4	(35)	EAMERNTRTPCSLIRDPDTISTPGSTTRRSHSSSHCKVQTPVRHNIIP	
HYB ICK4	(101)	EAMERNTRTPCSLIRDPDTISTPGSTTRRSHSSSHCKVQTPVRHNIIP	
		151	195
2-H ICK4	(85)	ASAELEAFFAAEEQRQRQAFIDKYNEFPVNDCLPGRFEWVKLD-	
HYB ICK4	(151)	ASAELEAFFAAEEQRQRQAFIDKYNEFPVNDCLPGRFEWVKLD-	

FIGURE 11

1- MGKYM RKAKV VVS GEV VAAA VMELAAAPLG VRTRARSLAL QKRQGGEYLE
51- LRSRRLEKLP P P P P P P P RRR ATAAAATADA TATESAEAEV SFGGENVLEL
101- EAMER [IAPFV SLNCVKNTWV APSPKYPRVG ATCLQGTKGV PYERDEQVLR
151- HFW] NTRETP CSLIRDPDTI STPGSTTRRS HSSSHCKVQT PVRHNIIPAS
201- AELEAFFAAE EQRQRQAFID KYNFDPVNDC PLPGRFEWVK LD

FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18

1 GAAACCCTAG CCCCCTCCCC TCCCGAGTCC CGACCGCCAT GGGCAAGTAC
51 ATGCGCAAGG CCAAGGTGGT GGTCTCCGGC GAGGTGGTGG CCGCCGCCGT
101 CATGGAGCTC GCCGCGGCGC CGCTCGGGGT GCGCACCCGC GCCCGCTCCC
151 TCGCGCTGCA GAAGAGGCAG GGCGGGGAGT ACCTCGAGCT CAGGAGCCGC
201 AGGCTCGAGA AGCTCCCTCC TCCCCGCCG CCGCCGCCGA GGAGGAGGGC
251 GACGGCTGCG GCTGCGACTG CTGATGCGAC GGCGGCGGAG AGCGCGGAGG
301 CGGAGGTGTC GTTCGGGGGG GAGAACGTCC TCGAGCTGGA GGCCATGGAA
351 AGGTGGGGAT TCTCTCTCTC TTCTTATTGT GCGATTCTTT TTTTGTTTTT
401 CGTGGGTTTC TTGGTTGGAT TGATTGGGGG AATCGCGTGA TTAGGGTTCA
451 GGGTTTAAGC ACCGTACGGG AGTTCCTGGG GTTCGATGTT TCTATCCGGT
501 TTTTCGCATC GGAAAATTTT GGGGATTTTT TTTCGGTGCG ATTGTGGCGC
551 TCGGAATTCC TGTGGCCAGT TTTGGGGTTT CGAAAGTATC GAAATGGAGG
601 CGAGGAATCT TTTTTTTTTT CATCACACGC GGTTGTAAAG CCCCAGTGCT
651 TTCTTGGTGG GATTCCTGTG CCTTTGCTAA TTGAGACATG CAATTCGTGC
701 TTTCTTGTT GCCTAAATTT GTTCTTTTTT CATGTTTCTT GTGGCGATAC
751 AGCCTTTTTT TTTTGCCAAT TTCTTGTCCT TTAGCTTGTT TACAAGTTAG
801 AACCCATTTT AACTTCTTTT GAAGAAGGGA AAAAAAGAAG AAGAGAAGGT
851 GTTCCCAAGT TTAATCCAA ATGGTTGCAA GAACCACTTC TTTGCCCCC
901 AAATTTACCT CGAAGAATCC CCCCAAATTT GTTATTGTTT TGGATGATAA
951 AAAGGTAGGA ACTGTGCAGT AGTGCTCAAG CTCTCAACTC AAATCCCAAT
1001 TGAAACTTGA TCAATTGATT GAGCCCCCTT CTTAGTGGGG TTACTCCAG
1051 TGGCCATGGC CTCCTGCTTT TCCTTAGTGG AAGGGAAAAG CAGCATCCTT
1101 TCCCTCCTGT TCTTTGTGTT TTGTTTGGGG GGTAGGGACC CCTCTCAATC
1151 TTTTACCAAT CAAAAGCCCT CACCTTTTGC AAGAAATTTT TCTCATAAAC
1201 ATCCTTCCCA AAGGCACCCC CCATCTCACC ACCCACCTCA AGGCCTCATT
1251 CTTGCAACTA ACTAGCCTGT CACTTCTCTG GGTTCTGGAA GGGTGATGAA
1301 ATGGCATGCC TTGGTAAAC CATCTTCCTG GGCCATGCCC CCAAATTGTC
1351 ACCACCATTA AATGTTTGAG GTGAAAGGAG GGGGTCCCTC CCCTCCCCAC
1401 AAGTACTAGA AGTTGATTTG TTGGTGATCT TTGGTTCAAG CTAGGGGGAT
1451 GGAAGAACAT TTTAGGATCA GCTAGCTAGG CTACTACTAC TACTACTTGC
1501 TTCTGCAGTT CTTGGCAGGA TAATATTTTT AGCTACTACT ACTGTATCTC
1551 ACAAGCTAGC AAACGTTCTT GGTTCTAGCA CTATCTTGTT GAGGTGGGGG
1601 ATCTTCCTCA GCCTAAACAG GTCAAAGACC CTATTTTGCT GCGGTGTCCT
1651 TTGGTGTAGG ATAGCTCCAT TTGTTAGCTT GAATTGTGTG AAAAAATACAT
1701 GGGTTGCACC ATCACCAGAG TACCCAAGAG TGGGGGCAAC TTGCTTGCAA
1751 GGGACAAAGG GCGTGCCGTA TGAGAGAGAT GAGCAAAGTG TGCGTCATTT
1801 TTGGTTTGTC ATCTTGGGTG CAAGATCAAG CAGCAGGTGT CACAGGACTC
1851 ACCACAGCTT GGGCTGTCTT TGGTGCCCCA TGTCCAAGGG TGCATTCAAT
1901 GCACCTCCTC TAGCCATGGC CTAATGGTGC ATACTTCTGT GCCTCAAGGA
1951 CTGTTGTCTT TGAACCATTG ATGGATATCT ATCTGCATCC ATTTGTTTTA
2001 ATCCTTGGAA GCACCATGCG TGGCCTAAAT AGTGTGATCT GAACAGTGAG
2051 CATCTAAGCT AGCCATGGCC CTCCCAAGCA TTTGCCATGG TGAAGCTGC
2101 AGTGCAGAGT CAGCATGTGG TGTTGTTGCT GGGCCACTGT TGGTGACCGT
2151 CCTACCACCT TTTGCATGCA GCAGCAGCCA GCAGCAGCTT CGGATGCCGG
2201 TGCTTGGGTC TCTAGGATGG AGTTATGGCC GGGGGGATCA CCTCACCTGA

FIGURE 19

```
2251 GCTAGTCATG TGATTCAGAT ATGGGAGCTC CTTAGACCAA ACCATTTTCT
2301 TGTTTCACTT GGCCTTGTGT TTGGTTGTCC CTTAGCCTTT TTTTGGCATG
2351 TGAGATAAAC ATTCAGAGGT GGAACATGGT TTATTTTGCA GGACCACGGC
2401 GATGCTGATT TTTTTTCTCA ATATTACCGG TGCATTTTTC TTGTTTAGTT
2451 TTTGGTACAA AAGAAAAAAA AGCTTACGTT GCATGTTCTG TTTTAAATTT
2501 GTATGCTTTT GTTTCCTTGCA GGAATACCAG GGAGACGACA CCTTGCAGCT
2551 TGATCAGGGA CCCCATAACG ATTAGCACCC CTGGATCTAC CACAAGGCGC
2601 AGCCACTCGA GTTCTCATTG CAAGGTGCAA ACACCCGTGC GCCACAACAT
2651 TATTCCAGCA TCAGCAGAGC TGGAAGCGTT CTTGCTGCTC GAAGAGCAAC
2701 GGCAACGACA GGCTTTCATC GACAAGTACG ATCTTGCTTT GCTCTTCTAT
2751 TATGTTTCACT AAATATATCC CTGGATGCAT TGTGATAATG TCCATGGCCT
2801 TGCAACTTAG AAATACTATA ATGGTGTATT ATCGCTGACT GACAATTTAA
2851 CTTCTTTGTC GTAATCTTCA GGTATAACTT TGATCCTGTG AATGACTGCC
2901 CTCCTCCCGG CCGGTTTGAA TGGGTCAAGC TAGACTGATA GATTTTCAGG
2951 AAAAGAAGGG CACCATGGAC CTCTCTGCTC CCTCCACAGT AGTAGCGTGG
3001 CAGAGGCGCT TACCGTCAAG TTAGCTTTGA TCCTGTTGTA AAAATTTAGG
3051 GTTAGCCTGT AGACTCAATG GTCAATGTGA ACATACAGAA CTGATGCTGA
3101 GTTACAACCC TAATCCCTCA ACTACAATGT AACCCTTAAC AGCTCATTTCT
3151 GTAAGGAACC ACCTCCTCCT CTAGGGCCTA GCTAGCCTTA TCATCTGTTA
3201 TTACCAGTTG CTGGATTAAT GAAGTTAGAT CTAGATATTG TGTCACAGTT
3251 TAACCTGTTT TGTGTGTGGT GGTAGCATTG GCATTGGCAA TGGGGTATGG
3301 CAGTGTGTGT GTGGTGCTGC ACTGCACCTC CCGAAGTGCT GTAATTTTGG
3351 TCTATACTTC TGCT
```

FIGURE 19 (cont'd)

1	ATGGGGAAGA	AGAAGAAGCG	CGACGGCGCG	GCGGCGAGGA	GGCAGGCGCG
51	GGTGGTGGTC	GGCGGCGTCC	GTACGCGGGC	CGCCGTCACG	GCGAGGAGGG
101	TGGTGGCGAG	CGCGGAGGAG	GGTTGTGGTT	TGGTGGGCCG	TGGCGGTGGC
151	GGTGGCAGTG	GCGGAGACGA	TGGCGAGGGC	GGATGCTATC	TGCGTCTGCG
201	GAGCAGGAGG	CTGCCCTTCG	TGGCGGCCGC	GGTGGTGTCT	TGCGGAGGGG
251	AGGAGGCGCT	CGGTGATTCT	GTGGCGGAGG	CGGCTTCGTC	GTCGTCGTCG
301	CGGGCGGTGG	AATTGTTGGG	CTGTTCTGGT	GAGGAGGAGG	CTATGGCCGA
351	GAAGGTGATT	GATGAGCCCT	AGAATTCCTC	CGCGGCTCGA	GTGCTCGATC
401	GCCCGCTTCC	ATCTCTTGCT	GAATGATGCG	GCTTGGGATG	TGGTGGTTTT
451	GCAGGTTTGC	ACGCAGGCAG	GCGAGGATCA	CGACGAGGAG	AGCTCCGTCG
501	GCGACTCCGG	CTGCGGCCGC	GAGAGGTGAT	CGAGCTCCTC	TCCACGCGTT
551	CTTGCTTGTC	CTTGACATGA	TTAATTACAA	CCGCCGTTCT	CTCAATTGAA
601	TTATCGCAAT	TCAATCCAGG	AGCGCGACGA	CGCCGTCGAG	CCGCCGGCCG
651	CCGGGAGACG	CGGACTCGAG	CGACGCGGAG	TCAAACCAGG	AGGCCAAGCA
701	GCAAATGTGC	CGCCGGAGTT	CGACGACCTC	AGCAGCTGCA	TTTCACGCGG
751	GAGCGACGAC	GAGGAGCTTC	AGGATGATGG	CACCGCCGGC	GGCGGCGGCA
801	GAGATCGAGG	AGTTCCTCGC	CGCTGCGGAG	AGGTCCGAGG	CCGAGCGCTT
851	CGCCGCCAAG	TGAGTGCTGC	ATCACATATT	GTCGTCCGTG	CGTCGTGTCG
901	TACATATCGT	CGTCGTGCTC	AAAATCGGCC	TCGATCGCGA	CATGCATGGC
951	CGCATGGGAG	CTGATTAACG	TGCGCTCCTC	CTCCTCAGGT	ACAACTTCGA
1001	CGTGGTGCGC	GGCGTGCCGC	TCGACGCCGG	CGGCGCCGGG	CGGTTTCGAAT
1051	GGACCGCGGT	GGGCAGCGGC	TGA		

FIGURE 20

A.

```

1  ATCGGGGAAGA AGAAGAAGCG CGACGGCGCG GCGGCGAGGA GGCAGGCGCG
51 GGTGGTGGTC GCGGCGGTCC GTACGCGGGC CGCCGTCACG GCGAGGAGGG
101 TGGTGGCGAG CCGGAGGAG / GGTGTGGTT TGGTGGGCCG TGGCGGTGGC
151 GGTGGCAGTG GCGGAGACGA TGGCGAGGGC GGATGCTATC TCGTCTGCG
201 GAGCAGGAGG CTGCCCTTCG TGGCGGCCGC GGTGGTGTCTG TCGCGGAGGG
251 AGGAGGCGCT CCGTGATTCTG GTGGCGGAGG CGGCTTCGTC GTCGTCGTCG
301 CGGGCGGTGG AATTGTTGGG CTGTTCTGGT GAGGAGGAGG CTATGGCCGA
351 GAAGNNGAGC GCGACGACGC CGTCGAGCCG CCGGCCGCCG GGAGACGCGG
401 ACTCGAGCGA CCGGAGTCA AACCAGGAGG CCAAGCAGCA AATGTGCCGC
451 CGGAGTTCGA CGACCTCAGC AGCTGCATTT CACGCGGGAG CGACGACGAG
501 GAGCTTCAGG ATGATGGCAC CGCCGGCGGC GGCGGCAGAG ATCGAGGAGT
551 TCCTCGCCGC TCGGAGAGAG TCCGAGGCCG AGCGCTTCGC CGCCAAGTAC
601 AACTTCGACG TGGTGCGCGG CGTGCCGCTC GACGCCGGCG GCGCCGGGCG
651 GTTCGAATGG ACCGCGGTGG GCAGCGGCTG A

```

B.

```

1  MGKKKKRDGA AARRQARVVV GGVRTAAVT ARRVASAEE GCGLVGRGGG
51 GGS GGDDGEG GCYLRLRSRR LPFVAAVVS SRREEALGDS VAEAASSSSS
101 RAVELLGCSG EEEAMAEXS / ATTPSSRRPP GDADSSDAES NQEAQQMCR
151 RSSTTSAAAF HAGATTRSFR MMAPPAAAAE IEEFLAAER SEAERFAAKY
201 NFDVVRGVPL DAGGAGRFEW TAVGSG

```

FIGURE 21

SEQUENCE LISTING

<110> CROPDESIGN N.V., et al.

<120> NOVEL PLANT CYCLIN-DEPENDENT KINASE
INHIBITORS

<130> CNN-003PC

<150> 60/218,471

<151> 2000-07-14

<150> 60/241,219

<151> 2000-10-13

<160> 59

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 493

<212> DNA

<213> Oryza sativa

<221> misc_feature

<222> 52, 180, 181, 186, 461

<223> n = A,T,C or G

<400> 1

```
ccgccgagat cgaggcggtt ttcgcggcgg cccaggaggc tgaggccaag cnttcgccgc 60
caagtacaac ttcgacgtcg ttcgcggcgt gccctcgcac gccggtcggt tcgagtggac 120
tccggtgggt agcagccgaa gctgaagcga gcgtgcagat taagcggaag ctgaaaaggn 180
nggtancagg ggggcgcggt gtagaaaagg aaggcgagct agagagagga gaagaagaag 240
aagaaaagat gctcatccaa aggaataaaa ctggaaaagt gggagactac aaaaaaagaa 300
gcattatagc ctaacaacca ccgattcgac tcttttttct ttcacatttt ctttgcattt 360
ttactcttac tgtgtactag aaagtagtag cagtagtaaa ctagtaattc gtcccagtat 420
ttatcagagg tttatctcga taggaataga tatattatcc nctaaaaaaa aaaaaaaaaa 480
aaaaaaaaaa aaa                                     493
```

<210> 2

<211> 696

<212> DNA

<213> Oryza sativa

<400> 2

```
aagctaagct aaatcaagct aattagtttt ttaattaato tgcttaattt gcaaactaat 60
tacctgcga gctgccggtt ttgcaggtag aattacgaca ttgccctcga ccgcccggtg 120
caaggccgct acgagtggga gccagtgagc acgtgaaagg gaggggtaga agtgtcaact 180
caactcacac ccatgtctgc aactcacaag tgatgcaaag ctagcttaat catcagcagc 240
taattatctg ggagaggctg gggatcgagt tagtgacctt gtttctcctg ctaattctca 300
attagggaat taattaatta ctctcaatc ctcatctcca cctgttgtca gttggatctc 360
actaccatat atatctcagc tctgtcaatt aatcttttgt atagtgggta ggaaataatc 420
aaggataatc caggtgattt ggagatgct tctgatgagc tcccctcttg ctaattacta 480
atatgtatct tcacataat ttgcctaata ttactgttta ttactactta ttaagcccct 540
tcaaaaataa gtatttcacg cgtttcacia ggtaagactt tctagcattg tacacattta 600
tttatatatt aatgaattta gacatatgta ttgatttaga atcattaata tctatatgta 660
tatgtgcaat gctagattgt cttatattgt aaaacg                                     696
```

<210> 3
<211> 415
<212> DNA
<213> *Oryza sativa*

<400> 3
ctcctgtgta gtcactaata agcacaaatc ttatatattca aaattaaacc atacgtaagt 60
cgaaaaatattt atttttacaaa aggtaattcg tgacaatttt ttttctagct tagtaattaa 120
ttacactgtc agtctgtcac aactcacac tcacactaat taactcttgc ttctactctc 180
tccaattcag aaagtctttg aagccaaatt cttgttcccg cgaagtggcg gcggaacacg 240
ccggcgagca caagcacaaac cctgcagccg ccggcgccgc cggccgccg ccaccgctgt 300
cgccgccgga agcggagatc gaggcgttct tcgccgccgc ggagctcgcc gagcgccggc 360
gattcgcaga gaagtacgta tacacacaca cataatcact catctctctc tagct 415

<210> 4
<211> 1614
<212> DNA
<213> *Oryza sativa*

<400> 4
ttcttggccc atgcccccaa attgtcacca ccattaaatg tttgaggtga aaggaggggt 60
cctcccccggt cccacaaagt actagaagtt gatttgttgg tgatctttgg ttcaagctag 120
gggatggaa gaacatttta ggatcagcta gctaggctac tactactact acttgcttct 180
gcagtctcttg gcaggataat attttttagct actactactg tatctcacia gctagcaaac 240
gttcttgggt ctagcactat cttgtggagg tgggggatct tcctcagcct aaacagggtca 300
aagaccctat tttgctggcg tgtcctttgg tgtaggatag ctccatttgt tagcttgaat 360
tgtgtgaaaa atacatgggt tgcaccatca ccgaagtacc caagagtggg ggcaacttgc 420
ttgcaaggga caaaggggcg gccgtatgag agagatgagc aagtgtctgc tcattttttg 480
tttgtcatct tgggtgcaag atcaagcagc aggtgtcaca ggactcacca cagcttgggc 540
tgtccttgggt gcccctatgc caagggtgca ttcattgcac ctctcttagc catggcctaa 600
tgggtgcatac ttctgtgcct caaggactgt tgtctttgaa ccattgatgg atatctatct 660
gcatccattt gttttaatcc ttggaagcac catgcgtggc ctaaaatagt tgatctgaac 720
agtgcagc taagctagcc atggccctcc caagcatttg ccatgggtga agctgcagtg 780
cagagtcaag atgtggtgtt gttgctggc cactgttggg gaccgtccta ccaccttttg 840
catgcagcag cagccagcag cagcttcgga tgcgggtgct tgggtctcta ggatggagt 900
atggccgggg ggatcacctc acctgagcta gtcattgtat tcagatatgg gagctcctta 960
gaccaaacca ttttcttgtt tcaattggcc ttgtgttttg ttgtccccta gccctttttt 1020
ggcatgtgag ataaacattc agaggtggaa catgggttat tttgcaggac caggcgatg 1080
ctgatttttt ttctcaatat taccgggtgca ttttcttgtt ttagtttttg gtacaaaaga 1140
aaaaaaagct tacgttgcat gttctgtttt aaatttgtat gcttttgttt cttgcaggaa 1200
taccaggag acgacacctt gcagcttgat cagggaacct gatacgatta gcaccttg 1260
atctaccaca aggcgcagcc actcgagtgc tcattgcaag gtgcaaacac ccgtgcgcca 1320
caacattatt ccagcatcag cagagctgga agcgttcttc gctgccgaag agcaacggca 1380
acgacaggct ttcacgaca agtacgatct tgctttgctc ttctattatg ttcagtaaat 1440
atatccctgg atgcattgtg ataattgtcca tggccttgca acttagaaat actataatgg 1500
tgtattatcg ctgactgaca atttaacttc tttgtcgtta tcttcaggta taactttgat 1560
cctgtgaatg actgccctct tccggcccg tttgaatggg tcaagctaga ctga 1614

<210> 5
<211> 568
<212> DNA
<213> *Zea mays*

<221> misc_feature
<222> 32
<223> n = A, T, C or G

<400> 5

```

aggttacggg gatcacgtcc cggatgtcgt cnccgcgagc aactcgggga gcgtcccgga 60
ccgcgagagg agagagacga cggcatcgtc gagccgggag caccggcgcg agctcagcga 120
tctggagtcg gatctggtgg ggccgcagaa gactggctgc tcgtcgtcgc cggcgacaac 180
aacatcggct gcggagctga tcgtgccgcc agcacaggag atccaggaat tcttcgcggc 240
cgccgaggcg gcccatgcc aacgctttgc ttccaagtac aacttcgact tcgtccgcgg 300
cgtgcccctc gacgccggcc ggttcgagtg gacgccaggg gtcagcatct gaagcgagcg 360
tgccgtgcaa ggtgaagcta ctactagcta gaaagtgagg agaaaaaag aaaagatgcc 420
gccccaaaaa cataacggaa aggagaaaag gcaaaggagc tttataggct agctaagcta 480
accaccattc aacatctgcc ttgctttttt ctccggagta gacttgtaga atgacagcgt 540
agttattttac tgtttatcca gaggttat
568

```

<210> 6

<211> 543

<212> DNA

<213> Zea mays

<400> 6

```

cgagtccgag gccatgggga ggaataccag ggagacgacg ccctgcagct tgattaactc 60
tgagatgata agcaotcccg gatccacaac aagatccagc cactcttccc accgcagggt 120
gaaagctcct cctgtgcacg ccatcccaag ttcaacggag atgaacgagt acttcgctgc 180
tgaacagcga cgccaacaac aggttttcat tgacaagtac aactttgata ctgtaaatga 240
ctgccctctc ccaggcaggt ttgaatgggt gaagctagac tgatagattc agaggacatg 300
agagcagcag catggaactc acctccgctc cctccaccgc cgcagcgctg tggcagagcg 360
gcataccgct gtgttagctt tgtttctgtt gtaaaaactt agcgtagct tgtagcctta 420
attgtcgcgt gtcacagtac agaactgatg ctgagttaca gcaccctgat atgatctggt 480
ccctcaactc caatgtaacc cttaacagct cattctgtaa ggaacctatc atcctgttac 540
cag
543

```

<210> 7

<211> 1334

<212> DNA

<213> Sorghum bicolor

<400> 7

```

atgggcaagt gcgtcaggat ccgcggcagc agcagcaagc cggccccggc ggccggccgcc 60
gaggccgagg ccgcgtcgtc gtgcctcacg ctgcgcagcg gccgcccggt gccgccgggtg 120
gcagccgcgt gcggcccgcc gaggaccagc ggccggccgc ggccgccacc cgccggggtct 180
gccctccgac gatggtgcgg ccgcgcgagc gccgcggaca agcaggtgca gcagcgcgcg 240
tgccggcagcc cccggcgcgg gagtgacgca ggccgggtgc tcggtctcgg actcgggtgca 300
cgccggcagc tctgccacga cgacggggcg acgacggagg cggaggtgcc gccgtcgcgg 360
gcggcagata toggcgtcga cgacggggcg ggagactgct tgagttagtg cagtttttat 420
ttattcctgc tgcctttcat tcttcggatc acaattcaca aaacaaagcc agtttttagt 480
gttttttttt tgcgaggata agccagtttt cagttaatcg caaaaggaaa gccaattttc 540
agtttcgagg aaatttacga aacaatatat atcatatact ctctccattc caaattgtaa 600
gtcattacaa gaatcttgga gagtcaaaact tttctaagtt tgaccaaaatt tatattataa 660
aataataata attatgatac taactaagta tcattagatt ctttcttaatt tatattttta 720
tagtatactc actttacggt ataaatctta gtatttttct ttataatttt ggtcaaactg 780
gaaaatgctt tgactcttta agattcttaa aatgatttac aatttgggat ggagagagta 840
tttgacaggg ttattttttt tttttgagca tgtcaagtta tatattcatt aggcacacat 900
cgttaattaa ccagttgttt ttaatgcttt caaatcgtgt ttatatatat acatatataa 960
gcagacaaa gacgcccctg atgaccggcg acgactgcca cgcggccgtg gtgaaagtga 1020
aggcgaaaca cgagaacgag agccgctgca ggggcctcgt cgcggccaga cgccgtcgcc 1080
accgccggcg ccgcgcggcg agccgagata gaggccttct tcgcggcgcg 1140
cggagctcgc cgagcgccgg cgatttgagc aggcgtaagc accacggcgt ttgggacgtt 1200
ggtgtactgt aatctagctt gtacaagtcg ttggctgacg ggagctcgcc acgccttctt 1260
gcaggtacaa ttacgacgtt gccctcgact gcccggttga agggcgcttc gaatggacgc 1320
cgggtgaacac gtga
1334

```

<210> 8
 <211> 595
 <212> DNA
 <213> Pinus teeds

<221> misc_feature
 <222> 520, 531, 537, 574, 584, 594
 <223> n = A,T,C or G

<400> 8
 gcaaaacgaa ggtaggagtg ctccaaccto acatgaaatg gaggaattct ttgctggggc 60
 agagcaacag caacaaaggc tgttcataga aaggtaaat tatgatcctg tcaatgactt 120
 gcccttttct ggacggtatg agtgggtcag gttgagacca tgagagtagc gtcattctctt 180
 cagactgggc aaaatcactt acttattgtt gaagtgactt cccttcacat atcttttttg 240
 gtcaaaatga aaaatacaaa ggaagaggca ttctctgcac atcattttatt agttccagtc 300
 agtgcagact gtgaagattg ttacagaaat gtagctgtat gatgtcaatg tataatatgg 360
 gagagttggg cactttcagt tttgtacaga ttcttactgg gatattctcc ttttaaacag 420
 aatccccaaag catctgtagg aaaaaatgat gcctgttttg ttcattggatc acttactgca 480
 atcaaccgcc ttgcctcggt tcaatgaaac ttttttgaac ccaatcttcc ngctgtntat 540
 cccccgggtg gttactgctc actcattgta aacncctcga ttcnctacaa aaana 595

<210> 9
 <211> 1242
 <212> DNA
 <213> Oryza sativa

<400> 9
 ggcacgaggc ggcgcagatg ggcaagtaca tgaggaaagt cagggggggcc acggggggagg 60
 agttggccgc catggaggtc acgcagggtg ttggcgctcc gacgaggctc aggtcggcag 120
 cggcgggcgg cgcgacgacg acgaagggtg agcgggcgct ccaggaggga 180
 ggaaggcgct gctgccgacg gcggctcggt ggactactcg ccgtgacggc gggagctgct 240
 acctccagct gaggagccgc atgctgttca tggccccgcc gaggccggcg ccggccgcga 300
 gggctccggt tgtagcggag gcggcggtt ccgggaacgg agcggcgggc catgcggcgg 360
 ctggcctctc gcgttgctcc agcacggcgt cgtccgtgga cgcggcggtc caggacagga 420
 gcctcgcgtg ccgctccgac gtcgcggagg caggcagcga gcatgtcccg gagggctccg 480
 cgagcgactc ggcgagcggc cgtgaccgcg agaggagaga aacaactcca tcaagctttc 540
 tccccggcga ggtgagcgat ctggagtcgg atctggctgg aggacagaag cgcagccgtc 600
 cactaccttc tgccgcaaca gcctcagcac agcaagccac gcggccgaag attccgcggc 660
 ccgccgagat cgaggcggtc ttgcggcgcg ccgaggaggc tgaggccaag cgcttcgccg 720
 ccaagtacaa ctctgacgtc gttcgcggcg tgccctcga cgcgggtcgg ttcgagtgga 780
 ctccggtggt cagcagccga agctgaagcg agcgtgcaga ttaagcggaa gctagaaagg 840
 aaggtagcag ggggcgcggt gtagaaaggg aaggcgagct agagagagga gaagaagaag 900
 aaaagatgct catccaaagg gaataaacgg gaaaagtggg agactacaaa aaaagaagca 960
 ttatagccta acaaccaccg attogactct tttttctttc acattttctt tgcattttta 1020
 ctcttactgt gtactagaaa gtagtagcag tagtaacta gtaattcgtc ccagttattta 1080
 tcagaggttt atctcgatag gaatagatat attatccctt tactgtaatt gcctccatct 1140
 tgtatttgga tggaaattaa atttactgta cagcagcagc agctgttctg caagtttaag 1200
 ttaacatca ccgttttatt acttaaaaaa aaaaaaaaaa aa 1242

<210> 10
 <211> 262
 <212> PRT
 <213> Oryza sativa

<400> 10
 Met Gly Lys Tyr Met Arg Lys Phe Arg Gly Ala Thr Gly Glu Glu Leu
 1 5 10 15

Ala Ala Met Glu Val Thr Gln Val Val Gly Val Arg Thr Arg Ser Arg
 20 25 30
 Ser Ala Ala Ala Gly Ala Thr Thr Lys Val Gln Ala Ala Ser
 35 40 45
 Ala Ala Ser Thr Arg Arg Arg Lys Ala Leu Leu Pro Thr Ala Val Val
 50 55 60
 Gly Thr Thr Arg Arg Asp Gly Gly Ser Cys Tyr Leu Gln Leu Arg Ser
 65 70 75 80
 Arg Met Leu Phe Met Ala Pro Pro Arg Pro Ala Pro Ala Ala Arg Ala
 85 90 95
 Pro Val Val Ala Glu Ala Ala Gly Ser Gly Asn Gly Ala Ala Ala His
 100 105 110
 Ala Ala Ala Gly Leu Ser Arg Cys Ser Ser Thr Ala Ser Ser Val Asp
 115 120 125
 Ala Ala Ala Gln Asp Arg Ser Leu Ala Cys Arg Ser Asp Val Ala Glu
 130 135 140
 Ala Gly Ser Glu His Val Pro Glu Gly Ser Ala Ser Asp Ser Ala Ser
 145 150 155 160
 Gly Arg Asp Arg Glu Arg Arg Glu Thr Thr Pro Ser Ser Phe Leu Pro
 165 170 175
 Gly Glu Val Ser Asp Leu Glu Ser Asp Leu Ala Gly Gly Gln Lys Arg
 180 185 190
 Ser Arg Pro Leu Pro Ser Ala Ala Thr Ala Ser Ala Gln Gln Ala Thr
 195 200 205
 Arg Pro Lys Ile Pro Pro Ala Ala Glu Ile Glu Ala Phe Phe Ala Ala
 210 215 220
 Ala Glu Glu Ala Glu Ala Lys Arg Phe Ala Ala Lys Tyr Asn Phe Asp
 225 230 235 240
 Val Val Arg Gly Val Pro Leu Asp Ala Gly Arg Phe Glu Trp Thr Pro
 245 250 255
 Val Val Ser Ser Arg Ser
 260

<210> 11
 <211> 22
 <212> PRT
 <213> Oryza sativa

<400> 11
 Tyr Asn Tyr Asp Ile Ala Leu Asp Arg Pro Leu Gln Gly Arg Tyr Glu
 1 5 10 15
 Trp Glu Pro Val Ser Thr
 20

<210> 12
 <211> 87
 <212> PRT
 <213> Oryza sativa

<400> 12
 Leu Ile Thr Leu Ser Val Cys His Thr Leu Thr Leu Thr Leu Ile Asn
 1 5 10 15
 Ser Cys Phe Tyr Ser Leu Gln Phe Arg Lys Ser Leu Lys Pro Asn Ser
 20 25 30
 Cys Ser Arg Glu Val Ala Ala Glu His Ala Gly Glu His Lys His Asn
 35 40 45

Pro Ala Ala Ala Ala Ala Gly Arg Arg Pro Pro Leu Ser Pro Pro
 50 55 60
 Glu Ala Glu Ile Glu Ala Phe Phe Ala Ala Ala Glu Leu Ala Glu Arg
 65 70 75 80
 Arg Arg Phe Ala Glu Lys Tyr
 85

<210> 13
 <211> 90
 <212> PRT
 <213> Oryza sativa

<400> 13
 Arg Asn Thr Arg Glu Thr Thr Pro Cys Ser Leu Ile Arg Asp Pro Asp
 1 5 10 15
 Thr Ile Ser Thr Pro Gly Ser Thr Thr Arg Arg Ser His Ser Ser Ser
 20 25 30
 His Cys Lys Val Gln Thr Pro Val Arg His Asn Ile Ile Pro Ala Ser
 35 40 45
 Ala Glu Leu Glu Ala Phe Phe Ala Ala Glu Glu Gln Arg Gln Arg Gln
 50 55 60
 Ala Phe Ile Asp Lys Tyr Asn Phe Asp Pro Val Asn Asp Cys Pro Leu
 65 70 75 80
 Pro Gly Arg Phe Glu Trp Val Lys Leu Asp
 85 90

<210> 14
 <211> 116
 <212> PRT
 <213> Zea mays

<221> VARIANT
 <222> 11
 <223> Xaa = Any Amino Acid

<400> 14
 Gly Tyr Gly Asp His Val Pro Asp Val Val Xaa Ala Ser Asn Ser Gly
 1 5 10 15
 Ser Val Pro Asp Arg Glu Arg Arg Glu Thr Thr Pro Ser Ser Ser Arg
 20 25 30
 Ala His Gly Gly Glu Leu Ser Asp Leu Glu Ser Asp Leu Val Gly Arg
 35 40 45
 Gln Lys Thr Gly Cys Ser Ser Ser Pro Ala Thr Thr Thr Ser Ala Ala
 50 55 60
 Glu Leu Ile Val Pro Pro Ala Gln Glu Ile Gln Glu Phe Phe Ala Ala
 65 70 75 80
 Ala Glu Ala Ala His Ala Lys Arg Phe Ala Ser Lys Tyr Asn Phe Asp
 85 90 95
 Phe Val Arg Gly Val Pro Leu Asp Ala Gly Arg Phe Glu Trp Thr Pro
 100 105 110
 Gly Val Ser Ile
 115

<210> 15
 <211> 93
 <212> PRT

<213> Zea mays

<400> 15

```

Glu Ser Glu Ala Met Gly Arg Asn Thr Arg Glu Thr Thr Pro Cys Ser
 1           5           10           15
Leu Ile Asn Ser Glu Met Ile Ser Thr Pro Gly Ser Thr Thr Arg Ser
          20           25           30
Ser His Ser Ser His Arg Arg Val Lys Ala Pro Pro Val His Ala Ile
          35           40           45
Pro Ser Ser Thr Glu Met Asn Glu Tyr Phe Ala Ala Glu Gln Arg Arg
          50           55           60
Gln Gln Gln Ala Phe Ile Asp Lys Tyr Asn Phe Asp Pro Val Asn Asp
65           70           75           80
Cys Pro Leu Pro Gly Arg Phe Glu Trp Val Lys Leu Asp
          85           90

```

<210> 16

<211> 108

<212> PRT

<213> Sorghum bicolor

<400> 16

```

Val Phe Asn Ala Phe Lys Ser Cys Leu Tyr Ile Tyr Ile Tyr Lys Gln
 1           5           10           15
Thr Lys Asp Ala Pro Asp Asp Arg Arg Arg Leu Arg Arg Gly Arg Gly
          20           25           30
Glu Ser Glu Gly Glu Thr Arg Glu Arg Glu Pro Leu Gln Gly Pro Arg
          35           40           45
Arg Arg Gln Thr Pro Ser Pro Pro Pro Pro Pro Pro Pro Pro Thr
          50           55           60
Glu Ala Glu Ile Glu Ala Phe Phe Ala Ala Ala Glu Leu Ala Glu Arg
65           70           75           80
Arg Arg Phe Ala Glu Ala Tyr Asn Tyr Asp Val Ala Leu Asp Cys Pro
          85           90           95
Leu Glu Gly Arg Phe Glu Trp Thr Pro Val Asn Thr
          100          105

```

<210> 17

<211> 53

<212> PRT

<213> Pinus taeda

<400> 17

```

Gln Asn Glu Gly Arg Ser Ala Pro Thr Ser His Glu Met Glu Glu Phe
 1           5           10           15
Phe Ala Gly Ala Glu Gln Gln Gln Gln Arg Leu Phe Ile Glu Arg Tyr
          20           25           30
Asn Tyr Asp Pro Val Asn Asp Leu Pro Leu Ser Gly Arg Tyr Glu Trp
          35           40           45
Val Arg Leu Arg Pro
          50

```

<210> 18

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> consensus ICK motif 1

<221> VARIANT

<222> 2, 3, 7

<223> Xaa = Any Amino Acid

<400> 18

Phe Xaa Xaa Lys Tyr Asn Xaa Asp
1 . 5

<210> 19

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> consensus ICK motif 2

<221> VARIANT

<222> 1, 3, 6

<223> Xaa = Any Amino Acid

<400> 19

Xaa Leu Xaa Gly Arg Xaa Glu Trp
1 5

<210> 20

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> consensus ICK motif 3

<221> VARIANT

<222> 2, 4, 7, 8, 9

<223> Xaa = Any Amino Acid

<400> 20

Glu Xaa Glu Xaa Phe Phe Xaa Xaa Xaa Glu
1 5 10

<210> 21

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> consensus ICK motif 4

<221> VARIANT
<222> 2
<223> Xaa = Any Amino Acid

<400> 21
Tyr Xaa Gln Leu Arg Ser Arg Arg
1 5

<210> 22
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> consensus ICK motif 5

<221> VARIANT
<222> 5, 6, 8, 9
<223> Xaa = Any Amino Acid

<400> 22
Met Gly Lys Tyr Xaa Xaa Lys Xaa Xaa
1 5

<210> 23
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> consensus ICK motif 6

<221> VARIANT
<222> 2
<223> Xaa = Any Amino Acid

<400> 23
Ser Xaa Gly Val Arg Thr Arg Ala
1 5

<210> 24
<211> 4
<212> PRT
<213> artificial sequence

<220>
<223> Cy-box

<221> VARIANT
<222> 2, 3
<223> Xaa = Any Amino Acid

<400> 24
Arg Xaa Xaa Phe
1

<210> 25
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 25
taactcgatc cccagcctct ccca

24

<210> 26
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 26
tacaattacg acattgccct cgac

24

<210> 27
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 27
cgcgcgagat cgaggcggtc ttcg

24

<210> 28
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 28
aaacctctga taaatactgg gacg

24

<210> 29
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 29
ctgtcacaca ctcacactca cact

24

<210> 30
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 30
cgaagaacgc ctgatctcc 20

<210> 31
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 31
gaataccagg gagacgacac cttgc 25

<210> 32
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 32
tcagtctagc ttgacccatt caaac 25

<210> 33
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 33
agggatgttt aataccacta c 21

<210> 34
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 34
gcacagttga agtgaacttg c 21

<210> 35
<211> 26
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 35
cgttgtcaat atcctggaaa ttttgc 26

<210> 36
<211> 26
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 36
ctgccattct ttagagggga tgcttg

26

<210> 37
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> Tag.100 epitope

<400> 37
Glu Glu Thr Ala Arg Phe Gln Pro Gly Tyr Arg Ser
1 5 10

<210> 38
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> c-myc epitope

<400> 38
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
1 5 10

<210> 39
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> FLAG-epitope

<400> 39
Asp Tyr Lys Asp Asp Asp Lys
1 5

<210> 40
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> HA-epitope

<400> 40
 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 1 5

<210> 41
 <211> 12
 <212> PRT
 <213> artificial sequence

<220>
 <223> protein C epitope

<400> 41
 Glu Asp Gln Val Asp Pro Arg Leu Ile Asp Gly Lys
 1 5 10

<210> 42
 <211> 11
 <212> PRT
 <213> artificial sequence

<220>
 <223> VSV epitope

<400> 42
 Tyr Thr Asp Ile Glu Met Asn Arg Leu Gly Lys
 1 5 10

<210> 43
 <211> 1067
 <212> DNA
 <213> Oryza sativa

<400> 43
 gaaaccctag cccctcccca tcccaggtcc cgaccgccat gggcaagtac atgcgcaagg 60
 ccaaggtggt ggtctccggc gaggtggtgg ccgccgccgt catggagctc gccgcggcgc 120
 cgctcggggg gcgcaccgc gcccgctccc tcgcgctgca gaagaggcag ggcggggagt 180
 acctcgagct caggagccgc aggctcgaga agctccctcc tccccgccg ccgcgccga 240
 ggaggagggc gacggctgcg gctgcgactg ctgatgcgac ggcgacggag agcgcgagg 300
 cggaggtgtc gttcgggggg gagaacgtcc tcgagctgga ggccatggaa aggaatacca 360
 gggagacgac accttgacgc ttgatcaggg acccgatac gattagcacc cctggatcta 420
 ccacaaggcg cagccactcg agttctcatt gcaagggtgca aacaccctg cgccacaaca 480
 ttattccagc atcagcagag ctggaagcgt tcttcgcygc cgaagagcaa cggcaacgac 540
 aggctttcat cgacaagtat aactttgatc ctgtgaatga ctgccctett cccggccgrt 600
 ttgaatgggt caagctagac tgatagattt tcaggaaaag aagggcacca tggacctctc 660
 tgctccctcc acagtagtag cgtggcagag gcgcttaccg tcaagttagc tttgatcctg 720
 ttgtaaaaat ttagggtag cctgtagact caatggtcaa tgtgaacata cagaactgat 780
 gctgagttac aaccctaata cctcaactac aatgtaacce ttaacagctc attctgtaag 840
 gaaccacctc ctctctaggg gcctagctag ccttatcatc tgttattacc agttgctgga 900
 ttaatgaagt tagatctaga tattgtgtca cagtttaacc tgttgtgtgt gtggtggtag 960
 cattggcatt ggcaatggg tatggcagtg tgtgtgtggt gctgcactgc acctcccgaa 1020
 gtgctgtaat ttttgtctat acttctgcta aaaaaaaaaa aaaaaaa 1067

<210> 44
 <211> 194
 <212> PRT
 <213> Oryza sativa

<400> 44
 Met Gly Lys Tyr Met Arg Lys Ala Lys Val Val Val Ser Gly Glu Val
 1 5 10 15
 Val Ala Ala Ala Val Met Glu Leu Ala Ala Ala Pro Leu Gly Val Arg
 20 25 30
 Thr Arg Ala Arg Ser Leu Ala Leu Gln Lys Arg Gln Gly Gly Glu Tyr
 35 40 45
 Leu Glu Leu Arg Ser Arg Arg Leu Glu Lys Leu Pro Pro Pro Pro Pro
 50 55 60
 Pro Pro Pro Arg Arg Arg Ala Thr Ala Ala Ala Thr Ala Asp Ala
 65 70 75 80
 Thr Ala Thr Glu Ser Ala Glu Ala Glu Val Ser Phe Gly Gly Glu Asn
 85 90 95
 Val Leu Glu Leu Glu Ala Met Glu Arg Asn Thr Arg Glu Thr Thr Pro
 100 105 110
 Cys Ser Leu Ile Arg Asp Pro Asp Thr Ile Ser Thr Pro Gly Ser Thr
 115 120 125
 Thr Arg Arg Ser His Ser Ser Ser His Cys Lys Val Gln Thr Pro Val
 130 135 140
 Arg His Asn Ile Ile Pro Ala Ser Ala Glu Leu Glu Ala Phe Phe Ala
 145 150 155 160
 Ala Glu Glu Gln Arg Gln Arg Gln Ala Phe Ile Asp Lys Tyr Asn Phe
 165 170 175
 Asp Pro Val Asn Asp Cys Pro Leu Pro Gly Arg Phe Glu Trp Val Lys
 180 185 190
 Leu Asp

<210> 45
 <211> 3364
 <212> DNA
 <213> Oryza sativa

<400> 45
 gaaaccctag ccccccctccc tcccgagtcg cgaccgccat gggcaagtac atgcgcaagg 60
 ccaagggtgg ggtctccggc gaggtggtgg ccgcgcgcgt catggagctc gccgcggcgc 120
 cgctcggggt gcgcacccgc gcccgctccc tcgcgctgca gaagaggcag ggcggggagt 180
 acctcgagct caggagccgc aggtctcgaga agctccctcc tccccgcgcg ccgcgcgcga 240
 ggaggagggc gacggctgcg gctgcgactg ctgatgcgac ggcggcggag agcgcggagg 300
 cggaggtgtc gttcgggggg gagaacgtcc tcgagctgga ggccatggaa aggtggggat 360
 tctctctctc ttcttattgt gcgattcttt ttttgttttt cgtgggtttc ttggttggat 420
 tgattggggg aatcgcgtag ttaggggttca gggtttaagc accgtacggg agttcttggg 480
 gttcgatgtt tctatccggt ttttcgcacg ggaaaatttt ggggattttt tttcgggtgcg 540
 attgtgcgcg tcggaattcc tgtggccagt tttggggttt cgaaagtatc gaaatggagg 600
 cgaggaatct tttttttttc catcacacgc ggttgtaaaag ccccgatgct ttcttgggtg 660
 gattcttgtc cctttgctaa ttgagacatg caattcgtgc tttccttgtt gcctaaattt 720
 gttctttttc catgtttctt gtggcgatac agccttttct ttttgccaat ttcttgtccc 780
 ttagcttggt tacaagttag aacccatttt aacttctttt gaagaaggga aaaaaagaag 840
 aagagaaggt gttcccaagt tttaatccaa atggttgcaa gaaccacttc ttgcccccc 900
 aaatttacct cgaagaatcc ccccaaattt gttattgttt tggatgataa aaaggtagga 960
 actgtgcagt agtgctcaag ctctcaactc aaatcccaat tgaaacttga tcaattgatt 1020
 gagccccct cttagtgggg ttactcccag tggccatggc ctctgcttt tccttagtgg 1080
 aagggaaaag cagcatcctt tccctcctgt tctttgtgtt ttgtttgggg ggtagggacc 1140


```

cctctcaatc ttttaccaat caaaagccct caccttttgc aagaaatttc tctcataaac 1200
atccttccca aaggcaccoc ccatctcacc acccaoctca aggcctcatt cttgcaacta 1260
actagcctgt cacttctctg ggttctggaa ggggtgatga atggcatgcc ttggtaaac 1320
catcttctctg ggccatgccc ccaaattgtc accaccatta aatgtttgag gtgaaaggag 1380
ggggtcctcc cctcccccac aagtactaga agttgatttg ttgggtgatct ttgggtcaag 1440
ctagggggat ggaagaacat ttttaggatca gctagctagg ctactactac tactacttgc 1500
ttctgcagtt cttggcagga taatattttt agctactact actgtatctc acaagctagc 1560
aaacgttctt ggttctagca ctatcttggt gaggtggggg atcttccctc gcctaaacag 1620
gtcaaagacc ctatttttgc ggctgtcct ttgggtgtagg atagctccat ttgttagctt 1680
gaattgtgtg aaaaatacat ggggtgcacc atcaccgaag taccgaagag tgggggcaa 1740
ttgcttgcaa gggacaaagg gcgtgccgta tgagagagat gagcaagtgc tgcgtcattt 1800
ttggtttgtc atcttgggtg caagatcaag cagcaggtgt cacaggactc accacagctt 1860
gggctgtcct tgggtgcccc tgtccaaggg tgcattcatt gcacctcctc tagccatggc 1920
ctaattggtg atacttctgt gcctcaagga ctgttgtcct tgaaccattg atggatatct 1980
atctgcatcc atttgtttta atccttggaa gcacctgcg tggcctaaat agtgtgatct 2040
gaacagttag catctaagct agccatggcc ctcccaagca tttgccattg ttgaagctgc 2100
agtgcagagt cagcatgtgg tgttgttgc ttgggtgtagg tgggtgacct cctaccacct 2160
tttgcatgca gcagcagcca gcagcagctt cggatgccgg tgcctgggtc tctaggatgg 2220
agttatggcc ggggggatca cctcacctga gctagtcag tgattcagat atgggagctc 2280
cttagacca accattttct tgtttcactt ggccttgtgt ttggttgtcc cctagccttt 2340
ttttggcatg tgagataaac attcagaggt ggaacatggt ttatttttga ggaccacggc 2400
gatgctgatt tttttctca atattaccgg tgcatttttc ttgttttagt ttgtgtacaa 2460
aagaaaaaaa agcttacgtt gcatgttctg ttttaaattt gtatgctttt gtttcttgca 2520
ggaataccag ggagacgaca ccttgcaact tgatcaggga ccccgatacg attagcacc 2580
ctggatctac cacaaggcgc agccactcga gttctcattg caaggtgcaa acaccgtgc 2640
gccacaacat tattccagca tcagcagagc tggaaagcgt cttcgctgcc gaagagcaac 2700
ggcaacgaca ggctttcacc gacaagtacg atcttgcttt gctcttctat tatgttcagt 2760
aaatatatcc ctggatgcat tgtgataatg tccatggcct tgcaacttag aaatactata 2820
atggtgtatt atcgctgact gacaatttaa cttctttgtc gtaatcttca ggtataactt 2880
tgatcctgtg aatgactgcc ctcttccggg ccggtttgaa tgggtcaagc tagactgata 2940
gattttcagg aaaagaaggg caccatggac ctctctgctc cctccacagt agtagcgtgg 3000
cagaggcgct taccgtcaag ttagctttga tcctgttgta aaaatttagg gttagcctgt 3060
agactcaatg gtcaatgtga acatacagaa ctgatgctga gttacaaccc taatccctca 3120
actacaatgt aacccttaac agctcattct gtaaggaaac acctcctcct ctagggccta 3180
gctagcctta tcatctgtta ttaccagttg ctggattaat gaagtttagat ctagatattg 3240
tgtcacagtt taacctgttc tgtgtgtggt ggtagcattg gcattggcaa tggggtatgg 3300
cagtgtgtgt gtggtgctgc actgcacctc ccgaagtgtc gtaatttttg tctatacttc 3360
tgct

```

<210> 46
 <211> 30
 <212> DNA
 <213> artificial sequence

<220>
 <223> probe or primer

<400> 46
 gaattccttc tacatcggct taggtgtage

30

<210> 47
 <211> 30
 <212> DNA
 <213> artificial sequence

<220>
 <223> probe or primer

<400> 47
 ccattggtgt gttggattct actactatgc

30

<210> 48
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 48
gaacaaagat ggtcagccaa tacattgatc

30

<210> 49
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 49
ggccatggct aagctagcta gcaagatgaa

30

<210> 50
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 50
agaagaaaga taaataaccg aaactatttg

30

<210> 51
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 51
ggacatgttt ttgtgggact gaactcaatg

30

<210> 52
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> probe or primer

<400> 52
actccttgct cctatcgaca cacc

24

<210> 53
<211> 24
<212> DNA
<213> artificial sequence

<220>
 <223> probe or primer

 <400> 53
 ccatggggga cgcctcggca tcca

24

<210> 54
 <211> 681
 <212> DNA
 <213> artificial sequence

<220>
 <223> probe or primer

<221> misc_feature
 <222> 355, 356
 <223> n = A,T,C or G

<400> 54
 atggggaaga agaagaagcg cgacggcgcg gcggcgagga ggcaggcgcg ggtggtggtc 60
 ggcggcgtcc gtacgcgggc cgccgtcacg gcgaggaggg tggtagcgag cgcggaggag 120
 ggttggtggt tggtagggcg tggcggtggc ggtggcagtg gcggagacga tggcgagggc 180
 ggatgctatc tgcgtctcg cgagcaggagg ctgcccttcg tggcggccgc ggtggtggtc 240
 tcgcggaggg aggaggcgct cggtgattcg gtggcgagg cggttcgtc gtcgtcgtc 300
 cggcggtgg aattggtgg ctgttctggt gaggaggagg ctatggccga gaagngagc 360
 gcgacgacgc cgtcgagccg ccggccgccg ggagacgcgg actcgagcga cgcggagtca 420
 aaccaggagg ccaagcagca aatgtgccgc cggagttcga cgacctcagc agctgcattt 480
 cgcgcgggag cgacgacgag gagcttcagg atgatggcac cgccggcggc ggcggcagag 540
 atcgaggagt tcctcgccgc tgcggagagg tccgaggccg agcgcttcgc cgccaagtac 600
 aacttcgacg tggtagcgcg cgtgccgctc gacgccggcg gcgcggggcg gttcgaatgg 660
 accgcggtgg gcagcggtg a 681

<210> 55
 <211> 226
 <212> PRT
 <213> artificial sequence

<220>
 <223> probe or primer

<221> VARIANT
 <222> 119
 <223> Xaa = Any Amino Acid

<400> 55
 Met Gly Lys Lys Lys Lys Arg Asp Gly Ala Ala Ala Arg Arg Gln Ala
 1 5 10 15
 Arg Val Val Val Gly Gly Val Arg Thr Arg Ala Ala Val Thr Ala Arg
 20 25 30
 Arg Val Val Ala Ser Ala Glu Glu Gly Cys Gly Leu Val Gly Arg Gly
 35 40 45
 Gly Gly Gly Gly Ser Gly Gly Asp Asp Gly Glu Gly Gly Cys Tyr Leu
 50 55 60
 Arg Leu Arg Ser Arg Arg Leu Pro Phe Val Ala Ala Ala Val Val Ser
 65 70 75 80
 Ser Arg Arg Glu Glu Ala Leu Gly Asp Ser Val Ala Glu Ala Ala Ser
 85 90 95
 Ser Ser Ser Ser Arg Ala Val Glu Leu Leu Gly Cys Ser Gly Glu Glu
 100 105 110
 Glu Ala Met Ala Glu Lys Xaa Ser Ala Thr Thr Pro Ser Ser Arg Arg
 115 120 125

Pro Pro Gly Asp Ala Asp Ser Ser Asp Ala Glu Ser Asn Gln Glu Ala
 130 135 140
 Lys Gln Gln Met Cys Arg Arg Ser Ser Thr Thr Ser Ala Ala Ala Phe
 145 150 155 160
 His Ala Gly Ala Thr Thr Arg Ser Phe Arg Met Met Ala Pro Pro Ala
 165 170 175
 Ala Ala Ala Glu Ile Glu Glu Phe Leu Ala Ala Ala Glu Arg Ser Glu
 180 185 190
 Ala Glu Arg Phe Ala Ala Lys Tyr Asn Phe Asp Val Val Arg Gly Val
 195 200 205
 Pro Leu Asp Ala Gly Gly Ala Gly Arg Phe Glu Trp Thr Ala Val Gly
 210 215 220
 Ser Gly
 225

<210> 56
 <211> 1073
 <212> DNA
 <213> *Oryza sativa*

<400> 56
 atggggaaga agaagaagcg cgacggcgcg gcggcgagga ggcaggcgcg ggtggtggtc 60
 ggcggcggtcc gtacgcgggc cgccgtcaag gcgaggaggg tgggtggcgag cgcgaggag 120
 ggttggtggtt tgggtgggccc tggcggtggc ggtggcagtg gcggagacga tggcgagggc 180
 ggatgctatc tgcgtctgcg gagcaggagg ctgcccttcg tggcggccgc ggtggtgtcg 240
 tcgcggaggg aggaggcgct cgggtattcg gtggcgaggg cggcttcgtc gtcgtcgtcg 300
 cgggcgggtg aattggttggg ctgttctggt gaggaggagg ctatggccga gaaggtgatt 360
 gatgagccct agaattcctc cgcggctcga gtgctcgatc gcccgcttcc atctcttgc 420
 gaatgatgcg gcttgggatg tgggtggttt gcaggtttgc acgcaggcag gcgaggatca 480
 cgacgaggag agctccgtcg gcgactccgg ctgcggccgc gagaggatgat cgagctcctc 540
 tccacgcggt cttgcttgct cttgacatga ttaattacaa ccgcggttct ctcaattgaa 600
 ttatcgcaat tcaatccagg agcgcgacga cgccgtcgag ccgcggccgc ccgggagacg 660
 cggactcgag cgacgcggag tcaaaccagg aggccaaagca gcaaatgtgc cgccggagtt 720
 cgacgacctc agcagctgca ttacacgcgg gagcgacgac gaggagcttc aggatgatgg 780
 caccgcgggc ggcggcgcca gagatcgagg agttcctcgc cgctgcggag aggtccgagg 840
 ccgagcgctt ccgcgccaag tgagtgtgct atcacatatt gtcgtccgtg cgtcgtgtcg 900
 tacatatcgt cgtcgtcgtc aaaatcggcc tcgatcgca catgcatggc cgcattgggag 960
 ctgattaacg tgcgtcctc ctctcaggt acaacttcga cgtggtgcgc ggcgtgccgc 1020
 tcgacgcggg cggcgccggg cggttcgaat ggaccgcggt gggcagcggc tga 1073

<210> 57
 <211> 59
 <212> DNA
 <213> artificial sequence

<220>
 <223> sense primer OsICK5

<400> 57
 ggggacaagt ttgtacaaaa aagcaggctt cacaatgggg aagaagaaga agcgcgacg 59

<210> 58
 <211> 49
 <212> DNA
 <213> artificial sequence

<220>
 <223> antisense primer OsICK5

<400> 58
ggggaccact ttgtacaaga aagctggggt cagccgctgc ccaccgcgg 49

<210> 59
<211> 265
<212> DNA
<213> Oryza Sativa

<400> 59
gtgattgatg agccctagaa ttccctccgcg gctcgagtgc tcgatcgccc gcttccatct 60
cttgctgaat gatgcggctt gggatgtggt ggttttgcag gtttgacgc aggcaggcga 120
ggatcacgac gaggagagct ccgtcggcga ctccggctgc ggccgcgaga ggtgatcgag 180
ctcctctcca cgcgttcttg cttgtccttg acatgattaa ttacaaccgc cgttctctca 240
attgaattat cgcaattcaa tccag 265

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/028893 A3

(51) International Patent Classification⁷: C07K 14/47,
C12N 9/12, 15/54, 15/82, C07K 16/40, A01H 5/00, G01N
33/573

(74) Agent: DE CLERCQ, Ann; De Clerq, Brants & Partners,
E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem (BE).

(21) International Application Number: PCT/IB01/01492

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(22) International Filing Date: 29 June 2001 (29.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/218,471 14 July 2000 (14.07.2000) US
60/241,219 13 October 2000 (13.10.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant (*for all designated States except US*):
CROPDESIGN N.V. [BE/BE]; Technologiepark 3,
B-9052 Gent (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): FRANKARD,
Valérie, Marie-Noëlle, S. [BE/BE]; 40, rue du Ham,
B-1180 Bruxelles (BE). PERES BOTA, Adrian, Marius
[RO/BE]; Holdaalstraat 31, B-9000 Gent (BE). DROUAL,
Anne-Marie [FR/BE]; Voskenslaan 437, B-9000 Gent
(BE). MIRONOV, Vladimir [BE/BE]; Gentbruggestraat
142, B-9040 Gent (BE). INZE, Dirk [BE/BE]; Driesstraat
18, B-9310 Moorsel-Aalst (BE). HATZFELD, Yves
[FR/FR]; 292, rue Nationale, F-59000 Lille (FR).

Published:

— with international search report

(88) Date of publication of the international search report:
12 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/028893 A3

(54) Title: PLANT CYCLIN-DEPENDENT KINASE INHIBITORS

(57) Abstract: The invention provides isolated nucleic acids molecules, designated ICK nucleic acid molecules, which encode novel plant cyclin-dependent kinase inhibitors. The invention also provides antisense nucleic acid molecules, gene silencing and recombinant expression vectors containing ICK nucleic acid molecules, host cells into which the expression vectors have been introduced, and transgenic plants in which an ICK gene has been introduced or disrupted. The invention still further provides isolated ICK proteins, fusion proteins, antigenic peptides and anti-ICK antibodies. Agricultural, diagnostic, and screening methods utilizing compositions of the invention are also provided.

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/IB 01/01492

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 C12N9/12 C12N15/54 C12N15/82 C07K16/40
 A01H5/00 G01N33/573

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, SEQUENCE SEARCH, MEDLINE, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 14331 A (ALMEIDA JANICE DE ;LANDRIEU ISABELLE (BE); VEYLDER LIEVEN DE (BE);) 25 March 1999 (1999-03-25) cited in the application	1-41, 55-64
Y	* abstract, p.4:8-16:21, 27:26-34:9, 36:11-37:30, 41:13-44:30, fig. 1, example 1, SEQ: ID NOs 3,4,5, claims *	42-54, 65-67
X	WO 99 66055 A (INZE DIRK GUSTAAF ;CAMP WIM VAN (BE); CROPDESIGN N V (BE); GHEYSEN) 23 December 1999 (1999-12-23) * abstract, p. 8:15-14:34, 16:5-11, 19:8-38, 21:27-35, 36:14-32, example 3, claims *	1-13, 19-42, 55-64
Y		46-54, 66,67

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

5 August 2002

Date of mailing of the international search report

29.08.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, T.x. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Puonti-Kaerlas, J

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/IB 01/01492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 64599 A (FOWKE LARRY C ;WANG HONG (CA); CANADA AGRICULTURE (CA); CANADA NAT) 16 December 1999 (1999-12-16) cited in the application	1-8, 14-18, 24-29, 31, 33-36, 38-41, 55-64
	* abstract, p. 18:5-22:18, 23:12-26:24, 32:19-34:20, fig. 6,7,8, SEQ ID NOs 13,14,15,16, claims *	
Y		42-54, 65-67
Y	LUI HELEN ET AL: "The Arabidopsis Cdc2a-interacting protein ICK2 is structurally related to ICK1 and is a potent inhibitor of cyclin-dependent kinase activity in vitro." PLANT JOURNAL., vol. 21, no. 4, February 2000 (2000-02), pages 379-385, XP002195194 ISSN: 0960-7412 cited in the application * summary, fig 1, p. 380-383 *	1-67
Y	WANG ET AL: "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both Cdc2a and CycD3, and its expression is induced by abscisic acid" PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 15, no. 4, 1 August 1998 (1998-08-01), pages 501-510, XP002095094 ISSN: 0960-7412 * summary, p.502-503,505-508 *	1-67
Y	FOUNTAIN ET AL: "Chenopodium rubrum G1 cyclin-dependent kinase inhibitor mRNA, complete cds" EMBL NUCLEOTIDE SEQUENCE, XX, XX, 27 November 1997 (1997-11-27), XP002067552 cited in the application	1-67

-/-

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/IB 01/01492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WANG H ET AL: "A PLANT CYCLIN-DEPENDENT KINASE INHIBITOR GENE" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 386, 3 April 1997 (1997-04-03), pages 451-452, XP002054969 ISSN: 0028-0836 cited in the application * p. 451 * & DATABASE EMBL 'Online! retrieved from EBI Database accession no. U94772 XP002067455</p>	1-67
P,X	<p>WO 00 60087 A (DU PONT ;WENG ZUDE (US); CAHOON REBECCA E (US); KLEIN THEODORE M () 12 October 2000 (2000-10-12)</p> <p>* abstract, p.1:35-4:15, example 1,2,3, 4,5,7, SEQ ID NOs 1,2,9,10,11,12,20,21, 22,31,34,35, fig 1, claims *</p>	1-8, 24-29, 33-41, 55-64
P,Y		9-23, 30-32, 42-54, 65-67
P,X	<p>WANG HONG ET AL: "Expression of the plant cyclin-dependent kinase inhibitor ICK1 affects cell division, plant growth and morphology." PLANT JOURNAL, vol. 24, no. 5, December 2000 (2000-12), pages 613-623, XP002197980 ISSN: 0960-7412</p>	1-8, 24-29, 33-35, 37,38, 41,55-64
P,Y	* abstract, p. 615-618,620-621 *	9-23, 30-32, 36,39, 40, 42-54, 65-67
P,X	<p>WO 00 69883 A (FRED HUTCHINSON CANCER RES CT ;ROBERTS JAMES (US); KELLY BETH (US)) 23 November 2000 (2000-11-23)</p>	1-8, 24-29, 33-41, 55-64
P,Y	* p. 3:1-4:15,5:4-29,17:13-22:13, ex.1,2,3 *	42-54
	-/-	

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/IB 01/01492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! retrieved from EBI Database accession no. AC069145 XP002208618 cited in the application	46,47,49
Y	----	1-45,48, 50-67
X	PLANCHAIS ET AL: "Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension" PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 12, no. 1, 1 July 1997 (1997-07-01), pages 191-202, XP002094755 ISSN: 0960-7412 * summary, p. 192-193, 197 *	28,29
Y	CHO JEONG W ET AL: "Cell cycle control study in plant: Control of plant growth by G1 specific cyclin D1 and a novel D1 and D3 specific cyclin dependent kinase inhibitor, p23ack1." MOLECULAR BIOLOGY OF THE CELL, vol. 10, no. SUPPL., November 1999 (1999-11), page 432a XP001083895 39th Annual Meeting of the American Society for Cell Biology; Washington, D.C., USA; December 11-15, 1999 ISSN: 1059-1524 * abstract *	1-67
Y	SCHULTZ T F AND QUATRANO R S: "Characterization and expression of a rice RAD23 gene" PLANT MOLECULAR BIOLOGY, NIJHOFF PUBLISHERS, DORDRECHT, NL, vol. 34, no. 3, June 1997 (1997-06), pages 557-562, XP002134623 ISSN: 0167-4412 * abstrat, p. 558 *	67
Y	WO 98 41642 A (VEYLDER LIEVEN DE ;VLAAMS INTERUNIV INST BIOTECH (BE); INZE DIRK () 24 September 1998 (1998-09-24) * abstract, p. 1:7-4:18, 6:28-14:22, claims *	1-67
Y	WO 99 13083 A (VEYLDER LIEVEN DE ;INZE DIRK (BE); CROPDESIGN N V (BE); SEGERS GER) 18 March 1999 (1999-03-18) * p. 4:1-11:8, 20:23-33:3, claims *	1-67
	----- -/-	

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/IB 01/01492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 01 20020 A (VEYLDER LIEVEN DE ;INZE DIRK (BE); BOUNAGA SAKINA (BE); CROPDESIGN) 22 March 2001 (2001-03-22) * abstract, p. 1:30-8:22, 9:25-12:29, 17:15-21 *	1-67
A	--- DATABASE EMBL 'Online! retrieved from EBI Database accession no. AA556411 XP002208619 cited in the application & ALLONA ET AL. : "Analysis of xylem formation in pine by cDNA sequencing" PROC. NATL.ACAD. SCI USA, vol. 95, no. 16, 1998, pages 9693-9698, XP002186770	
A	--- VEREECKE DANNY ET AL: "The Rhodococcus fascians-plant interaction: Morphological traits and biotechnological applications." PLANTA (BERLIN), vol. 210, no. 2, January 2000 (2000-01), pages 241-251, XP002208615 ISSN: 0032-0935	
A	--- DATABASE EMBL 'Online! retrieved from EBI Database accession no. AW267370 XP002208620 cited in the application	
A	--- DEN BOER BART G W ET AL: "Triggering the cell cycle in plants." TRENDS IN CELL BIOLOGY, vol. 10, no. 6, June 2000 (2000-06), pages 245-250, XP002208616 ISSN: 0962-8924	
A	--- DE ALMEIDA ENGLER ET AL: "molecular markers and cell cycle inhibitors show the importance of cell cycle progression in nematode-induced galls and syncytia" PLANT CELL, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 11, May 1999 (1999-05), pages 793-807, XP002126398 ISSN: 1040-4651 --- -/--	

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/IB 01/01492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KOVTUN YELENA ET AL: "Functional analysis of oxidative stress-activated mitogen-activated protein kinase cascade in plants" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2940-2945, XP002176207 ISSN: 0027-8424 -----	
A	CAZALE ANNE-CLAIRE ET AL: "MAP kinase activation by hypoosmotic stress of tobacco cell suspensions: Towards the oxidative burst response?" PLANT JOURNAL, vol. 19, no. 3, August 1999 (1999-08), pages 297-307, XP002208617 ISSN: 0960-7412 -----	
A	KARIMI M ET AL: "ARM1: Application for engineered resistance to plant-parasitic nematodes." MEDEDELINGEN FACULTEIT LANDBOUWKUNDIGE EN TOEGEPASTE BIOLOGISCHE, vol. 64, no. 5b, 1999, pages 439-442, XP001083894 Thirteenth Forum for Applied Biotechnology.;Gent, Belgium; September 22-23, 1999, 1999 -----	

INTERNATIONAL SEARCH REPORT

Int. application No.
PCT/IB 01/01492

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor OsICK2 and subject-matter relating thereto.

2. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor OsICK1 and subject-matter relating thereto.

3. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor OsICK3 and subject-matter relating thereto.

4. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor OsICK4 and subject-matter relating thereto.

5. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor ZmICK1 and subject-matter relating thereto.

6. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor ZmICK2 and subject-matter relating thereto.

7. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor SbICK and subject-matter relating thereto.

8. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor PtICK and subject-matter relating thereto.

9. Claims: 1-64,66,67 partially

Cyclin-dependent kinase inhibitor OsICK5 and subject-matter relating thereto.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: 65 complete, 66 partially

An isolated nucleic acid molecule encoding a monocot ICK polypeptide comprising a motif 1, motif 2, motif 3, motif 4, motif 5, motif 6, a Cy-box, a nuclear localisation sequence, a PEST sequence and an alfa-helical stretch between motifs 5 and 6 as well as between 6 and 4.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The technical term "ICK modulator" employed in claims 1-36, 38-40 and 55-64 is meaningless to a person skilled in the art. Due to the absence of any technical features the subject-matter of said claims is not clearly defined by the present wording. Consequently, present claims 1-36, 38-40 and 55-64 relate to an undefined number of possible compounds. Thus, a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the claims which do appear to be clear (and concise), namely those parts relating to sequence ID numbers 1-17, 43-45 and 54-56 as well as to the general concept of plant cyclin-dependent kinase inhibitors.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/IB 01/01492	

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9914331	A	25-03-1999	AU 9540698 A	05-04-1999
			CA 2303759 A1	25-03-1999
			WO 9914331 A2	25-03-1999
			EP 1015590 A2	05-07-2000
			JP 2001516582 T	02-10-2001
WO 9966055	A	23-12-1999	AU 4772599 A	05-01-2000
			WO 9966055 A2	23-12-1999
			EP 1088091 A2	04-04-2001
WO 9964599	A	16-12-1999	AU 4126999 A	30-12-1999
			CA 2329684 A1	16-12-1999
			WO 9964599 A1	16-12-1999
			EP 1086226 A1	28-03-2001
			US 2001025379 A1	27-09-2001
WO 0060087	A	12-10-2000	AU 4203300 A	23-10-2000
			EP 1165793 A2	02-01-2002
			WO 0060087 A2	12-10-2000
WO 0069883	A	23-11-2000	AU 5018500 A	05-12-2000
			EP 1179003 A1	13-02-2002
			WO 0069883 A1	23-11-2000
WO 9841642	A	24-09-1998	AU 744834 B2	07-03-2002
			AU 6730198 A	12-10-1998
			WO 9841642 A1	24-09-1998
			EP 0972060 A1	19-01-2000
			JP 2001516217 T	25-09-2001
WO 9913083	A	18-03-1999	AU 9537498 A	29-03-1999
			CA 2301830 A1	18-03-1999
			WO 9913083 A2	18-03-1999
			EP 1007684 A2	14-06-2000
			JP 2001515722 T	25-09-2001
WO 0120020	A	22-03-2001	AU 7517200 A	17-04-2001
			WO 0120020 A2	22-03-2001